Anti-STEAP1 antigen-binding protein

By developing an antigen-binding protein that binds to STEAP1 and preparing heterodimer antibodies, the problem of high side effects in prostate cancer treatment has been solved, achieving a highly effective treatment with low side effects.

CN112584859BActive Publication Date: 2026-11-17AMGEN INC +1
View PDF 153 Cites 0 Cited by

Patent Information

Application Number
CN201980044261.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-02-01
Filing Date
2019-07-02
Publication Date
2026-11-17
Estimated Expiration
2039-07-02

AI Technical Summary

Technical Problem

Current treatments for prostate cancer carry risks of nerve damage, erectile dysfunction, and various side effects. Traditional chemotherapy has significant side effects, and there is a lack of effective antibody-based alternative treatments.

Method used

Develop antigen-binding proteins that bind to STEAP1, containing specific heavy and light chain CDR sequences, for the preparation of heterodimeric antibodies that bind to human STEAP1 and trigger T cell-dependent cytotoxicity or redirected lysis of prostate cancer cells.

Benefits of technology

It has achieved effective treatment for prostate cancer, reduced the side effects of traditional treatments, improved patients' quality of life, and enhanced treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002869175300000381
    Figure BDA0002869175300000381
  • Figure BDA0002869175300001011
    Figure BDA0002869175300001011
  • Figure BDA0002869175300001031
    Figure BDA0002869175300001031
Patent Text Reader

Abstract

This disclosure provides a novel antigen-binding protein that binds to STEAP1 and methods of use.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure provides a novel antigen-binding protein that binds to prostatic six-transmembrane epithelial antigen 1 (STEAP1) and its uses.

[0002] Cross-references to related applications

[0003] This application claims U.S. Provisional Patent Application No. 62 / 693,216, filed July 2, 2018, and U.S. Provisional Patent Application No. 62 / 800,259, filed February 1, 2019, the disclosures of which are incorporated herein by reference in their entirety.

[0004] sequence list

[0005] As a separate part of this disclosure, this application includes a sequence list in computer-readable form (filename: 52601_Seqlisting.txt; size: 298,914 bytes; creation date: June 27, 2019), which is incorporated herein by reference in its entirety. Background Technology

[0006] Prostate cancer remains one of the most common cancers among men in the United States. (US Cancer Statistics Working Group. US Cancer Statistics: Incidence and Mortality Web-based Report, 1999–2014; Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2017.) While survival rates for prostate cancer are relatively high compared to other cancer types, current treatment options come with risks and undesirable side effects. For example, surgery carries risks of nerve damage and erectile dysfunction, and radiation therapy can increase the risk of developing bladder or gastrointestinal cancers. Traditional chemotherapy is associated with numerous side effects that limit patients' quality of life during treatment.

[0007] Antibody-based therapies have been successfully used to treat a variety of diseases, including cancer and autoimmune / inflammatory disorders. Prostate cancer is believed to be particularly well-suited for antibody-based therapies, at least in part due to the presence of prostate cancer-specific antigens. Despite recent advances in elucidating the underlying biological mechanisms of carcinogenesis and potential biomarkers, there remains a need for alternative antibody-based treatment options for cancers, including prostate cancer. Summary of the Invention

[0008] This disclosure provides an antigen-binding protein of STEAP1 that binds to SEQ ID NO:2, and the antigen-binding protein comprises: (a) a heavy chain CDR comprising an amino acid sequence differing from i) vhCDR1 SEQ ID NO:14, vhCDR2 SEQ ID NO:15 or vhCDR2 SEQ ID NO:21, and vhCDR3 SEQ ID NO:16; or ii) vhCDR1 SEQ ID NO:33, vhCDR2 SEQ ID NO:34, and vhCDR3 SEQ ID NO:35 by no more than 3, 2, or 1 amino acid sequence; or (b) a light chain CDR comprising an amino acid sequence differing from i) vlCDR1 SEQ ID NO:11, vlCDR2 SEQ ID NO:12, and vlCDR3 SEQ ID NO:13; or ii) vlCDR1 SEQ ID NO:30, vlCDR2 SEQ ID NO:31, and vlCDR3 SEQ ID NO:25 by no more than 3, 2, or 1 amino acid sequence. NO:32 An amino acid sequence differing by no more than 3, 2, or 1 amino acid; or (c) a light chain variable domain comprising an amino acid sequence having at least 90% identity with SEQ ID NO:183 or SEQ ID NO:186; or (d) a heavy chain variable domain comprising an amino acid sequence having at least 90% identity with SEQ ID NO:182, SEQ ID NO:184, or SEQ ID NO:185. In several aspects, the antigen-binding protein comprises: vhCDR1 containing SEQ ID NO:14, vhCDR2 containing SEQ ID NO:15 or SEQ ID NO:21, vhCDR3 containing SEQ ID NO:16, vlCDR1 containing SEQ ID NO:11, vlCDR2 containing SEQ ID NO:12, and vlCDR3 containing SEQ ID NO:13. Alternatively, the antigen-binding protein comprises: vhCDR1 containing SEQ ID NO:33, vhCDR2 containing SEQ ID NO:34, vhCDR3 containing SEQ ID NO:35, vlCDR1 containing SEQ ID NO:30, vlCDR2 containing SEQ ID NO:31, and vlCDR3 containing SEQ ID NO:32.In several aspects, the antigen-binding protein comprises: a variable heavy chain domain containing SEQ ID NO:182 or SEQ ID NO:184 and a variable light chain domain containing SEQ ID NO:183; for example, the antigen-binding protein comprises: a variable heavy chain domain containing SEQ ID NO:182 and a variable light chain domain containing SEQ ID NO:183, or a variable heavy chain domain containing SEQ ID NO:184 and a variable light chain domain containing SEQ ID NO:183. Alternatively, the antigen-binding protein comprises: a variable heavy chain domain containing SEQ ID NO:185 and a variable light chain domain containing SEQ ID NO:186. This disclosure further provides an antigen-binding protein comprising: a heavy chain containing SEQ ID NO:201 and a light chain containing SEQ ID NO:200; or a heavy chain containing SEQ ID NO:203 and a light chain containing SEQ ID NO:200.

[0009] This disclosure further provides a heterodimeric antibody comprising a first monomer comprising a first heavy chain, the first heavy chain comprising: 1) a first variable heavy chain domain; 2) a first constant heavy chain comprising a first CH1 domain and a first Fc domain; and 3) an scFv that binds to human CD3 and comprises an scFv variable light chain domain, an scFv linker, and an scFv variable heavy chain domain; wherein the scFv is covalently attached between the C-terminus of the CH1 domain and the N-terminus of the first Fc domain using one or more domain linkers. The heterodimeric antibody further comprises a second monomer comprising: a second heavy chain comprising a second variable heavy chain domain and a second constant heavy chain containing a second Fc domain; and a common light chain comprising a variable light chain domain and a constant light chain domain.The first variable heavy chain domain and the variable light chain domain are bound to STEAP1, the second variable heavy chain domain and the variable light chain domain are bound to STEAP1, and wherein (i) the first variable heavy chain domain and the second variable heavy chain domain contain heavy chain CDRs, which contain amino acid sequences differing from vhCDR1 SEQ ID NO:14, vhCDR2 SEQ ID NO:15 or vhCDR2 SEQ ID NO:21, and vhCDR3 SEQ ID NO:16 by no more than 3, 2, or 1 amino acid sequences, and the variable light chain domain contains light chain CDRs, which contain amino acid sequences differing from vlCDR1 SEQ ID NO:11, vlCDR2 SEQ ID NO:12, and vlCDR3 SEQ ID NO:16 by no more than 3, 2, or 1 amino acid sequences, and the variable light chain domain contains light chain CDRs, which contain amino acid sequences differing from vlCDR1 SEQ ID NO:11, vlCDR2 SEQ ID NO:12, and vlCDR3 SEQ ID NO:16 by no more than 3, 2, or 1 amino acid sequences, and the variable light chain domain contains light chain CDRs, which contain amino acid sequences differing from vlCDR1 SEQ ID NO:11, vlCDR2 SEQ ID NO:12, and vlCDR3 SEQ ID NO:16 by no more than 1 ... NO:13 An amino acid sequence differing from SEQ ID NO:33 by no more than 3, 2, or 1 amino acid; or (ii) The first variable heavy chain domain and the second variable heavy chain domain contain heavy chain CDRs containing amino acid sequences differing from vhCDR1 SEQ ID NO:33, vhCDR2 SEQ ID NO:34, and vhCDR3 SEQ ID NO:35 by no more than 3, 2, or 1 amino acid, and the variable light chain domain contains light chain CDRs containing amino acid sequences differing from vlCDR1 SEQ ID NO:30, vlCDR2 SEQ ID NO:31, and vlCDR3 SEQ ID NO:32 by no more than 3, 2, or 1 amino acid; or (iii) The first variable heavy chain domain and the second variable heavy chain domain contain amino acid sequences having at least 90% identity with SEQ ID NO:182 or SEQ ID NO:184, and the variable light chain domain contains amino acid sequences differing from SEQ ID NO:182 or SEQ ID NO:184 by no more than 90% identity. NO:183 has an amino acid sequence with at least 90% identity; or (iv) the first variable heavy chain domain and the second variable heavy chain domain contain an amino acid sequence with at least 90% identity to SEQ ID NO:185, and the variable light chain domain contains an amino acid sequence with at least 90% identity to SEQ ID NO:186. In several aspects, the first variable heavy chain domain and the second variable heavy chain domain contain CDR sequences: vhCDR1 containing SEQ ID NO:14, vhCDR2 containing SEQ ID NO:15 or SEQ ID NO:21, and vhCDR3 containing SEQ ID NO:16; and the variable light chain domain contains CDR sequences: vlCDR1 containing SEQ ID NO:11, vlCDR2 containing SEQ ID NO:12, and vlCDR3 containing SEQ ID NO:13.In several aspects, the first variable heavy chain domain and the second variable heavy chain domain comprise CDR sequences: vhCDR1 containing SEQ ID NO:33, vhCDR2 containing SEQ ID NO:34, and vhCDR3 containing SEQ ID NO:35; and the variable light chain domain comprises CDR sequences: vlCDR1 containing SEQ ID NO:30, vlCDR2 containing SEQ ID NO:31, and vlCDR3 containing SEQ ID NO:32. In several aspects, the first variable heavy chain domain and the second variable heavy chain domain comprise SEQ ID NO:182 or SEQ ID NO:184, and the variable light chain domain comprises SEQ ID NO:183 (e.g., SEQ ID NO:182 and 183 or SEQ ID NO:184 and 183), or the first variable heavy chain domain and the second variable heavy chain domain comprise SEQ ID NO:185, and the variable light chain domain comprises SEQ ID NO:186. The scFv contains CDRs, which include: vhCDR1 containing SEQ ID NO:170, vhCDR2 containing SEQ ID NO:171, vhCDR3 containing SEQ ID NO:172, vlCDR1 containing SEQ ID NO:174, vlCDR2 containing SEQ ID NO:175, and vlCDR3 containing SEQ ID NO:176; or the variable heavy chain region and the variable light chain region of SEQ ID NO:169 and SEQ ID NO:173.

[0010] It also provides methods for treating cancers (such as prostate cancer) that involve administering the antigen-binding protein described herein to subjects who require it.

[0011] The use of section headings in this document is solely for ease of reading and not intended to be limiting. The entire document is intended to be viewed as a unified disclosure, and it should be understood that all combinations of the features described herein can be considered.

[0012] Unless otherwise defined herein, the technical terms used in connection with this application shall have the meanings commonly understood by one of ordinary skill in the art. Furthermore, unless the context otherwise requires, singular terms shall include plural forms, and plural terms shall include singular forms. Unless otherwise stated, the terms “comprising,” “having,” “including,” and “containing” shall be interpreted as open-ended terms. If aspects of the invention are described as “comprising” features, embodiments are also considered to be “consisting of” or “substantially consisting of” that feature. The application of any and all instances or exemplary language (e.g., “for example”) provided herein is intended only to better illustrate this disclosure and not to limit the scope of the additionally claimed disclosure. The language in the specification should not be construed as indicating any unclaimed element necessary for the practice of this disclosure. Except in operational examples or where otherwise indicated, all figures used herein to indicate amounts of ingredients or reaction conditions shall be understood to be modified in all cases by the term “about,” which will be interpreted by one of skill in the art.

[0013] The range of values ​​cited herein is intended only as a shorthand for individually referring to each individual value falling within that range and each endpoint, unless otherwise stated herein, and each individual value and endpoint is incorporated into this specification as if it were cited individually herein.

[0014] In general, the terminology and techniques used herein for cell and tissue culture, molecular biology, immunology, microbiology, genetics, protein and nucleic acid chemistry, manufacturing, formulation, pharmacology, and pharmaceuticals are those well-known and commonly used in the art. Unless otherwise indicated, the methods and techniques of this application are generally performed according to conventional methods well-known in the art and as described in the various general and more specific references cited and discussed throughout this specification. See, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2001); Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates (1992); and Harlow and Lane Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1990), which are incorporated herein by reference. Enzymatic reactions and purification techniques were performed according to the manufacturer's instructions, as is commonly practiced in the art or as described herein. The terminology, experimental methods, and techniques used in conjunction with the analytical chemistry, synthetic organic chemistry, and pharmaceutical and medicinal chemistry described herein are those well-known and commonly used in the art. Standard techniques can be used for chemical synthesis, chemical analysis, drug preparation, formulation and delivery, and patient treatment. Percentage identity is calculated using methods conventionally used in the art, including those described, for example, in U.S. Patent Publication No. 2017 / 0342155, which is incorporated herein by reference in its entirety and particularly with respect to paragraphs

[0075] -

[0083] . Attached Figure Description

[0015] Figure 1 The bispecific antibody disclosed herein is described.

[0016] Figure 2 The sequence of the human CD3ε chain (SEQ ID NO:1) is depicted.

[0017] Figure 3The sequence of human STEAP1 (SEQ ID NO:2) is depicted. The sequence of the extracellular loop is underlined.

[0018] Figures 4A-4E A useful set of heterodimerization variant pairs (including skew variants and pI variants) is described.

[0019] Figure 5 A list depicting the constant regions of isosteric variant antibodies and their respective substitutions is provided. pI_(-) indicates variants with lower pI, while pI_(+) indicates variants with higher pI. These can optionally and independently be combined with other heterodimerizing variants disclosed herein (and other variant types as outlined herein).

[0020] Figure 6 Useful ablation variants (sometimes referred to as "knockout" or "KO" variants) that ablate FcγR binding are described.

[0021] Figure 7 Two embodiments of this disclosure are depicted.

[0022] Figure 8A and 8B Useful linkers are described, including charged scFv linkers and domain linkers that can be used in the antigen-binding protein and heterodimeric antibody forms provided herein. Among the various aspects disclosed, the charged linkers can be used, for example, to increase or decrease the pI of heterodimeric antibodies utilizing one or more scFvs as components. The only prior art scFv linker with a single charge is called “Whitlow,” from Whitlow et al., Protein Engineering 6(8):989-995 (1993). This linker is used to reduce aggregation in scFvs and enhance proteolytic stability.

[0023] Figure 9 A list is provided of engineered heterodimer-skewed Fc variants, along with heterodimer yields (determined by HPLC-CIEX) and thermal stability (determined by DSC). Undetermined thermal stability is indicated by “nd”. Further information is provided in U.S. Patent No. 9,822,186, which is incorporated herein by reference in its entirety.

[0024] Figure 10A and 10BA stable, optimized humanized anti-CD3 variant scFv is described. Substitutions relative to the H1_L1.4 scFv sequence are given. Amino acid numbers are Kabat numbers. Specific variable light chain regions and variable heavy chain regions are indicated; the listed substitutions may be used in other variable light chain regions and variable heavy chain regions besides those specifically listed. Further information is provided in International Patent Publication No. 2017 / 091656, which is incorporated herein by reference in its entirety.

[0025] Figure 11 A and 11B show the specific detection of STEAP1 on the surface of C4-2B luc cells using mouse STEAP1 antibody Ab-Am.

[0026] Figures 12A-12C The use of mouse STEAP1 antibody Ab-Am (shows results) Figure 12A ); Ab-A1 XmAb(●) or Ab-A1 XmAb 2 +1 (■) Continue at 4℃ for 1 hour Figure 12B ) and antibody Ab-A1 XmAb 2+1 ( Figure 12C ) Specific detection of STEAP1 on C4-2B luc prostate cancer cells.

[0027] Figure 13 This demonstrates the specific detection of STEAP1 in C4-2B luc prostate cancer cells using the STEAP1 antibody Ab-Bx (Ab-B1 XmAb).

[0028] Figure 14 A-14C shows STEAP1 antibody Ab-Ax ( Figure 14 A) STEAP1 antibody Ab-A1 Xmab 2+1 ( Figure 14 B), and STEAP1 antibody Ab-A2(N67Q)Xmab 2+1 ( Figure 14 C) Mediates the lysis of target cells of human tumor cell line C4-2B luc by human T cells.

[0029] Figure 15 The STEAP1 antibody Ab-A1 Xmab was shown. 2+1 and Ab-A2(N67Q)Xmab 2+1 Mediates dose-dependent target cell lysis of human tumor cell line C4-2B luc (instead of C4-2B luc STEAP1KO) by human T cells.

[0030] Figure 16A-16B shows STEAP1 expressed in 293T cells as detected by mouse STEAP1 antibody Ab-Am. Figure 16 C shows STEAP1 binder Ab-A2(N67Q)Xmab 2+1 Mediated dose-dependent target cell lysis of human 293T cell line stably transfected with human STEAP1 instead of parental 293T cell line.

[0031] Figure 17 A displays Ab-Bx(Ab-B1-XmAb) and Ab-B1 Xmab 2+1 Mediates the lysis of target cells in C4-2B luc prostate cancer cells. Figure 17 B displays Xmab 2+1 Ab-B1 variants (i.e., Ab-B1-G37A, Ab-B1-S39A, and Ab-B1-G37A / S39A) mediate target cell lysis in C4-2B luc prostate cancer cells. Figure 17C Display Xmab 2+1 Ab-B1 variants (i.e., Ab-B1-G37A, Ab-B1-S39A, and Ab-B1-G37A / S39A) do not mediate target cell lysis in C4-2B luc STEAP1 knockout prostate cancer cells.

[0032] Figures 18A-18I depict several morphologies of antigen-binding proteins: "bottle opener" type, mAb-Fv, mAb-scFv, center-scFv, center-Fv, single-arm center-scFv, single scFv-mAb, scFv-mAb, and double scFv. For all the depicted scFv domains, they can be N-terminal to C-terminal variable heavy chain-(optional linker)-variable light chain, or vice versa. Additionally, for single-arm scFv-mAb, the scFv can be attached to the N-terminus of either the heavy chain monomer or the light chain.

[0033] Figure 19 The sequences of CDR, variable heavy chain domain, variable light chain domain, scFv, linker sequence, and monomer sequence disclosed herein are provided. The underlined variable region sequence indicates the CDR sequence.

[0034] Figure 20A and 20B The results of the T cell-dependent cytotoxicity assay described in Example 9 are presented. Figure 20A This describes the process in a representative T-cell donor (y-axis = Log(pM)) consisting of a single Ab-A2(N67Q) × mAb. 2+1 (open circle) and Ab-A2(N67Q)XmAb 2+1A graph of specific cytotoxicity (%) mediated by combination with anti-PD-1 antibody (closed circle). Figure 20B This describes the individual Ab-A2(N67Q)XmAb samples from four different T-cell donors. 2+1 (Left side) and Ab-A2(N67Q)XmAb 2+1 EC50 (pM) of combination with anti-PD-1 antibody (right side).

[0035] Figures 21A-21C This indicates that exposure to different amounts of Ab-A2(N67Q)XmAb 2+1 Total T cells ( Figure 21A CD8 + T cells ( Figure 21B ), and CD4 + T cells ( Figure 21C Line graph of PD-1 expression (%CD3+) in T cells. Circles and squares in the graph represent different T cell donors. PD-1 expression is increased in T cells exposed to the heterodimer antibody disclosed herein.

[0036] Figure 22 This describes the tumor volume (mm). 3 Line graph (y-axis) over time (number of days in the study, x-axis). On day 1, human SK-N-MC cells (5 x 10⁻⁶ cells) were... 6 Human CD3+ T cells (2 x 10^10 cells / mouse) were subcutaneously injected into the right dorsal side of female, sublethal irradiated NOD / SCID mice. On day 8, except for group 1, human CD3+ T cells (2 x 10^10 cells / mouse) were injected subcutaneously into the right dorsal side of the mice. 7 (1 cell / mouse) was injected into the peritoneal cavity of all animals. On days 12, 19, and 26 (top arrows in the figure), the mediator (groups 1 and 2) or Ab-A2(N67Q)XmAb was administered via intravenous bolus at dose levels of 1.0, 0.1, or 0.01 mg / kg (groups 3, 4, and 5, respectively). 2+ Tumor volume was measured three times per week using electronic calipers. The average tumor volume for the group is shown in mm. 3 + / - SEM. The asterisks in the figure indicate the presence of an asterisk in the medium (Group 2) and Ab-A2(N67Q)XmAb. 2+ Statistically significant differences between treatment groups (one-way ANOVA; * = p < 0.05; *** = p < 0.001).

[0037] Figure 23 Mean and median SK-N-MC human neuroblastoma tumor volume in female NOD / SCID mice Detailed Implementation

[0038] STEAP1 is a 339-amino acid protein comprising six transmembrane domains, generating three extracellular loops and two intracellular loops. The amino acid sequence of human STEAP1 is shown herein as SEQ ID NO:2. The estimated positions of the extracellular loops are amino acids 92-118 (extracellular loop 1), amino acids 185-217 (extracellular loop 2), and amino acids 279-290 (extracellular loop 3). STEAP1 is differentially expressed in prostate cancer compared to normal tissues, and increased expression was observed in bone and lymph node metastases of prostate cancer compared to primary prostate cancer samples. STEAP1 represents an ideal target for diagnostics and antibody-based therapies, such as bispecific anti-STEAP1 / anti-CD3 T cell recruitment antibodies to trigger, for example, T cell-dependent cytotoxicity or redirected lysis of prostate cancer cells. As further described herein, this disclosure provides antigen-binding proteins that bind to STEAP1.

[0039] antigen-binding proteins

[0040] An antigen-binding protein is a protein that contains a portion that binds to a specific target antigen (e.g., STEAP1). An antigen-binding protein includes a scaffold or framework portion that allows the antigen-binding portion to adopt a conformation that facilitates the binding of the antigen-binding protein to the antigen. In an exemplary aspect, the antigen-binding protein is an antibody or immunoglobulin (e.g., a heterodimer and / or a bispecific antibody), an antigen-binding antibody fragment, or an antibody protein product.

[0041] The term "antibody" refers to a complete antigen-binding immunoglobulin. An antibody is an antigen-binding protein. Antibodies can be IgA, IgD, IgE, IgG, or IgM antibodies, including any one of IgG1, IgG2, IgG3, or IgG4. In several embodiments, a complete antibody comprises two full-length heavy chains and two full-length light chains. Antibodies have variable and constant regions. In the IgG form, the variable region is typically about 100-110 or more amino acids long, contains three complementarity-determining regions (CDRs), is primarily responsible for antigen recognition, and differs significantly from other antibodies that bind different antigens. Variable regions typically contain at least three heavy or light chain CDRs (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Public Health Service, NIH, Bethesda, Maryland; see also Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917; Chothia et al., 1989, Nature 342:877-883), located within the frame regions (frame regions 1-4, FR1, FR2, FR3, and FR4, as specified by Kabat et al., 1991; see also Chothia and Lesk, 1987, ibid.). Constant regions allow antibodies to recruit cells and molecules of the immune system.

[0042] In many respects, an antibody is a monoclonal antibody. In some respects, an antibody is a human antibody. In some respects, an antibody (or other antigen-binding protein) is chimeric or humanized. The term "chimeric" refers to an antibody containing domains from two or more different antibodies. A chimeric antibody may, for example, contain a constant domain from one species and a variable domain from a second species, or more generally, may contain segments of amino acid sequences from at least two species. Both "chimeric" and "humanized" generally refer to antigen-binding proteins that combine regions from more than one species. Chimeric antibodies may also contain domains from two or more different antibodies within the same species. In one embodiment, a chimeric antibody is a CDR-grafted antibody.

[0043] When used in relation to antigen-binding proteins, the term "humanization" refers to an antigen-binding protein (e.g., an antibody) that has at least a CDR region derived from a non-human source and is engineered to have a structure and immune function more similar to a real human antibody than the antibody of the original source. For example, humanization may involve grafting a CDR from a non-human antibody (e.g., a mouse antibody) into a human frame region. Typically, in humanized antibodies, the entire antibody, except for the CDR, is encoded by a human-derived polynucleotide or is identical to that antibody (except within its CDR). The CDR (entirely or entirely encoded by nucleic acids derived from non-human organisms) is grafted into the β-sheet frame region of the human antibody's variable region to produce an antibody whose specificity is determined by the grafted CDR. The production of such antibodies is described, for example, in International Patent Publication No. WO 92 / 11018; Jones, 1986, Nature 321:522-525; and Verhoeyen et al., 1988, Science 239:1534-1536, all of which are incorporated herein by reference in their entirety. Typically, a “reverse mutation” of selected receptor framework residues to corresponding donor residues is employed to regain the affinity lost in the initially grafted construct (see, for example, U.S. Patent Nos. 5530101; 5585089; 5693761; 5693762; 6180370; 5859205; 5821337; 6054297; and 6407213, all of which are incorporated herein by reference in their entirety). Humanized antibodies optionally also contain at least a portion of the immunoglobulin (typically human immunoglobulin) constant region, and therefore typically contain the human Fc region.

[0044] Various techniques and methods for generating chimeric antibodies, humanized antibodies, and reconstructed nonhuman antibodies are well known in the art. See Tsurushita and Vasquez, 2004, Humanization of Monoclonal Antibodies, Molecular Biology of B Cells, 533-545, Elsevier Science, and the references cited therein; Jones et al., 1986, Nature 321:522-525; Riechmann et al., 1988; Nature 332:323-329; Verhoeyen et al., 1988, Science 239:1534-1536; Queen et al., 1989, Proc Natl Acad Sci, USA [Proceedings of the National Academy of Sciences] 86:10029-33; He et al., 1998; J. Immunol. [Journal of Immunology] 160:1029-1035; Carter et al., 1992; Proc Natl Acad Sci USA [Proceedings of the National Academy of Sciences] 89:4285-9; Presta et al., 1997; Cancer Res. [Cancer Research] 57(20):4593-9; Gorman et al., 1991, Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America] 88:4181-4185; O'Connor et al., 1998, Protein Engineering 11:321-8, US Patent Publication No. 20030039649; US Patent Nos. 5,869,619, 5,225,539, 5,821,337, 5,859,205; Padlan et al., 1995, FASEB J. [Journal of the Federation of American Societies for Experimental Biology] 9:133-39; and Tamura et al., 2000, J. Immunol. [Journal of Immunology] 164:1432-41, all of which are incorporated in full by reference. Humanization or other methods for reducing the immunogenicity of the variable region of a nonhuman antibody may include surface remodeling methods, as described, for example, in Roguska et al., 1994, Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences] 91:969-973, which is incorporated herein by reference in its entirety. The parent antibody may be affinity-matured, as is well understood in the art. Structure-based methods may be used for humanization and affinity maturation, as described, for example, in U.S. Patent Publication No. 20060008883.Selection-based approaches can be used for the variable regions of humanized and / or affinity-matured antibodies, including but not limited to those described in the following: Wu et al., 1999, J. Mol. Biol. [Journal of Molecular Biology] 294:151-162; Baca et al., 1997, J. Biol. Chem. [Journal of Biochemistry] 272(16):10678-10684; Rosok et al., 1996, J. Biol. Chem. [Journal of Biochemistry] 271(37):22611-22618; Rader et al., 1998, Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America] 95:8910-8915; Krauss et al., 2003, Protein Engineering [Proceedings of the National Academy of Sciences of the United States of America] 16(10):753-759, all of which are incorporated herein by reference in their entirety. Humanization can also involve the substitution of selected amino acids to make the non-human sequence more similar to the human sequence. Other humanization methods can involve transplanting only a portion of the CDR, including but not limited to those described in Tan et al., 2002, J. Immunol. [Journal of Immunology] 169:1119-1125; DePascalis et al., 2002, J. Immunol. [Journal of Immunology] 169:3076-3084, all of which are incorporated herein by reference in their entirety.

[0045] In other embodiments, the antigen-binding protein is an antigen-binding antibody fragment, i.e., an antibody fragment lacking part or all of the antibody light chain and / or part or all of the antibody heavy chain. The antibody fragment can be recombined or prepared by cleaving a complete antibody using an enzyme (e.g., papain and pepsin). Papain cleaves the antibody to produce two Fab fragments and a single Fc fragment. Pepsin cleaves the antibody to produce an F(ab')2 fragment and a pFc' fragment. In exemplary instances, the antigen-binding antibody fragment is either a Fab fragment or an F(ab')2 fragment. A Fab fragment is a monovalent fragment having VL, VH, CL, and CH1 domains. Fab can refer to the region alone or in the context of a full-length antibody, antibody fragment, etc. An F(ab')2 fragment is a bivalent fragment having two Fab fragments connected by disulfide bridges in the hinge region.

[0046] Antibody constructions have been developed to produce an increasing number of alternative modalities, spanning a molecular weight range of at least about 12–150 kDa and exhibiting titers (n) ranging from monomers (n=1) to dimers (n=2), trimers (n=3), tetramers (n=4), and potentially higher; these alternative modalities are referred to herein as “antibody protein products” and are examples of antigen-binding proteins. Antibody protein products include those based on the intact antibody structure and those mimicking antibody fragments that retain the intact antigen-binding ability, such as scFv and VHH / VH (discussed below). Single-chain antibodies (scFv) are antibodies in which the VL and VH regions are linked via a linker (e.g., a synthetic sequence of amino acid residues typically about 15 amino acids in length) to form a continuous protein chain, wherein the linker is long enough to allow the protein chain to fold back itself and form a monovalent antigen-binding site (see, for example, Bird et al., 1988, Science 242:423-26 and Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-83).

[0047] The antigen-binding fragment that retains its complete antigen-binding site is the Fv fragment, which consists entirely of variable (V) regions (the VL and VH domains of a single antibody). Soluble, flexible amino acid peptide linkers are commonly used to connect the V regions to scFv (single-chain variable fragment) fragments for molecule stabilization, or to add constant (C) domains to the V regions to create Fab fragments (fragments, antigen-binding). Both scFv and Fab fragments can be readily generated in host cells, such as prokaryotic or eukaryotic host cells. Other antibody protein products include disulfide-stabilized scFv (ds-scFv), single-chain Fab (scFab), single-chain antibodies (SCA), domain-specific antibodies (dAb) (e.g., peptides containing antigen-binding fragments of VH, VL, or VH or VL domains), peptides containing Fd fragments (containing VH and CH1 domains), complementarity-determining region (CDR) fragments, and dimer and multimeric antibody forms (e.g., diabetic, triabetic, and tetraabetic antibodies, or miniAbs), which comprise different types of scFvs linked to oligomeric domains. The smallest fragments are the VHH / VH of camel heavy chain Abs and single-domain Abs (sdAbs). Peptibody or peptide-Fc fusion is another type of antibody protein product. The structure of a peptibody consists of a bioactive peptide grafted onto an Fc domain. Peptibody is further described in the art. See, for example, Shimamoto et al., mAbs. 4(5):586-591(2012).

[0048] Alternatively, the antibody protein product may comprise, for example, an alternative protein scaffold or an artificial scaffold with grafted CDRs or CDR derivatives. Such scaffolds include, but are not limited to, antibody-derived scaffolds (containing mutations that introduce, for example, a mutation stabilizing the three-dimensional structure of the antigen-binding protein) and fully synthetic scaffolds (containing, for example, biocompatible polymers). See, for example, Korndorfer et al., 2003, Proteins: Structure, Function, and Bioinformatics, Vol. 53, No. 1: 121-129; Roque et al., 2004, Biotechnol. Prog. 20: 639-654. Additionally, peptide antibody mimics (“PAMs”) and scaffolds based on antibody mimics utilizing fibronectin components as scaffolds may be used.

[0049] In several respects, the antigen-binding protein comprises heavy chain CDRs containing amino acid sequences that differ from i)vhCDR1 SEQ ID NO:14, vhCDR2 SEQ ID NO:15 or vhCDR2 SEQ ID NO:21, and vhCDR3 SEQ ID NO:16; or ii)vhCDR1 SEQ ID NO:33, vhCDR2 SEQ ID NO:34, and vhCDR3 SEQ ID NO:35 by no more than 3, 2, or 1 amino acid sequence; and / or comprises light chain CDRs containing amino acid sequences that differ from i)vlCDR1 SEQ ID NO:11, vlCDR2 SEQ ID NO:12, and vlCDR3 SEQ ID NO:13; or ii)vlCDR1 SEQ ID NO:30, vlCDR2 SEQ ID NO:31, and vlCDR3 SEQ ID NO:32 by no more than 3, 2, or 1 amino acid sequence. Although substitution (e.g., conservative substitution) is preferred, each such sequence difference is independently a deletion, insertion, or substitution. Examples of conservative substitution include, but are not limited to, exchanges within the following groups: small aliphatic nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, Gly; polar negatively charged residues and their amides and esters: Asp, Asn, Glu, Gln, cysteine, and homocysteine; polar positively charged residues: His, Arg, Lys, ornithine (Orn); large aliphatic nonpolar residues: Met, Leu, Ile, Val, Cys, leucine (Nle), homocysteine; and large aromatic residues: Phe, Tyr, Trp, acetylphenylalanine.

[0050] In several respects, the antigen-binding protein comprises the following CDR sequences: a) vhCDR1 containing SEQ ID NO:14, vhCDR2 containing SEQ ID NO:15 or SEQ ID NO:21, and vhCDR3 containing SEQ ID NO:16; or b) vhCDR1 containing SEQ ID NO:33, vhCDR2 containing SEQ ID NO:34, and vhCDR3 containing SEQ ID NO:35. Alternatively or additionally, the antigen-binding protein comprises the following CDR sequences: a) vlCDR1 containing SEQ ID NO:11, vlCDR2 containing SEQ ID NO:12, and vlCDR3 containing SEQ ID NO:13; or b) vlCDR1 containing SEQ ID NO:30, vlCDR2 containing SEQ ID NO:32, and vlCDR3 containing SEQ ID NO:33.

[0051] Therefore, in several respects, the antigen-binding protein comprises: vhCDR1 containing SEQ ID NO:14, vhCDR2 containing SEQ ID NO:15 or SEQ ID NO:21, vhCDR3 containing SEQ ID NO:16, vlCDR1 containing SEQ ID NO:11, vlCDR2 containing SEQ ID NO:12, and vlCDR3 containing SEQ ID NO:13. Alternatively, the antigen-binding protein comprises: vhCDR1 containing SEQ ID NO:33, vhCDR2 containing SEQ ID NO:34, vhCDR3 containing SEQ ID NO:35, vlCDR1 containing SEQ ID NO:30, vlCDR2 containing SEQ ID NO:31, and vlCDR3 containing SEQ ID NO:32.

[0052] In several embodiments, the antigen-binding protein comprises a light chain variable domain containing an amino acid sequence having at least 90% identity (e.g., at least 95% or 100% identity) with SEQ ID NO:183 or SEQ ID NO:186; and / or comprises a heavy chain variable domain containing an amino acid sequence having at least 90% identity (e.g., at least 95% or 100% identity) with SEQ ID NO:182, SEQ ID NO:184, or SEQ ID NO:185. For example, the antigen-binding protein may comprise (i) SEQ ID NO:183 and SEQ ID NO:182; (ii) SEQ ID NO:184 and SEQ ID NO:183; or (iii) SEQ ID NO:185 and SEQ ID NO:186. In several respects, the antigen-binding protein comprises a light chain variable region and / or a heavy chain variable region, which contains an amino acid sequence differing from the aforementioned amino acid sequence by only 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 residue, wherein each such sequence difference is independently a deletion, insertion, or substitution (e.g., a conserved substitution). In several respects, one or more sequence differences are located outside the CDR (e.g., within the frame region).

[0053] In several embodiments, the antigen-binding protein comprises a light chain containing an amino acid sequence having at least 90% identity (e.g., at least 95% or 100% identity) with SEQ ID NO:17 or SEQ ID NO:36; and / or comprises a heavy chain containing an amino acid sequence having at least 90% identity (e.g., at least 95% or 100% identity) with SEQ ID NO:18, SEQ ID NO:199, or SEQ ID NO:37. For example, the antigen-binding protein may comprise (i) SEQ ID NO:17 and SEQ ID NO:18; (ii) SEQ ID NO:17 and SEQ ID NO:199; or (iii) SEQ ID NO:36 and SEQ ID NO:37.

[0054] In several embodiments, the antigen-binding protein comprises a light chain having an amino acid sequence having at least 90% identity (e.g., at least 95% or 100% identity) with SEQ ID NO:200 or SEQ ID NO:204; and / or comprises a heavy chain having an amino acid sequence having at least 90% identity (e.g., at least 95% or 100% identity) with SEQ ID NO:201, SEQ ID NO:203, or SEQ ID NO:205. For example, the antigen-binding protein may comprise (i) SEQ ID NO:200 and SEQ ID NO:201; (ii) SEQ ID NO:200 or SEQ ID NO:203; (iii) SEQ ID NO:204 and SEQ ID NO:205.

[0055] Competition, epitope, and cohesive affinity

[0056] The antigen-binding protein binds to STEAP1 of SEQ ID NO:2. Specific binding (i.e., binding to STEAP1 is measurably different from non-specific interactions) can be determined, for example, by measuring the binding to a molecule compared to a control molecule (which is typically a molecule with a similar structure but no binding activity). Specific binding can also be determined, for example, by competition with a target-like control molecule.

[0057] The binding affinity of an antigen-binding protein to STEAP1 can be described by a dissociation constant (Kd). In an exemplary aspect, the Kd of the antigen-binding proteins provided herein is in micromolar, nanomolar, picomolar, or femtomolar quantities. Typically, an antigen-binding protein that specifically binds to a target antigen or epitope has a Kd of 20, 50, 100, 500, 1000, 5,000, 10,000, or more times that of a control molecule. Similarly, specific binding to a particular antigen can be manifested, for example, by an antibody having an antigen or epitope KA or Ka of at least 20, 50, 100, 500, 1000, 5,000, 10,000, or more times that of a control, where KA or Ka refers to the dissociation rate of the specific antibody-antigen interaction. In an exemplary aspect, the KD of the antigen-binding protein provided herein against STEAP1 is less than or equal to 10. -7 M, less than or equal to 10 -8 M, less than or equal to 10 -9 M, less than or equal to 10 -10 M, less than or equal to 10 -11 M, or less than or equal to 10 -12 M. For example, the KD of an antigen-binding protein is optionally at about 10 -4 Up to 10-6 M, or approximately 10 -7 Up to 10 -9 M, or approximately 10 -10 Up to 10 -12 M, or approximately 10 -7 Up to 10 -12 or about 10 -9 Up to 10 -12 or about 10 -13 Up to 10 -15 Within the range of M. Alternatively (or additionally), this antigen-binding protein has a low dissociation rate with STEAP1. In some embodiments, this antigen-binding protein has K 解离 1x10 -4 s -1 Or lower. In another embodiment, K 解离 5x10 -5 s -1 Or lower. In several respects, antigen-binding proteins distinguish between target cells expressing high levels of STEAP1 and off-target cells displaying less STEAP1. For example, in several respects, antigen-binding proteins preferentially bind to cells containing more than about 100,000 STEAP receptors / cells (e.g., about 200,000 STEAP1 receptors / cells) and as low as about 10,000 STEAP1 receptors / cells. It will be understood that this disclosure regarding competition, binding affinity, and binding specificity associated with STEAP1 also applies to the binding of multispecific antigen-binding proteins to a second or third antigen (e.g., CD3) or to different antibodies used to conjugate anti-STEAP1 antigen-binding proteins. For example, in an exemplary respect, the antigen-binding proteins provided herein have a Kd of less than or equal to 10 against CD3 (or PD-1 as described below). -7 M, less than or equal to 10 -8 M, less than or equal to 10 - 9 M, less than or equal to 10 -10 M, less than or equal to 10 -11 M, or less than or equal to 10 -12 M. For example, Kd of antigen-binding proteins is optionally at about 10 -4 Up to 10 -6 M, or approximately 10 -7 Up to 10 -9 M, or approximately 10 -10 Up to 10 -12 M, or approximately 10 -7 Up to 10 -12 or about 10 -9 Up to 10 -12 or about 10 -13 Up to 10 -15Within the range of M. Alternatively (or additionally), this antigen-binding protein has a low dissociation rate with CD3. In some embodiments, the antigen-binding protein has K 解离 1x10 -4 s -1 Or lower. In another embodiment, regarding CD3, K 解离 It is 5x10 -5 s -1 Or lower.

[0058] This disclosure further provides antigen-binding proteins (e.g., antibodies) that bind to any antigen-binding protein described herein (e.g., Ab-A, Ab-A1, Ab-A2, Ab-B, or Ab-B1, including those present as described herein). XmAb2+1(Type) Competitive binding to STEAP1. In other words, this disclosure provides an antigen-binding protein that cross-blocks the binding of the reference antigen-binding protein described herein to STEAP1, or whose binding to STEAP1 is cross-blocked by the reference antigen-binding protein. The term "competitive" indicates that an antigen-binding protein prevents, reduces, or inhibits the binding of the reference antigen-binding protein to STEAP1. Many types of competitive binding assays can be used, such as surface plasmon resonance, solid-phase direct or indirect radioimmunoassay (RIA), solid-phase direct or indirect enzyme immunoassay (EIA), sandwich competitive assay (see, e.g., Stahli et al., 1983, Methods in Enzymology 9:242-253), solid-phase direct biotin-avidin EIA (see, e.g., Kirkland et al., 1986, J. Immunol 137:3614-3619), solid-phase direct labeling assay, and solid-phase direct labeling sandwich assay (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor). Press [Antibody, Laboratory Manual, Cold Spring Harbor Press]), using 1-125 labeled solid-phase directly labeled RIA (see, e.g., Morel et al., 1988, Molec. Immunol. [Molecular Immunology] 25:7-15), solid-phase direct biotin-avidin EIA (see, e.g., Cheung et al., 1990, Virology [Virusology] 176:546-552), and directly labeled RIA (Moldenhauer et al., 1990, Scand. J. Immunol. [Scandinavian Journal of Immunology] 32:77-82). Typically, this assay involves using purified antigen bound to a solid surface or exposed to cells, unlabeled test antigen-binding protein, and labeled reference antigen-binding protein. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test antigen-binding protein. Typically, the test antigen-binding protein is present in excess. Antigen-binding proteins identified by competitive assays (competitive antigen-binding proteins) include those that bind to the same epitopes as the reference antigen-binding protein (epitopes that overlap with epitopes recognized by the reference antigen-binding protein, and epitopes that do not overlap but allow steric hindrance between the test antigen-binding protein and the reference antigen-binding protein). Typically, when a competitive antigen-binding protein is present in excess, it will inhibit the binding of the reference antigen-binding protein to the common antigen by at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%.In some cases, binding is inhibited by at least 80%, 85%, 90%, 95%, or 97% or more. In at least one aspect, the antigen-binding protein (e.g., an antibody) binds to a reference antigen-binding protein (e.g., Ab-A, Ab-A1, Ab-A2, Ab-B, or Ab-B1 as described herein), optionally in a bispecific antibody form, such as the bispecific antibody form described in the examples (e.g., XmAb). 2+1 Competition reduces the binding of the reference antigen-binding protein to STEAP1 by at least 80% or at least 90%.

[0059] The antigen-binding protein binds to STEAP1 of SEQ ID NO:2. Competitive (or cross-blocking) antigen-binding proteins can bind to epitopes that overlap with those recognized by a reference antigen-binding protein, or epitopes that do not overlap but allow steric hindrance between the test antigen-binding protein and the reference antigen-binding protein. In several respects, the antigen-binding protein binds to the same epitopes as the reference antigen-binding protein, which is, for example, Ab-A, Ab-A1, Ab-A2 (N67Q), Ab-B, or Ab-B1, or its bispecific or heterodimeric forms as described herein (e.g., Ab-A1 XmAb). 2+1 Ab-A2(N67Q)XmAb 2+1 Or Ab-B1XmAb 2+1 For example, the antigen-binding protein disclosed herein optionally binds to the outer region of the second extracellular loop of STEAP1. In at least one embodiment, the antigen-binding protein binds to regions within amino acids 92-118 (extracellular loop 1) and / or amino acids 279-290 (extracellular loop 3) of STEAP1. In several aspects, this disclosure provides an antigen-binding protein that binds to regions within amino acids 92-118 and 279-290 of STEAP1. Also optionally, the antigen-binding protein does not bind to STEAP2 (UniProtKB No. Q8NFT2; SEQ ID NO: 177). If desired, epitopes of the reference antigen-binding protein and / or the test antigen-binding protein can be determined by resolving the X-ray crystal structure of the antigen-binding protein bound to STEAP1 or a portion thereof. In one such embodiment, an epitope is defined as those residues on the extracellular portion of STEAP1 to which solvent accessibility is reduced by at least 10% compared to when not bound, when the antigen-binding protein (reference antigen-binding protein or test antigen-binding protein) binds.

[0060] Methods for preparing antigen-binding proteins

[0061] Suitable methods for preparing antigen-binding proteins (e.g., antibodies, antigen-binding antibody fragments, and antibody protein products) are known in the art. For example, standard hybridoma methods for producing antibodies are described in, for instance, Harlow and Lane (eds.), Antibodies: A Laboratory Manual, CSH Press (1988); and CA. Janeway et al. (eds.), Immunobiology, 5th Ed., Garland Publishing, New York, NY (2001). EBV-hybridoma methods and phage vector expression systems are described, for example, in Haskad and Archer, J. Immunol. Methods, 74(2), 361-67 (1984); Roder et al., Methods Enzymol., 121, 140-67 (1986); and Huse et al., Science, 246, 1275-81 (1989). Methods for generating antibodies in non-human animals are described, for example, in U.S. Patent Nos. 5,545,806, 5,569,825, 5,714,352, and 5,814,318; and U.S. Patent Application Publication No. 2002 / 0197266 (all cited and incorporated herein by reference). In some aspects, recombinant antigen-binding proteins that bind STEAP1 are provided. In this context, "recombinant protein" refers to a protein prepared using recombinant technologies, such as by expressing recombinant nucleic acids. Methods and techniques for producing recombinant proteins are well known in the art.

[0062] Molecular evolution of CDRs at binding sites has also been used to generate antigen-binding proteins (e.g., antibodies) with increased affinity, such as antibodies with increased affinity for c-erbB-2 as described by Schier et al., 1996, J. Mol. Biol. [Journal of Molecular Biology] 263:551. Such techniques are useful in the preparation of anti-STEAP1 antigen-binding proteins (or other antigen-binding proteins described herein).

[0063] Methods for testing the binding ability of antigen-binding proteins to antigens (e.g., STEAP1) are known in the art and include, for example, radioimmunoassay (RIA), ELISA, Western blotting, immunoprecipitation, and surface plasmon resonance (SPR) assays. And competitive inhibition assays (see, for example, Janeway et al., hereinafter; U.S. Patent Publication No. 2002 / 0197266; ​​and U.S. Patent No. 7,872,106, the entire contents of which are incorporated herein by reference in their entirety, and particularly with respect to the disclosure of competitive assays). In fact, assays testing the ability of an antigen-binding protein to compete with a second antigen-binding protein for binding to an antigen, or to its epitope, are known in the art and can be used to test the ability of an antibody to bind to, for example, STEAP1. See, for example, U.S. Patent Application Publication No. 2014 / 0178905; Chand et al., Biologicals 46:168-171 (2017); Liu et al., Anal Biochem 525:89-91 (2017); and Goolia et al., J Vet Diagn Invest 29(2):250-253 (2017). Surface plasmon resonance can be used to determine the binding constants of antigen-binding proteins and second antigen-binding proteins, and these two binding constants can be compared.

[0064] Multispecific antigen-binding protein

[0065] A persistent problem in antibody technology is the need for bispecific (and / or multispecific) antibodies that simultaneously bind to two (or more) different antigens, typically allowing different antigens to approach and generate novel functions and therapies. This disclosure provides a novel multispecific antigen-binding protein that binds STEAP1 and one or more additional target antigens. In a preferred embodiment, this disclosure provides a novel bispecific antigen-binding protein (e.g., a bispecific antibody) comprising an anti-STEAP1 binding domain as described above and a binding region that binds to a second target antigen (which may be a different STEAP1 epitope, but is typically a different antigen). In several respects, the second antigen is a cell surface molecule present on effector cells, i.e., leukocytes expressing one or more FcRs (e.g., FcγRIII) and performing one or more effector functions attributed to the Fc region of the antibody.

[0066] Examples of effector functions include, but are not limited to, Clq binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, downregulation of cell surface receptors, and B cell activation. Examples of effector cells involved in ADCC include, but are not limited to, cytotoxic T cells, peripheral blood monocytes (PBMCs), natural killer (NK) cells, monocytes, and neutrophils. In several aspects, this disclosure provides bispecific antigen-binding proteins (e.g., bispecific antibodies) that bind both CD3 (e.g., SEQ ID NO:1) and STEAP1 (SEQ ID NO:2). In several aspects, this disclosure provides bispecific antigen-binding proteins (e.g., bispecific antibodies) that bind extracellular loops 1 and 3 of CD3 and STEAP1.

[0067] In several respects, multispecific antigen-binding proteins distinguish between target cells expressing high levels of STEAP1 and off-target cells exhibiting lower levels of STEAP1. In this regard, in some embodiments, the bispecific antigen-binding proteins disclosed herein (e.g., heterodimeric antibodies) are able to preferentially mediate T-cell-dependent killing of tumor cells, demonstrating reduced "off-target" effects. For example, in some respects, bispecific antibodies comprising the STEAP1 antigen-binding protein described herein, together with the CD3 antigen-binding region, preferentially mediate T-cell-dependent killing of cells where the surface density of STEAP1 is greater than 10,000 (e.g., EC90 is at least 10-fold lower for cells with a surface density of STEAP1 greater than 10,000 compared to cells with a surface density of STEAP1 less than 10,000).

[0068] This disclosure provides a bispecific antigen-binding protein comprising novel anti-CD3 sequences, including multiple sets of CDRs and fully variable light and heavy chains. In some aspects, the CD3-binding domain of the bispecific construct (optionally scFv as discussed below) comprises: a variable heavy chain domain containing heavy chain CDRs comprising an amino acid sequence differing from vhCDR1 SEQ ID NO:170, vhCDR2 SEQ ID NO:171, and vhCDR3 SEQ ID NO:172 by no more than 3, 2, or 1 amino acid; and a variable light chain domain containing light chain CDRs comprising an amino acid sequence differing from vlCDR1 SEQ ID NO:174, vlCDR2 SEQ ID NO:175, and vlCDR3 SEQ ID NO:176 by no more than 3, 2, or 1 amino acid. For example, this disclosure provides a multispecific (e.g., bispecific) construct comprising a variable heavy chain domain containing an amino acid sequence having at least 90% identity (e.g., at least 95% or 100% identity) with SEQ ID NO:169; and comprising a variable light chain domain containing an amino acid sequence having at least 90% identity (e.g., at least 95% or 100% identity) with SEQ ID NO:173.

[0069] For example, the anti-CD3 portion optionally includes CDR sequences comprising: vhCDR1 containing SEQ ID NO:170, vhCDR2 containing SEQ ID NO:171, vhCDR3 containing SEQ ID NO:172, vlCDR1 containing SEQ ID NO:174, vlCDR2 containing SEQ ID NO:175, and vlCDR3 containing SEQ ID NO:176. In this regard, the CD3 binding region optionally includes the variable heavy chain region of SEQ ID NO:169 and the variable light chain region of SEQ ID NO:173.

[0070] Bispecific antigen-binding proteins may contain two antigen-binding domains (e.g., each antigen is monovalently bound) or three (or more) antigen-binding domains (e.g., one antigen is bivalently bound and another is monovalently bound), such as the STEAP1 and CD3 binding domains described herein. Bispecific antibodies include, but are not limited to, conventional bispecific immunoglobulins (e.g., BsIgG); IgG containing additional antigen-binding domains (e.g., the amino or carboxyl terminus of the light or heavy chain is linked to an additional antigen-binding domain, such as a single-domain antibody or a paired antibody variable domain (e.g., Fv or scFv)); BsAb fragments (e.g., bispecific single-chain antibodies); bispecific fusion proteins (e.g., antigen-binding domains fused to the effector moiety); and BsAb conjugates. See, for example, Spiess et al., Molecular Immunology 67(2) Part A: 97-106 (2015), which describes a variety of bispecific types and is incorporated herein by reference. Examples of bispecific constructs include, but are not limited to, biantibodies, single-chain biantibodies, tandem scFvs, and Fab2 bispecific antibodies, as well as engineered constructs containing full-length antibodies. See, for example, Chames & Baty, 2009, mAbs 1[6]:1-9; and Holliger & Hudson, 2005, Nature Biotechnology 23[9]:1126-1136; Wu et al., 2007, Nature Biotechnology 25

[11] :1290-1297; Michaelson et al., 2009, mAbs 1[2]:128-141; International Patent Publication Nos. 2009032782 and 2006020258; Zuo et al., 2000, Protein Engineering 13[5]:361-367; U.S. Patent Application Publication No. 20020103345; Shen et al., 2006, J Biol Chem [Journal of Biochemistry] 281

[16] :10706-10714; Lu et al., 2005, J Biol Chem [Journal of Biochemistry] 280

[20] :19665-19672; and Kontermann, 2012 MAbs4(2):182, so these are all explicitly incorporated into this paper.

[0071] In several respects, bispecific antigen-binding proteins are bispecific single-chain antibodies (BiScFv). A light chain variable region and a heavy chain variable region are linked together to form a single chain as a first antigen-binding domain, which is optionally linked via a linker to a second antigen-binding domain having a similar structure. When a linker is used, it preferably has a length and sequence sufficient to ensure that each of the first and second antigen-binding domains can independently retain its differential binding specificity. Bispecific single-chain molecules are known in the art and are further described in U.S. Patent No. 7,635,472 and International Patent Publication No. WO. The following references are cited in full: 99 / 54440; Mack, J. Immunol. [Journal of Immunology] (1997), 158, 3965-3970; Mack, PNAS, (1995), 92, 7021-7025; Kufer, Cancer Immunol. Immunother. [Cancer Immunology and Immunotherapy], (1997), 45, 193-197; Loffler, Blood, (2000), 95, 6, 2098-2103; Bruhl, Immunol. [Immunology], (2001), 166, 2420-2426; and Kipriyanov, J. Mol. Biol. [Journal of Molecular Biology], (1999), 293, 41-56.

[0072] Alternative bispecific antigen-binding constructs are described, for example, in U.S. Patent Application Publication No. 2011 / 0054151, which is incorporated herein by reference. For example, a bispecific antigen-binding protein may comprise a mAb-Fv construct in which an IgG antibody is fused to an Fv fragment at the C-terminus. Alternatively, a mAb-Fab construct may be used in which an IgG antibody is fused to a Fab fragment at the C-terminus. The mAb-Fab construct comprises constant CH and CL domains at the C-terminus of the C-terminal Fv fusion, which is absent in mAb-Fv. See Figure 8 of U.S. Patent Application Publication No. 2011 / 0054151. Optionally, the N-terminal binding regions of the mAb-Fv and mAb-Fab constructs lack a light chain and a CH1 domain (i.e., comprise a single-domain VHH region). The mAb-Fv and mAb-Fab constructs comprise three variable regions such that they bind a first antigen bivalently and a second antigen monovalently. Suitable bispecific antigen-binding constructs also include the Fab-Fv and Fab-Fab constructs described in U.S. Patent Application Publication No. 2011 / 0054151. Fab-Fv and Fab-Fab immunoglobulins comprise an N-terminal Fab fragment that binds to a first antigen and a C-terminal Fv or Fab fragment that binds to a second antigen.

[0073] In one aspect, this disclosure addresses the generation of heterodimeric antibodies that co-link the antigen and depend on amino acid variants in different constant regions on each chain to promote heterodimer formation and / or allow for simplified purification of heterodimers compared to homodimers. Typically, bispecific antibodies are prepared by including genes for each heavy and light chain in the host cell. This usually results in the formation of the desired heterodimer (AB) and two homodimers (AA and BB). However, a major obstacle to multispecific antibody formation is the difficulty in purifying heterodimeric antibodies separately from homodimers and / or the bias in heterodimer formation compared to homodimer formation.

[0074] This disclosure provides heterodimeric antibody formulations that overcome obstacles associated with prior art. Furthermore, in the context of the STEAP1 / CD3 bispecific antigen-binding protein, the heterodimeric antibodies disclosed herein allow for monovalent binding of CD3. CD3 activation of T cells occurs only when their associated T cell receptor (TCR) is attached to the antigen-loaded MHC on the antigen-presenting cell at a highly affinity cell-cell synapse (Kuhns et al., 2006, Immunity 24:133-139). Nonspecific bivalent cross-linking of CD3 using anti-CD3 antibodies triggers cytokine storms and toxicity (Perruche et al., 2009, J Immunol 183[2]:953-61; Chatenoud and Bluestone, 2007, Nature Reviews Immunology 7:622-632; explicitly incorporated by reference). Therefore, for practical clinical applications, the preferred mode for redirecting CD3 co-activation to kill target cells is monovalent binding, which results in activation only upon binding to a co-linked target. Thus, in one embodiment, the heterodimeric antibody disclosed herein offers the advantage of monovalent binding to CD3 and bivalent binding to STEAP1 in a form that provides an effective antibody production.

[0075] An exemplary heterodimeric antibody formulation comprises a heavy chain having a single-chain Fv (scFv) and a second heavy chain in a “regular” Fab configuration (i.e., comprising a variable heavy chain and a light chain). In other words, the heterodimeric antibody comprises a) a first heavy chain comprising a first variable Fc domain and a single-chain Fv region (scFv) that binds a first antigen (optionally CD3); b) a second heavy chain comprising a second variable Fc domain and a first variable heavy chain domain; and c) a first light chain comprising a first variable light chain domain and a first constant light chain domain, wherein the first variable heavy chain domain and the first variable light chain domain bind a second antigen (optionally STEAP1). For illustration, the construct comprises: a monomer having an scFv region-domain linker-Fc domain and a second monomer having a VH-CH1-hinge-CH2-CH3 plus an associated light chain, optionally having heterodimerized variants (including spatial and pI variants), Fc and FcRn variants, and additional antigen-binding domains (with optional linkers) included in these regions. In some embodiments, the linker is a hinge region or a fragment thereof. This structure is referred to herein as the XmAb type, the "triple F" type (scFv-FAb-Fc), or the "bottle opener" type. The two chains are preferably linked together by using amino acid variants in constant regions (e.g., the Fc domain and / or hinge region) that promote the formation of heterodimer antibodies, as described in detail below. Preferably, the scFv binds CD3 and optionally includes a positively charged scFv linker. Alternatively, the scFv binds STEAP1. The “triple F” form is further described in U.S. Patent No. 9,822,186, which is incorporated herein by reference in its entirety, and particularly with respect to the disclosure of the heterodimeric antibody structure.

[0076] In another aspect, the bispecific antigen-binding protein is a heterodimeric antibody comprising a first monomer containing a first heavy chain comprising a first variable heavy chain domain, a first constant heavy chain containing a first CH1 domain and a first Fc domain, wherein the scFv comprises an scFv variable light chain domain, an scFv linker, and an scFv variable heavy chain domain. Using one or more domain linkers, the scFv is covalently attached between the C-terminus of the CH1 domain and the N-terminus of the first Fc domain, and the scFv binds to CD3. The heterodimeric antibody further comprises a second monomer containing a second heavy chain comprising a second variable heavy chain domain and a second constant heavy chain containing a second Fc domain. The heterodimeric antibody further utilizes a common light chain comprising the variable light chain domain and the constant light chain domain, which binds to the heavy chain to form two identical Fabs binding STEAP1. Due to the bivalent binding to a target antigen, this form is sometimes referred to herein as “XmAb”. 2+1"Type. Therefore, in one embodiment, the heterodimeric antibody disclosed herein provides the advantage of monovalently binding CD3 and bivalently binding STEAP1 in the form of producing an effective antibody."

[0077] As further described below, heterodimeric antibodies may also include mutations to produce skewed variants, pI variants, ablation variants, additional Fc variants, etc. For example, in several aspects, the first and second Fc domains have a set of amino acid substitutions selected from the group consisting of: S364K / E357Q:L368D / K370S; L368D / K370S:S364K; L368E / K370S:S364K; T411T / E360E / Q362E:D401K; L368D / K370S:S364K / E357L; and K370S:S364K / E357Q.

[0078] This disclosure of XmAb 2+1 A diagram of heterodimeric antibody types is provided in Figure 1 The provision of the scFv domain and two Fab moieties forms three antigen-binding domains, wherein the Fab moieties of two monomers bind STEAP1, and the scFv domain binds CD3. The scFv domain is inserted between the Fc domain and the CH1-Fv region of one of these monomers.

[0079] Heterodimeric antibodies are preferably of the IgG class, which has several subclasses, including but not limited to IgG1, IgG2, IgG3, and IgG4, although IgM, IgD, IgG, IgA, and IgE are also considered. It should be understood that antibodies may also comprise hybrids of isotypes and / or subclasses. For example, the pI engineering of an IgG1 / G2 hybrid as shown in U.S. Patent Publication No. 2009 / 0163699 (incorporated by reference) is considered as part of this disclosure.

[0080] Numerous mechanisms exist that can be used to generate the heterodimers disclosed herein. Furthermore, as those skilled in the art will understand and which are described more fully below, these mechanisms can be combined to ensure high heterodimerization.

[0081] Alternatively, a mechanism commonly referred to in the art as “knobs and holes” (“KIH”) can be used, which refers to the engineering of amino acids that produce spatial effects to promote heterodimer formation and discourage homodimer formation; this is sometimes referred to as “knobs and holes”, as described in U.S. Patent Publication No. 20130205756, Ridgway et al., Protein Engineering 9(7):617(1996); Atwell et al., J. Mol. Biol. 1997 270:26; and U.S. Patent No. 8,216,805, all of which are incorporated herein by reference in their entirety, particularly concerning the disclosure of heterodimer antibody production. Furthermore, as described in Merchant et al., Nature Biotech 16:677(1998), these “knobs and holes” mutations can combine with disulfide bonds to induce skewed heterodimerization. Examples of mutations include T366S / L368A / Y407V paired with T366W, and the variant with a bridging disulfide, T366S / L368A / Y407V / Y349C paired with T366W / S354C, particularly in combination with other heterodimerized variants, including the pi variants outlined below.

[0082] Another mechanism for generating heterodimers has been discovered, sometimes referred to as “electrostatic reversal,” as described in Gunasekaran et al., J. Biol. Chem. 285(25):19637 (2010), which is incorporated herein by reference in its entirety. This is sometimes referred to herein as a “charge pair.” In this embodiment, electrostatics are used to induce the formation of a skewed heterodimer. As those skilled in the art will understand, these may also affect the pI and therefore the purification, and thus pI variants may also be considered in some cases. However, since these are generated to force heterodimerization and are not used as purification tools, they are classified as “spatial variants.” These include, but are not limited to, D221E / P228E / L368E, paired with D221R / P228R / K409R (i.e., these are monomeric counterparts); and C220E / P228E / 368E, paired with C220R / E224R / P228R / K409R. In some embodiments of the frame region, the position 220 mutation removes cysteine ​​residues that are no longer necessary for the formation of heavy and light chain disulfides. "Spatial variants" are optional embodiments of this disclosure.

[0083] Several mechanisms can lead to simplified purification of heterodimeric proteins; one relies on the use of pI variants, such that each monomer has a different pI, thus allowing isoelectric purification of AA, AB, and BB dimer proteins. Alternatively, separation can be based on size. It is also possible to “skew” the formation of heterodimers relative to homodimers, as generally outlined below. Therefore, combinations of spatially heterodimerized variants and pI or charge-pair variants can be used in the context of this disclosure. Additionally, scFv can include charged scFv linkers (positively or negatively charged), providing further pI enhancement for purification purposes. As those skilled in the art will understand, some triplet F-types (having only charged scFv linkers and no additional pI modulation) are useful, although the invention also does provide the use of skewed variants with charged scFv linkers (and combinations of the Fc, FcRn, and KO variants described herein).

[0084] In embodiments utilizing pI as a separation mechanism, amino acid variants can be introduced into one or both of the monomeric peptides; that is, the pI of one of the monomers (hereinafter referred to as "monomer A") can be engineered away from monomer B, or both monomers A and B can be altered, wherein the pI of monomer A is increased and the pI of monomer B is decreased. The pI changes of any one or both monomers can be accomplished by removing or adding charged residues (e.g., replacing a neutral amino acid with a positively or negatively charged amino acid residue, such as replacing glycine with glutamic acid), changing charged residues from positive or negative to opposite charges (aspartic to lysine), or changing charged residues to neutral residues (e.g., loss of charge; lysine to serine). Additionally, suitable pI variants for use in generating the heterodimeric antibodies described herein are those variants of the same type, such as introducing pI variants from different IgG isotypes, such that the pI is altered without introducing significant immunogenicity; see Figure 29 from U.S. Patent Publication No. 20140288275, the entire contents of which are incorporated herein by reference.

[0085] Therefore, the embodiments provide sufficient variation in generating pI within at least one monomer to allow the heterodimer to be separated from the homodimer. This can be achieved by using a "wild-type" heavy chain constant region and a variant region engineered to increase or decrease its pI (wt A-+B or wt A--B), or by increasing one region and decreasing others (A+-B- or A-B+). It should be noted that in this discussion, it is irrelevant which monomer contains scFv and which Fab contains scFv. A schematic diagram relating to the use of pI variants is shown in Figure 34 of U.S. Patent No. 9,822,186 (incorporated herein by reference in its entirety, particularly concerning the discussion of heterodimer antibody variants and anti-CD3 sequences). pI variants can be combined with skewed variants in a "plug and play" manner because the effects of these variants are readily transferable to different antibodies with different Fv regions and are very stable.

[0086] Therefore, aspects of this disclosure typically include amino acid variants in the constant region of an antibody, which are directed to alter the isoelectric point (pI) of at least one (if not two) antibody monomers by incorporating amino acid substitutions (“pI variants” or “pI substitutions”) into one or two monomers to form a “pI heterodimer” (i.e., a “pI antibody”). The heterodimer can be separated from two homodimers if the pIs of the two monomers differ by as little as 0.1 pH units (e.g., 0.2, 0.3, 0.4, and 0.5 pH or greater).

[0087] To achieve good separation, the number of pI variants included on each or both monomers will depend in part on the starting pI of one or more scFvs and Fabs. That is, to determine the monomer to be engineered or the "direction" (e.g., more positive or more negative), the Fv sequences of the two target antigens are calculated and the decision is made accordingly. As is known in the art, different Fvs will have different starting pIs to be developed and utilized. Typically, pIs are engineered to result in a total pI difference of at least about 0.1 log for each monomer, preferably 0.2 to 0.5.

[0088] Furthermore, in some cases (depending on the type), heterodimers can be separated from homodimers based on size (e.g., molecular weight). For example, as shown in some embodiments of Figures 18A-I, some types form homodimers and heterodimers of different sizes (e.g., for a bottle opener, one homodimer is a "double scFv" type, one homodimer is a standard antibody, and the heterodimer has one Fab and one scFv). Additionally, as shown in Figures 18A-I, it is possible for some antigens to bind bivalently (e.g., two antigen-binding sites bind to a single antigen). As will be understood, any combination of Fab and scFv can be used to achieve desired results and combinations.

[0089] In the case of heterodimerization using pI variants, a more modular approach to designing and purifying multispecific proteins (including antibodies) is provided by using constant regions of one or more heavy chains. Therefore, in some embodiments, heterodimerization variants (including skewed and purified heterodimerization variants) are not included in the variable region, making it necessary to engineer each individual antibody. Additionally, in some embodiments, the likelihood of immunogenicity induced by the pI variant is significantly reduced by introducing pI variants from different IgG isotypes, allowing the pI to be altered without introducing significant immunogenicity. Therefore, another problem to be addressed is to elucidate low pI constant domains with high human sequence content, e.g., minimizing or avoiding non-human residues at any particular position.

[0090] Collateral benefits that may arise from pI engineering include prolonged serum half-life and increased FcRn binding. Specifically, as described in U.S. Patent Publication No. 20120028304 (incorporated herein by reference in its entirety), reducing the pI for antibody constant domains (including those found in antibody-Fc fusions) can lead to longer serum retention in vivo. These pI variants designed to increase serum half-life also facilitate changes in pI used for purification.

[0091] The heterodimeric fusion proteins disclosed herein can exhibit various conformations, as generally shown in Figures 18A-I. Some figures depict “single-end” conformations, where one type of specificity exists on one “arm” of the molecule, while different types of specificity exist on the other “arms.” Other figures depict “double-end” conformations, where at least one type of specificity exists on the “top” of the molecule, and one or more different types of specificity exist on the “bottom” of the molecule. One type of heterodimeric scaffold that can be used in this disclosure is the “triple F” or “opener” scaffold type shown in Figure 18A and described above. The “triple F” type has several distinct advantages. Antibody analogs that rely on two scFv constructs typically have stability and aggregation problems, which can be mitigated by adding “conventional” heavy and light chain pairings to the constructs described herein. In addition, unlike types that rely on two heavy chains and two light chains, incorrect pairing of heavy and light chains (e.g., heavy 1 paired with light 2, etc.) does not cause problems. Other useful antigen-binding protein types are described below.

[0092] In several aspects, the scFv of the heterodimeric antibody comprises the anti-CD3CDR sequence described herein. For example, in several aspects, the scFv comprises: vhCDR1 containing SEQ ID NO:170, vhCDR2 containing SEQ ID NO:171, vhCDR3 containing SEQ ID NO:172, vlCDR1 containing SEQ ID NO:174, vlCDR2 containing SEQ ID NO:175, and vlCDR3 containing SEQ ID NO:176. For example, the scFv optionally comprises the variable heavy chain region of SEQ ID NO:169 and the variable light chain region of SEQ ID NO:173. In several aspects, the scFv comprises the sequence of SEQ ID NO:44.

[0093] In some embodiments, scFv includes Figure 19 The amino acid sequences listed, such as those listed in SEQ ID NO:44. Figure 19 The sequences listed provide antigen-binding domains with different affinities. In some indications, stronger affinity may be preferred, while in others, lower affinity may be used. Thus, in some embodiments, this disclosure provides heterodimeric antibodies comprising anti-CD3 antigen-binding domains that are “strong” or “high-affinity” binders of CD3 (e.g., one example is a heavy and light variable domain depicted as H1.30_L1.47 (optionally including a suitable charged linker)). In other embodiments, this disclosure provides heterodimeric antibodies comprising anti-CD3 antigen-binding domains that are “light” or “low-affinity” binders of CD3.

[0094] Typical scFv linkers are well known in the art and are generally 10 to 25 amino acids in length, including glycine and serine. The term "charged scFv linker" refers to an scFv linker utilizing charged amino acids for use in the production and purification of heterodimeric antibodies containing at least one scFv. Suitable charged scFv linkers are shown in [the diagram / illustration]. Figure 8A , 8B In 19, although others may also be used. Typically, such as with standard uncharged SCFV connectors (e.g., the traditionally used (GGGGS)). 3-5Compared to the (SEQ ID NO:179) sequence, the charged scFv connector intended for use in the context of this disclosure is expected to have a charge variation (negative or positive charge) of 3 to 8 (3, 4, 5, 6, 7, or 8 are all possible). The charged scFv optionally contains an amino acid sequence selected from: IRRRAIGGSKPRVA (SEQ ID NO: 145), GKGGSGKGGSGKGGS (SEQ ID NO: 146), GGKGSGGKGSGGKGS (SEQ ID NO: 147), GGGKSGGGKSGGGKS (SEQ ID NO: 148), GKGKSGKGKSGKGKS (SEQ ID NO: 149), GGGKSGGKGSGKGGS (SEQ ID NO: 150), GKPGSGKPGSGKPGS (SEQ ID NO: 151), GKPGSGKPGSGKPGSGKPGS (SEQ ID NO: 152), or GKGKSGKGKSGKGKSGKGKS (SEQ ID NO: 153). In several aspects, the scFv contains the amino acid sequence GKPGSGKPGSGKPGSGKPGS (SEQ ID NO: 152).

[0095] In an exemplary aspect, scFv comprises a CDR sequence that is identical to one or more of the sequences provided herein (e.g., SEQ ID NO: 4-6, 8-10, 11-17, 21, 23-25, 27-29, 30-35, 170-173, and 174-176); SEQ ID Variable region sequences of any one or more of SEQ ID NO: 3, 7, 22, 26, 41, 42, 45, 46, 49, 50, 53, 54, 57, 58, 61, 62, 65, 66, 69, 70, 73, 74, 77, 78, 81, 82, 85, 86, 89, 90, 93, 94, 97, 98, 101, 102, 105, 106, 109, 110, 113, 114, 117, 118, 121, 122, 125, 126, 129, 130, 133, 134, 137, 138, 141, 142, 169, 173, and 182-186; scFv connector sequences of any one of SEQ ID NO: 143-168; and / or SEQ ID NO:19, 20, 38, 40, 43, 44, 47, 48, 51, 52, 55, 56, 59, 60, 63, 64, 67, 68, 71, 72, 75, 76, 79, 80, 83, 84, 87, 88, 91, 92, 95, 96, 99, 100, 104, 104, 107, 108, 111, 112, 115, 116, 119, 120, 123, 124, 127, 128, 1 The scFv sequence of any one of SEQ ID NO: 31, 132, 135, 136, 139, and 140 has at least about 70%, at least about 80%, at least about 85%, at least about 90%, or has more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) sequence identity, a CDR sequence, a variable region sequence, an scFv adapter sequence, or an scFv sequence. For example, the scFv may contain a CDR sequence as listed in any one or more of SEQ ID NO: 4-6, 8-10, 11-17, 21, 23-25, 27-29, 30-35, 170-173, and 174-176, but contains one or two amino acid substitutions.Alternatively, in several aspects, the scFv may contain variable region sequences that are modified with respect to SEQ ID NO:3, 7, 22, 26, 41, 42, 45, 46, 49, 50, 53, 54, 57, 58, 61, 62, 65, 66, 69, 70, 73, 74, 77, 78, 81, 82, 85, 86, 89, 90, 93, 94, 97, 98, 101, 102, 105, 106, 109, 110, 113, 114, 117, 118, 121, 122, 125, 126, 129, 130, 133, 134, 137, 138, 141, 142, 169, 173, or 182-186, wherein these modifications are outside the CDR sequence.

[0096] In several aspects, the first and second variable heavy chain domains of the heterodimeric antibody comprise the anti-STEAP1 CDR or variable region sequence described herein. For example, in some embodiments, the first and second variable heavy chain domains of the heterodimeric antibody comprise: vhCDR1 containing SEQ ID NO:14, vhCDR2 containing SEQ ID NO:15 or SEQ ID NO:21, and vhCDR3 containing SEQ ID NO:16; and the variable light chain domain comprises: vlCDR1 containing SEQ ID NO:11, vlCDR2 containing SEQ ID NO:12, and vlCDR3 containing SEQ ID NO:13. Alternatively, the first and second variable heavy chain structural domains comprise: vhCDR1 containing SEQ ID NO:33, vhCDR2 containing SEQ ID NO:34, and vhCDR3 containing SEQ ID NO:35; and the variable light chain structural domain comprises: vlCDR1 containing SEQ ID NO:30, vlCDR2 containing SEQ ID NO:31, and vlCDR3 containing SEQ ID NO:32. In a preferred embodiment, the first and second variable heavy chain structural domains comprise SEQ ID NO:182 or SEQ ID NO:184, and the variable light chain structural domain comprises SEQ ID NO:183. Alternatively, the first and second variable heavy chain structural domains comprise SEQ ID NO:185, and the variable light chain structural domain comprises SEQ ID NO:186.

[0097] In several aspects of this disclosure, the heterodimer antibody comprises a) a first monomer containing the sequence of SEQ ID NO:19 or 20, a second monomer containing the sequence of SEQ ID NO:18, and a common light chain containing the sequence of SEQ ID NO:17; or b) a first monomer containing the sequence of SEQ ID NO:38, a second monomer containing the sequence of SEQ ID NO:37, and a common light chain containing the sequence of SEQ ID NO:36.

[0098] In several aspects of this disclosure, the heterodimeric antibody comprises: a first monomer containing the sequence of SEQ ID NO:202 or 207, a second monomer containing the sequence of SEQ ID NO:201 or 203, and a common light chain containing the sequence of SEQ ID NO:200 (e.g., a first monomer containing the sequence of SEQ ID NO:202, a second monomer containing the sequence of SEQ ID NO:201, and a light chain containing the sequence of SEQ ID NO:200; or a first monomer containing the sequence of SEQ ID NO:207, a second monomer containing the sequence of SEQ ID NO:203, and a light chain containing the sequence of SEQ ID NO:200). Alternatively, the heterodimeric antibody may comprise: a first monomer containing the sequence of SEQ ID NO:206, a second monomer containing the sequence of SEQ ID NO:205, and a common light chain containing the sequence of SEQ ID NO:204.

[0099] In an exemplary aspect, the first and / or second variable heavy chain domain may comprise a CDR sequence consistent with the sequences provided herein (e.g., any one or more of SEQ ID NO:4-6, 14-17, 21, 23-25, 33-35, and 170-172; or SEQ ID NO:4-6, 14-17, 21, 23-25, 33-35, and 170-172); or SEQ ID NO:4-6, 14-17, 21, 23-25, 33-35, and 170-172). CDR sequences or variable region sequences of any one of the following NO:3, 22, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 105, 109, 113, 117, 121, 125, 129, 133, 137, 141, 169, 182, 184, and 185, having at least about 70%, at least about 80%, at least about 85%, at least about 90%, or having more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) sequence identity. For example, the first and / or second variable heavy chain domain may contain CDR sequences as listed in any one or more of SEQ ID NO:4-6, 14-17, 21, 23-25, 33-35, and 170-172, but with one or two amino acid substitutions. Alternatively, in several aspects, the first and / or second variable heavy chain domain may contain variable region sequences that are modified with respect to SEQ ID NO:3, 22, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 105, 109, 113, 117, 121, 125, 129, 133, 137, 141, 169, 182, 184, or 185, wherein these modifications are outside the CDR sequence. Similarly, in several respects, the variable light chain domain may contain CDR sequences similar to those provided herein (e.g., any one or more of SEQ ID NO: 8-10, 11-13, 27-29, 30-32, and 174-176; or SEQ ID NO: 8-10, 11-13, 27-29, 30-32, and 174-176); or SEQ ID NO: 8-10, 11-13, 27-29, 30-32, and 174-176). A CDR sequence or variable region sequence having at least about 70%, at least about 80%, at least about 85%, at least about 90%, or more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) sequence identity among any of the variable region sequences of IDNO: 7, 26, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 96, 98, 99)For example, the variable light chain domain may contain CDR sequences as listed in any one or more of SEQ ID NO:8-10, 11-13, 27-29, 30-32, and 174-176, but with one or two amino acid substitutions. Alternatively, in several aspects, the variable light chain domain may contain variable region sequences that are modified with respect to SEQ ID NO:7, 26, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, 94, 98, 102, 106, 110, 114, 118, 122, 126, 130, 134, 138, 142, 173, 183, or 186, wherein these modifications are outside the CDR sequence. If desired, the first monomer may comprise an amino acid sequence having at least about 70%, at least about 80%, at least about 85%, at least about 90%, or having more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) sequence identity with any of the sequences provided herein (SEQ ID NO: 18, 199, or 37; or SEQ ID NO: 19, 20, 38, 202, 206, or 207); the second monomer may comprise an amino acid sequence having at least 70%, at least about 80%, at least about 85%, at least about 90%, or having more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) sequence identity with any of the sequences provided herein (SEQ ID NO: 18, 199, or 37; or SEQ ID NO: 19, 20, 38, 202, 206, or 207); Any one of the sequences (SEQ ID NO: 202, 207, or 206) having at least about 70%, at least about 80%, at least about 85%, at least about 90%, or having more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) sequence identity with the sequence provided herein (SEQ ID NO: 17, 36, 200, or 204) having at least about 70%, at least about 80%, at least about 85%, at least about 90%, or having more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) sequence identity with the sequence provided herein.

[0100] In some embodiments, full-length heterodimeric antibodies are used. "Full-length" refers to the structure of the native biological form constituting the antibody, including variable and constant regions, including one or more modifications as outlined herein. The heterodimeric antibodies disclosed herein can be monoclonal, synthetic, chimeric, and / or humanized. In the context of a heterodimeric antibody, the antigen-binding antibody fragment contains at least one constant domain that can be engineered to produce a heterodimer (e.g., pI-engineered). Other antibody fragments include fragments containing one or more of the CH1, CH2, CH3, hinge, and CL domains of the present invention that have been pI-engineered. For example, an Fc fusion is a fusion of the Fc region (CH2 and CH3, optionally having a hinge region) fused to another protein. Many Fc fusions are known in the art and can be improved by adding heterodimeric variants of the present invention. Antibody fusions comprising CH1; CH1, CH2 and CH3; CH2; CH3; CH2 and CH3; CH1 and CH3 can be prepared, wherein any or all of them may optionally be used with the hinge region, utilizing any combination of heterodimerized variants described herein.

[0101] The antigen-binding proteins disclosed herein (including heterodimeric antibodies) are typically isolated or recombinant. The nucleic acids, vectors, and host cells encoding all or part of the heterodimeric antibodies described herein are described herein and are intended to be part of this disclosure.

[0102] Antibody structure / Fc region modification

[0103] This disclosure includes antibodies with modified Fc variants having amino acid modifications relative to the wild-type antibody sequence. These variants are defined according to the amino acid modifications that constitute them. Thus, for example, N434S or 434S is an Fc variant with a substituted serine at position 434 relative to the parental Fc polypeptide, where the substitution is based on the EU index number. Similarly, M428L / N434S defines an Fc variant with substitutions for both M428L and N434S relative to the parental Fc polypeptide. The identity of wild-type amino acids may be unspecified, in which case the aforementioned variant is referred to as 428L / 434S. The order of substitutions provided is arbitrary, i.e., for example, 428L / 434S is the same Fc variant as M428L / N434S, and so on. Modifications may be additions, deletions, or substitutions. Substitutions may include naturally occurring amino acids and, in some cases, may include synthetic amino acids. Examples include U.S. Patent No. 6,586,207; U.S. Patent Publication No. 20040214988; International Patent Publications Nos. WO 98 / 48032, WO 03 / 073238, WO 05 / 35727A2, and WO 05 / 74524A2; JWChin et al., (2002), Journal of the American Chemical Society, 124:9026-9027; JWChin and PGSchultz, (2002), ChemBioChem, 11:1135-1137; JWChin et al., (2002), PICAS United States of America [PICAS United States of America] 99:11020-11024; and L. Wang and PGSchultz, (2002), Chem. 1-10, are incorporated in full by reference.

[0104] For all positions relating to antibodies and other antigen-binding proteins discussed in this disclosure, unless otherwise indicated, amino acid position numbering is based on the EU index. The EU index, or as in the Kabat or EU numbering scheme, refers to the number of the EU antibody (Edelman et al., 1969, Proc Natl Acad Sci USA [Proceedings of the National Academy of Sciences] 63:78-85, the full text of which is incorporated herein by reference). For example, it should be understood that each variable heavy chain region (VH) and variable light chain region (VL) consists of three hypervariable regions (“complementarity-determining regions”, “CDRs”) and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Hypervariable regions typically encompass amino acid residues from approximately 24 to 34 (LCDR1; "L" indicates light chain), 50 to 56 (LCDR2), and 89 to 97 (LCDR3) in the light chain variable region, and approximately 31 to 35B (HCDR1; "H" indicates heavy chain), 50 to 65 (HCDR2), and 95 to 102 (HCDR3) in the heavy chain variable region; Kabat et al., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 5th Ed. Public Health Service, National Institutes of Health. Health, [Sequences of Immunologically Targeted Proteins, 5th Edition, Public Health Service, National Institutes of Health], Bethesda, MD (1991) and / or those residues forming the hypervariable ring (e.g., residues 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3) in the light chain variable region and 26-32 (HCDR1), 53-55 (HCDR2), and 96-101 (HCDR3) in the heavy chain variable region; Chothia and Lesk (1987) J. Mol. Biol. [Journal of Molecular Biology] 196:901-917).

[0105] As will be understood by those skilled in the art, the exact numbering and placement of CDRs may differ between different numbering systems. However, it should be understood that the disclosure of variable heavy chain and / or variable light chain sequences includes the disclosure of the associated (inherent) CDR. Therefore, the disclosure of each variable heavy chain region is the disclosure of vhCDRs (e.g., vhCDR1, vhCDR2, and vhCDR3), and the disclosure of each variable light chain region is the disclosure of vlCDRs (e.g., vlCDR1, vlCDR2, and vlCDR3). A useful comparison of CDR numbering is provided below, see Lafranc et al., Dev. Comp. Immunol. [Developmental and Comparative Immunology] 27(l):55-77 (2003):

[0106]

[0107] Throughout the specification, when referring to residues in the variable domains (approximately residues 1-107 in the light chain variable region and residues 1-113 in the heavy chain variable region), the Kabat numbering system is generally used (e.g., Kabat et al., ibid. (1991)).

[0108] The carboxyl terminus of each chain defines a constant region, primarily responsible for effector functions. Kabat et al. collected numerous primary sequences of the variable regions of the heavy and light chains. Based on the degree of sequence conservation, they classified the individual primary sequences into CDRs and frames and made a list of them (see SEQUENCES OF IMMUNOLOGICAL INTEREST, 5th edition, NIH publication, No. 91-3242, E.A. Kabat et al., incorporated in full by reference).

[0109] Within the IgG subclass of immunoglobulins, several immunoglobulin domains exist within the heavy chain. The term "immunoglobulin (Ig) domain" is used herein to denote immunoglobulin regions with different tertiary structures. Of particular interest are the heavy chain domains, including the constant heavy chain (CH) domain and the hinge domain. In the context of IgG antibodies, each IgG isotype possesses three CH regions. Therefore, the "CH" domains in the IgG context are as follows: "CH1" refers to positions 118-220 according to the EU index as in Kabat; "CH2" refers to positions 237-340 according to the EU index as in Kabat; and "CH3" refers to positions 341-447 according to the EU index as in Kabat. As shown herein and described below, these pI variants may reside in one or more of the CH regions discussed below, as well as in the hinge region. In several respects, the sequences described herein begin with the CH1 region, position 118; variable regions are excluded unless otherwise stated.

[0110] Another type of heavy chain Ig domain is the hinge region. The terms "hinge," "hinge region," "antibody hinge region," or "immunoglobulin hinge region" used herein refer to a flexible polypeptide containing amino acids between the first and second constant domains of an antibody. Structurally, the IgG CH1 domain terminates at EU position 220, and the IgG CH2 domain begins at residue EU position 237. Therefore, for IgG, the antibody hinge is defined herein as encompassing positions 221 (D221 in IgG1) through 236 (G236 in IgG1), where this numbering is based on EU indexing as in Kabat. In some embodiments, such as in the context of the Fc region, a lower hinge is included, where "lower hinge" generally refers to position 226 or 230. As described herein, pI variants can also be prepared within the hinge region.

[0111] The term "Fc," "Fc region," or "Fc domain," as used herein, refers to a polypeptide containing an antibody constant region that does not include the first constant region immunoglobulin domain and, in some cases, a portion of the hinge. Therefore, Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge at the N-terminus of these domains. For IgA and IgM, Fc may include a J-chain. For IgG, the Fc domain contains the lower hinge region between the immunoglobulin domains Cγ2 and Cγ3 and between Cγ1 and Cγ2. Although the boundaries of the Fc region can vary, the human IgG heavy chain Fc region is generally defined as including residues C226 or P230 at its carboxyl terminus, numbered according to the EU index as in Kabat.

[0112] Amino acid variants can be introduced into the antigen-binding proteins disclosed herein (e.g., bispecific antibodies) to add additional functionality. For example, amino acid changes within the Fc region (for one monomer or both) can be added to promote increased ADCC or CDC (e.g., altered binding to the Fcγ receptor) to allow or increase the yield of added toxins and drugs (e.g., for ADCs), as well as to increase binding to FcRn and / or increase the serum half-life of the resulting molecule. Effector functions that can be regulated by altering the amino acid sequence include, but are not limited to, ADCC, ADCP, and CDC. Any and all variants outlined herein can be optionally and independently combined with other variants.

[0113] The term "FcRn" or "neonatal Fc receptor" refers to a protein that binds to the Fc region of an IgG antibody and is at least partially encoded by the FcRn gene. FcRn can originate from any organism, including but not limited to humans, mice, rats, rabbits, and monkeys. As is known in the art, a functional FcRn protein comprises two polypeptides, commonly referred to as a heavy chain and a light chain. The light chain is β-2-microglobulin, and the heavy chain is encoded by the FcRn gene. Unless otherwise stated herein, FcRn or FcRn protein refers to the complex of the FcRn heavy chain and β-2-microglobulin. Various FcRn variants are used to increase binding to the FcRn receptor and, in some cases, to increase serum half-life. Fc variants conferring increased binding to the FcRn receptor and a correspondingly increased serum half-life include, but are not limited to, 434A, 434S, 428L, 308F, 259I, 428L / 434S, 259I / 308F, 436I / 428L, 436I or V / 434S, 436V / 428L, 252Y, 252Y / 254T / 256E, and 259I / 308F / 428L. For clarity, FcRn variants (and Fc variants) may be present on one or two monomers due to differences in each heavy chain.

[0114] Another category of functional variants is the “Fcγ ablation variant” or “Fc knockout (FcKO or KO) variant.” In these embodiments, for some therapeutic applications, it is desirable to reduce or eliminate the normal binding of the Fc domain to one or more Fcγ receptors (e.g., FcγR1, FcγRIIa, FcγRIIb, FcγRIIIa, etc.) to avoid additional mechanisms of action. The terms “Fcγ receptor,” “FcγR,” or “FcgammaR” are used to denote any member of the protein family that binds to the Fc region of an IgG antibody and is encoded by the FcγR gene. In humans, this family includes, but is not limited to, FcγRI (CD64), including allotypes FcγRIa, FcγRIb, and FcγRIc; FcγRII (CD32), including allotypes FcγRIIa (including allotypes H131 and R131), FcγRIIb (including FcγRIIb-1 and FcγRIIb-2), and FcγRIIc; and FcγRIII (CD16), including allotypes FcγRIIIa (including allotypes V158 and F158) and FcγRIIIb (including allotypes FcγRIIb-NA1 and FcγRIIb-NA2) (Jefferis et al., 2002, Immunol Lett [Immunology Communications] 82:57-65, incorporated herein by reference in its entirety). FcγR can originate from any organism, including but not limited to humans, mice, rats, rabbits, and monkeys. Mouse FcγRs include, but are not limited to, FcγRI (CD64), FcγRII (CD32), FcγRIII (CD16), and FcγRIII-2 (CD16-2). In many embodiments, ablation of FcγRIIIa binding is typically required to eliminate or significantly reduce ADCC activity. Figure 36 of U.S. Patent No. 9,822,186 illustrates the use of an Fc knockout (or ablation variant) that preserves wild-type stability but removes all FcγR bindings.

[0115] Representative ablation variants include those selected from the group consisting of: G236R / L328R, E233P / L234V / L235A / G236del / S239K, E233P / L234V / L235A / G236del / S267K, E233P / L234V / L235A / G236del / S239K / A327G, E233P / L234V / L235A / G236del / S267K / A327G, and E233P / L234V / L235A / G236del. It should be noted that the ablation variants cited herein ablate FcyR binding, but generally do not eliminate FcRn binding.

[0116] As is known in the art, the Fc domain of human IgG1 has the highest binding affinity to the Fγ receptor, and therefore, when the constant domain (or Fc domain) in the heterodimeric antibody backbone is IgG1, an ablation variant can be used. Alternatively, or in addition to an ablation variant in the IgG1 background, for example, a mutation at glycosylation position 297 (typically A or S) can significantly ablate binding to FcγRIIIa. Human IgG2 and IgG4 have naturally reduced binding affinity to the Fcγ receptor, therefore these backbones can be used with or without an ablation variant.

[0117] Deamidation can severely affect antibody activity and stability. In several respects, heterodimeric antibodies contain one or more substitutions to remove the deamidation site. In this regard, heterodimeric antibodies optionally contain a substitution at position N67, such as substitution at N67Q.

[0118] Heterodimer heavy chain constant region

[0119] This disclosure provides heterodimeric antibodies based on monomers containing a variable heavy chain constant region as the first domain. The term "monomer" is used herein to refer to half of a heterodimeric protein. It should be noted that conventional antibodies are actually tetramers (two heavy chains and two light chains). For ease of reference, in the context of this disclosure, a pair containing both heavy and light chains is considered a "monomer." The heavy chain region containing the scFv (and in some cases, Fab) is considered a monomer. Essentially, each monomer contains a sufficient heavy chain constant region to allow for heterodimer engineering (whether the entire constant region, such as CH1-hinge-CH2-CH3, the Fc region (CH2-CH3), or only the CH3 domain).

[0120] These variable heavy chain constant regions may contain all or part of the heavy chain constant region, including full-length constructs, CH1-hinge-CH2-CH3, or portions thereof, including, for example, CH2-CH3 or CH3 alone. Additionally, the heavy chain region of each monomer may be the same backbone (CH1-hinge-CH2-CH3 or CH2-CH3) or different. N-terminal and C-terminal truncation and addition are also included in the definition; for example, some pI variants include the addition of charged amino acids to the C-terminus of the heavy chain domain.

[0121] In addition to the heterodimerization variants (e.g., steric variants and pI variants) outlined in this article, these heavy chain regions may also contain additional amino acid substitutions, including variations to alter the binding of FcγR and FcRn.

[0122] Heterodimerization variants include many different types of variants, including but not limited to spatial variants (including charged variants) and pI variants, which can optionally and independently be combined with any other variants. In these embodiments, it is important to match “monomer A” with “monomer B”; that is, if the heterodimeric protein depends on both the spatial variant and the pI variant, these need to be correctly matched with each monomer. For example, an effective set of spatial variants (one set on monomer A, one set on monomer B) combined with a pI variant (one set on monomer A, one set on monomer B) such that these variants on each monomer are designed to achieve the desired function. In cases where, for example, the spatial variant can also change the charge, the correct set must match the correct monomer.

[0123] The heterodimerization variants outlined in this article (e.g., including but not limited to those shown in the figures) can optionally and independently combine with any other variant and on any other monomer. It is important for heterodimerization to have “groups” of variants, one group targeting one monomer and another group targeting another. Whether these are combined one-to-one (e.g., a list of monomer 1 can be together) or transposed (monomer 1 pI variant with monomer 2 spatial variant) is irrelevant. However, when combining as outlined above, “strandedness” should be preserved so that heterodimerization is advantageous; for example, a charged variant with increased pI should be used with a variant with increased pI and / or an scFv linker with increased pI, etc. By referring to “strandedness” in the context of heterodimeric protein monomers, similar to two “matching” DNA strands, incorporating heterodimerization variants into each monomer preserves the ability to “match” and thus form a heterodimer. For example, if some pI variants are engineered into monomer A (e.g., to make the pI higher), spatial variants (which are "charge pairs") that do not interfere with the pI variants can also be used, for example, placing the charged variants that make the pI higher on the same "chain" or "monomer" to maintain both functionalities. Furthermore, for additional Fc variants (e.g., FcγR-binding, FcRn-binding, ablation variants, etc.), the monomer or two monomers can independently and optionally include any of the listed variants. In some cases, both monomers have additional variants, and in some cases, only one monomer has additional variants, or they can be combined.

[0124] Spatial variants

[0125] In some embodiments, the formation of heterodimers is promoted by adding spatial variants. That is, by changing the amino acids in each heavy chain, different heavy chains are more likely to combine to form a heterodimeric structure rather than a homodimer with the same Fc amino acid sequence. Representative suitable spatial variants are shown in the figure.

[0126] One mechanism used to generate spatial variants is the aforementioned "mortar and pestle" mechanism. Another mechanism for generating heterodimers has been found, sometimes referred to as "electrostatic turning," as described in Gunasekaran et al., J. Biol. Chem. 285(25):19637 (2010), which is incorporated herein by reference in its entirety. This is sometimes referred to herein as a "charge pair." In this example, electrostatics are used to induce the formation of skewed heterodimers. These may also affect pI and therefore purification, and thus pI variants may also be considered in some cases. However, since these are generated to force heterodimerization and are not used as purification tools, they are classified as "spatial variants." These include, but are not limited to, variants that result in heterodimerization of more than 75%, such as D221E / P228E / L368E paired with D221R / P228R / K409R (e.g., these are “monomer counterparts”) and C220E / P228E / 368E paired with C220R / E224R / P228R / K409R.

[0127] In some embodiments, based on both the "mortar and pestle" and "electrostatic redirection" mechanisms, the skewed variants advantageously and simultaneously promote heterodimerization. These variants appear in the form of "sets" or "pairs." That is, one set of the pair is incorporated into the first monomer, and the other set of the pair is incorporated into the second monomer. It should be noted that these sets do not necessarily exhibit "mortar and pestle" variants, where there is a one-to-one correspondence between residues on one monomer and residues on the other. In other words, the pairs of these sets can form an interface between the two monomers, thereby promoting heterodimer formation and inhibiting homodimer formation, thus allowing the percentage of heterodimers spontaneously formed under biological conditions to exceed 90%, rather than the expected 50% (25% homodimer A / A: 50% heterodimer A / B: 25% homodimer B / B). An exemplary heterodimerization "skewed" variant is depicted in Figure 4. Examples of such skewed variants include paired mutant groups, including but not limited to S364K / E357Q:L368D / K370S; L368D / K370S:S364K; L368E / K370S:S364K; T411T / E360E / Q362E:D401K; L368D / K370S:S364K / E357L; K370S:S364K / E357Q; and T366S / L368A / Y407V:T366W (optionally including bridging disulfides, T366S / L368A / Y407V / Y349C:T366W / S354C).

[0128] Other monomer A and monomer B variants may be optionally and independently combined with other variants in any amount, such as the pI variants outlined herein or other spatial variants shown in Figure 37 of U.S. Patent Publication No. 2012 / 0149876, which, along with its illustrations, is expressly incorporated herein by reference.

[0129] In some embodiments, the spatial variants outlined herein may optionally and independently be incorporated into one or both monomers with any heterodimerization variant (including pI variants (or other variants, such as Fc variants, FcRn variants, ablation variants, etc.)).

[0130] Targeting pI (isoelectric point) variants of heterodimers

[0131] Generally, there are two categories of pI variants: those that increase the protein pI (basic changes) and those that decrease the protein pI (acidic changes). As described herein, all combinations of these variants are possible: one monomer can be the wild type, or a variant that does not exhibit a pI significantly different from the wild type, and the other can be more basic or more acidic. Alternatively, each monomer can be altered, one becoming more basic and the other more acidic. Exemplary combinations of pI variants are shown in the figure.

[0132] In several embodiments, such as those in FIG18A, E, F, G, H, and I, a preferred combination of pI variants has a monomer (negatively charged Fab side) comprising the 208D / 295E / 384D / 418E / 421D variant (N208D / Q295E / N384D / Q418E / N421D when relative to human IgG1) and a second monomer (positively charged scFv side) comprising a positively charged scFv connector (including (GKPGS)4). However, as those skilled in the art will understand, the first monomer includes a CH1 domain, including position 208. Therefore, in constructs that do not contain a CH1 domain (e.g., for antibodies that do not utilize a CH1 domain on one of their domains, such as those in a dual scFv or “single-arm” configuration, such as those depicted in Figures 18B, C, or D), the preferred negatively charged pI variant Fc group includes the 295E / 384D / 418E / 421D variants (Q295E / N384D / Q418E / N421D when relative to human IgG1).

[0133] Changes in acidic pI

[0134] When making a monomer containing a modified heavy chain constant domain more positively charged (e.g., reducing pI), one or more of the following modifications (e.g., substitutions) are suitable in the context of this disclosure: S119E, K133E, K133Q, T164E, K205E, K205Q, N208D, K210E, K210Q, K274E, K320E, K322E, K326E, K334E, R355E, K392E, deletion of K447, addition of DEDE peptide at the C-terminus, G137E, N203D, K274Q, R355Q, K392N, and Q419E. These changes are described relative to IgG1, but all isotypes and isotype heterozygotes can be altered in this way. R133E and R133Q may also be used in cases where the heavy chain constant domain is derived from IgG2-4.

[0135] Alkaline pI changes

[0136] When a monomer containing a variable heavy chain constant domain is made more negatively charged (e.g., by increasing pI), one or more of the following exemplary substitutions are suitable in the context of this disclosure: Q196K, P217R, P228R, N276K, and H435R. These changes are described relative to IgG1, but all isotypes and isotype heterozygotes can be altered in this way.

[0137] Heterodimeric antibody light chain variant

[0138] pI variants can also be prepared in the antibody light chain. Amino acid modifications used to reduce the pI of the light chain include, but are not limited to, K126E, K126Q, K145E, K145Q, N152D, S156E, K169E, S202E, K207E, and the addition of a DEDE peptide at the C-terminus of the light chain. Variations in this category based on a constant λ light chain include, but are not limited to, one or more substitutions at R108Q, Q124E, K126Q, N138D, K145T, and Q199E. Additionally, increasing the pI of the light chain is also possible and is considered in several aspects of this disclosure.

[0139] Isotype variant

[0140] Furthermore, several embodiments of this disclosure require the "introduction" of pI amino acids at specific positions from one IgG isoform to another, thereby reducing or eliminating the possibility of introducing unwanted immunogenicity into the variant. Many of these variants are shown in Figure 21 of U.S. Patent Publication No. 2014 / 0370013, which is incorporated herein by reference. In other words, IgG1 is a common isoform used for therapeutic antibodies for various reasons, including high effector function. However, the heavy chain constant region of IgG1 has a higher pI (8.10 vs. 7.31) than IgG2. By introducing IgG2 residues at specific positions into the IgG1 backbone, the resulting monomer has a lower (or higher) pI and additionally exhibits a longer serum half-life. For example, IgG1 has glycine at position 137 (pI 5.97), and IgG2 has glutamate (pI 3.22); the introduced glutamate will affect the pI of the resulting protein. Often, many amino acid substitutions are required to significantly affect the pI of the variant antibody. However, it should be noted that even changes in IgG2 molecules can allow for an increase in serum half-life.

[0141] In other embodiments, non-isotype amino acid alterations are made to reduce the total charge state of the resulting protein (e.g., by changing higher pI amino acids to lower pI amino acids) or to allow for structural adaptation to stability, etc.

[0142] Furthermore, significant variations in each monomer of the heterodimer can be observed by engineering the pI of the heavy and light chain constant structural domains. As discussed herein, ensuring a pI difference of at least 0.5 between the two monomers allows for separation by ion-exchange chromatography, isoelectric focusing, or other methods sensitive to the isoelectric point.

[0143] Additionally, isotropic pI variants can be generated, such as charged variants that are approximately the same size as the parent amino acid, and are considered herein.

[0144] Calculate pI

[0145] The pI of each monomer may depend on the pI of the variable heavy chain constant domain and the pI of the total monomer, including the variable heavy chain constant domain and the fusion mating body. Therefore, in some embodiments, variations in the pI are calculated based on the variable heavy chain constant domain. Alternatively, the pI of each monomer may be compared. Similarly, the pI of the “starting” variable region (e.g., scFv or Fab) is calculated to indicate which monomer will be engineered in which direction.

[0146] pI variants confer better FcRn binding in vivo.

[0147] PI variants with reduced monomeric pI may show the additional benefit of improved serum retention in vivo.

[0148] The Fc region is believed to have a longer half-life in vivo because it chelates Fc with FcRn at pH 6 in endosomes (Ghetie and Ward, 1997 Immunol Today. 18(12):592-598, incorporated herein by reference). The endosome compartment then recycles Fc to the cell surface. Once the compartment opens to the extracellular space, a higher pH (around 7.4) induces the release of Fc back into the bloodstream. It is thought that the increased affinity of Fc for FcRn at pH 7.4 prevents the release of Fc back into the bloodstream. Therefore, an Fc mutation that would increase the half-life of Fc in vivo would ideally increase FcRn binding at lower pH while still allowing the release of Fc at higher pH. The amino acid histidine alters its charge state in the pH range of 6.0 to 7.4. Therefore, it is not surprising that His residues are found at important sites in the Fc / FcRn complex.

[0149] Recently, it has been proposed that antibodies with variable regions having lower isoelectric points can also have longer serum half-lives (Igawa et al., 2010 PEDS. 23(5): 385-392, cited in full). Constant region variants with reduced pI and extended half-lives offer a more modular approach to improving the pharmacokinetic properties of antibodies.

[0150] The accompanying drawings disclose pI variants that can be used in this embodiment, and their use for purification optimization.

[0151] Combination of variants

[0152] As those skilled in the art will understand, all the described heterodimerization variants can optionally and independently be combined in any manner, as long as they maintain their “chain state” or “monomer partitioning.” Furthermore, all these variants can be combined into any heterodimerization pattern. In the case of pI variants, although exemplary embodiments are shown in the figures, other combinations can be generated based on the fundamental rule of altering the pI difference between the two monomers to facilitate purification.

[0153] antigen-binding protein (e.g., antibody) type

[0154] One type of heterodimeric scaffold that can be used in the context of this disclosure is the “triple F” or “opener” scaffold type as described above and listed in Figure 18. In this embodiment, one heavy chain of the antibody comprises a single-chain Fv (“scFv”, as defined below), and the other heavy chain is a “regular” Fab type comprising a variable heavy chain and a light chain. Many embodiments outlined herein generally rely on an opener type comprising a first monomer containing scFv comprising a variable heavy chain domain and a variable light chain domain, covalently attached using scFv adapters (charged in many, but not all, instances), wherein the scFv is typically covalently attached to the N-terminus of the first Fc domain via domain adapters (which, as outlined herein, can be uncharged or charged and can be exogenous or endogenous (e.g., wholly or partially natural hinged domains)). The second monomer of the opener type is a heavy chain, and the composition further comprises a light chain.

[0155] Additionally, the Fc domain of the opener type typically includes skew variants (e.g., selected from the group consisting of: S364K / E357Q:L368D / K370S; L368D / K370S:S364K; L368E / K370S:S364K; T411T / E360E / Q362E:D401K; L368D / K370S:S364K / E357L; K370S:S364K / E357Q; T366S / L368A / Y407V:T366W; and T366S / L368A / Y407V / Y349C:T366W / S354C), optionally including ablation variants, optionally including charged scFv connectors, and heavy chains including pI variants. In some embodiments, the opener type includes a skew variant, a pI variant, and an ablation variant. Therefore, some embodiments include opener types comprising: a) a first monomer (“scFv monomer”) comprising a charged scFv connector, a skew variant S364K / E357Q, an ablation variant E233P / L234V / L235A / G236del / S267K, and an Fv; b) a second monomer (“Fab monomer”) comprising a skew variant L368D / K370S, a pI variant N208D / Q295E / N384D / Q418E / N421D, an ablation variant E233P / L234V / L235A / G236del / S267K, and a variable heavy chain domain (forming an Fv that binds to a second antigen together with a variable light chain domain); and c) a light chain.

[0156] In some embodiments, the opener type includes a skew variant, a pI variant, an ablation variant, and an FcRn variant. Therefore, some embodiments include opener types comprising: a) a first monomer (“scFv monomer”) comprising a charged scFv connector, a skew variant S364K / E357Q, an ablation variant E233P / L234V / L235A / G236del / S267K, an FcRn variant M428L / N434S, and an Fv conjugated to a first antigen; b) a second monomer (“Fab…”) The monomer comprises the skewed variant L368D / K370S, the pI variant, N208D / Q295E / N384D / Q418E / N421D, the ablation variant E233P / L234V / L235A / G236del / S267K, the FcRn variant M428L / N434S, and a variable heavy chain domain (which, together with the variable light chain domain, constitutes the Fv that binds to the second antigen); and c) the light chain.

[0157] Another heterodimeric scaffold that can be used in this disclosure is the mAb-Fv type shown in Figure 18H. In this embodiment, this type relies on attaching an “additional” variable heavy chain domain to the C-terminus of one monomer and an “additional” variable light chain domain to the C-terminus of another monomer, thus forming a third antigen-binding domain, wherein the Fab portions of the two monomers bind to one antigen, and the “additional” scFv domain binds to a different antigen.

[0158] In this embodiment, the first monomer comprises: a first heavy chain containing a first variable heavy chain structural domain, and a first constant heavy chain structural domain containing a first Fc structural domain, wherein the first variable light chain structural domain is covalently attached to the C-terminus of the first Fc structural domain using a structural domain connector (vhl-CHl-[structural domain connector (e.g., hinge)]-CH2-CH3-[optional structural domain connector]-vl2). The second monomer comprises: a second variable heavy chain structural domain containing a second constant heavy chain structural domain containing a second Fc structural domain, and a third variable heavy chain structural domain covalently attached to the C-terminus of the second Fc structural domain using a structural domain connector (vhl-CHl-structural domain connector (e.g., hinge)-CH2-CH3-[optional structural domain connector]-vh2). The two C-terminus-attached variable structural domains constitute scFv. This embodiment further utilizes a common light chain containing both the variable light chain structural domain and the constant light chain structural domain, which is combined with the heavy chain to form two identical Fabs. For many embodiments described herein, these constructs include, as desired and as described herein, skew variants, pI variants, ablation variants, additional Fc variants, etc.

[0159] Optionally, the Fc domain of the mAb-Fv type includes skew variants (e.g., selected from the group consisting of: S364K / E357Q:L368D / K370S; L368D / K370S:S364K; L368E / K370S:S364K; T411T / E360E / Q362E:D401K; L368D / K370S:S364K / E357L, K370S:S364K / E357Q, T366S / L368A / Y407V:T366W and T366S / L368A / Y407V / Y349C:T366W / S354C), optionally includes ablation variants, optionally includes charged scFv junctions, and heavy chains including pI variants. In some embodiments, the mAb-Fv type includes a skew variant, a pI variant, and an ablation variant. Therefore, some embodiments include a bottle opener type comprising: a) a first monomer comprising the skew variant S364K / E357Q, the ablation variant 233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv binding antigen with the first variable light chain domain of the light chain), and a second variable heavy chain domain; b) a second monomer comprising the skew variant L368D / K370S, pI variants N208D / Q295E / N384D / Q418E / N421D, ablation variants E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv binding to the first antigen together with the first variable light chain domain), and a second variable light chain (forming an Fv binding to the second antigen together with the second variable heavy chain); and c) a light chain comprising the first variable light chain domain and the constant light chain domain.

[0160] Another heterodimeric scaffold that can be used in this disclosure is the mAb-scFv type shown in Figure 18I. In this embodiment, this type relies on the use of scFv to attach to the C-terminus of one of the monomers, thus forming a third antigen-binding domain, wherein the Fab portions of the two monomers bind to one antigen, and the “additional” scFv domain binds to a different antigen. In this embodiment, the first monomer comprises a first heavy chain (containing a variable heavy chain domain and a constant domain), which includes an scFv variable light chain domain, an scFv linker, and scFv covalently attached to the C-terminus of the scFv variable heavy chain domain in either orientation (vhl-CHl-domain linker-CH2-CH3-[optional domain linker]-vh2-scFv linker-vl2 or vhl-CHl-domain linker-CH2-CH3-[optional domain linker]-vl2-scFv linker-vh2). This embodiment further utilizes a common light chain comprising a variable light chain domain and a constant light chain domain, which binds to the heavy chain to form two identical Fabs that bind one of the target antigens. For many embodiments herein, these constructs include biased variants, pI variants, ablation variants, additional Fc variants, etc., as desired and described herein.

[0161] Additionally, the Fc domain of the mAb-scFv type optionally includes skew variants (e.g., selected from the following group, which consists of: S364K / E357Q:L368D / K370S; L368D / K370S:S364K; L368E / K370S:S364K; T411T / E360E / Q362E:D401K; L368D / K370S:S364K / E357L; K370S:S364K / E357Q; T366S / L368A / Y407V:T366W; and T366S / L368A / Y407V / Y349C:T366W / S354C), optionally comprising an ablation variant, optionally comprising a charged scFv connector, and a heavy chain comprising a pI variant. In some embodiments, the mAb-scFv morphology includes a skew variant, a pI variant, and an ablation variant. Therefore, some embodiments include the following types, which include: a) a first monomer comprising the skewed variant S364K / E357Q, the ablation variant E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv binding to the first antigen with the first variable light chain domain of the light chain), and a second variable heavy chain domain; b) a second monomer comprising the skewed variant L368D / K370S, p I) variants N208D / Q295E / N384D / Q418E / N421D, ablation variants E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv binding to the first antigen together with the first variable light chain domain), and a second variable light chain (forming an Fv binding to the second antigen together with the second variable heavy chain); and c) a light chain comprising the first variable light chain domain and a constant light chain domain.

[0162] Another heterodimer scaffold that can be used in this disclosure is the center-scFv or “XmAb” shown in Figure 18F. 2 +1"Type". This type relies on the use of an inserted scFv domain, thus forming a third antigen-binding domain, in which the Fab portions of two monomers bind to one target, and the "additional" scFv domain binds to the other. The scFv domain is inserted between the Fc domain and the CH1-Fv region of one of these monomers, thus providing a third antigen-binding domain. In this embodiment, one monomer comprises a first heavy chain containing a first variable heavy chain domain, a CH1 domain (and optional connector / hinge), and an Fc domain, wherein the scFv contains a scFv variable light chain domain, a scFv connector, and a scFv variable heavy chain domain. Optional domain connectors (VH1-CH1-[optional domain connector]-VH2-scFv connector-VL2-[optional domain connector including hinge]-CH2-CH3) or the opposite orientation for the scFv are used. VH1–CH1-[optional domain connector]-VL2-scFv connector-VH2-[optional domain connector including hinge]-CH2-CH3), where scFv is covalently attached between the C-terminus of the heavy constant domain CH1 and the N-terminus of the first Fc domain. In some embodiments, the first monomer is VH1-CH1 domain connector-VH2-scFv connector-VL2-domain connector-CH2-CH3. Other monomers are standard Fab sides (i.e., VH1-CH1-domain connector (e.g., hinge)-CH2-CH3). This embodiment further utilizes a common light chain comprising a variable light chain domain and a constant light chain domain, which is coupled with the heavy chain to form two identical Fabs for binding the target. For many embodiments herein, these constructs include skew variants, pI variants, ablation variants, additional Fc variants, etc., as desired and described herein.

[0163] In several aspects, the antigen-binding protein comprises a first heavy chain comprising VH1-CH1-[domain linker]-VH2-scFv linker-VL2-[domain linker (optionally including hinge)]-CH2-CH3; a second heavy chain comprising VH1-CH1-domain linker-CH2-CH3; and a common light chain comprising VL1; wherein VH1 and VL1 bind STEAP1, and VH2 and VL2 bind CD3. In this form, VH2 optionally comprises the CDR sequences of SEQ ID NO:170 (CDR1), SEQ ID NO:171 (CDR2), and SEQ ID NO:172 (CDR3), while VL2 comprises the CDR sequences of SEQ ID NO:174 (CDR1), SEQ ID NO:175 (CDR2), and SEQ ID NO:176 (CDR3). VH1 contains the CDR sequences of SEQ ID NO:14 (CDR1), SEQ ID NO:15 or 21 (CDR2), and SEQ ID NO:16 (CDR3); and VL1 contains the CDR sequences of SEQ ID NO:11 (CDR1), SEQ ID NO:12 (CDR2), and SEQ ID NO:13 (CDR3). Alternatively, VH1 contains the CDR sequences of SEQ ID NO:33 (CDR1), SEQ ID NO:34 (CDR2), and SEQ ID NO:35 (CDR3); and VL1 contains the CDR sequences of SEQ ID NO:30 (CDR1), SEQ ID NO:31 (CDR2), and SEQ ID NO:32 (CDR3). Optionally, the antigen-binding protein comprises modifications in the first heavy chain, including but not limited to E233P, delL234, L235V, G236A, S267K, r292c, n297g, v302c, E357Q, and S364K (EU designations, lowercase letters indicating SEFL2 substitutions further described herein), and the second heavy chain comprises modifications including but not limited to N208D, E233P, delL234, L235V, G236A, S267K, r292c, Q295E, n297g, v302c, L368D, K370S, N384D, Q418E, and N421D (EU designations, lowercase letters indicating SEFL2 substitutions further described herein). The connector used for the context of this embodiment is optionally GKPGSGKPGSGKPGSGKPGS (SEQ ID NO: 152).

[0164] The Fc domain of the central scFv type optionally includes skew variants (e.g., selected from the group consisting of: S364K / E357Q:L368D / K370S; L368D / K370S:S364K; L368E / K370S:S364K; T411T / E360E / Q362E:D401K; L368D / K370S:S364K / E357L; K370S:S364K / E357Q; T366S / L368A / Y407V:T366W and T366S / L368A / Y407V / Y349C:T366W / S354C), optionally includes ablation variants, optionally includes charged scFv junctions, and heavy chains including pI variants. In some embodiments, the central scFv type includes a skew variant, a pI variant, and an ablation variant. Therefore, some embodiments include the following types comprising: a) a first monomer comprising the skew variant S364K / E357Q, the ablation variant E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv binding to a first target together with the first variable light chain domain of the light chain), and a second variable heavy chain domain; b) a second monomer comprising the skew variant L368D / K370S, pI variant, and pI variant. I) variants N208D / Q295E / N384D / Q418E / N421D, ablation variants E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv binding to a first target together with a first variable light chain domain), and a second variable light chain (forming an Fv binding to a second target together with a second variable heavy chain); and c) a light chain comprising a first variable light chain domain and a constant light chain domain.

[0165] Another heterodimeric scaffold that can be particularly used in this disclosure is the center-Fv type shown in Figure 18G. This type relies on the use of an inserted scFv domain, thus forming a third antigen-binding domain, in which the Fab portions of the two monomers bind to one target, and the “additional” scFv domain binds to the other. The scFv domain is inserted between the Fc domain and the CH1-Fv region of the monomer, thus providing a third antigen-binding domain, wherein each monomer contains a component of scFv (e.g., one monomer contains a variable heavy chain domain, and the other monomer contains a variable light chain domain). In this embodiment, one monomer contains a first heavy chain (which contains a first variable heavy chain domain, a CH1 domain, and an Fc domain) and an additional variable light chain domain. Using a domain connector (vhl-CH1-[optional domain connector]-vl2-hinge-CH2-CH3), the light chain domain is covalently attached between the C-terminus of the heavy chain constant CH1 domain and the N-terminus of the first Fc domain. Other monomers comprise a first heavy chain containing a first variable heavy chain domain, a CH1 domain, and an Fc domain, as well as additional variable heavy chain domains (vhl-CHI-[optional domain connector]-vh2-hinge-CH2-CH3). Using domain connectors, the light chain domains are covalently attached between the C-terminus of the CH1 domain of the heavy chain constant domain and the N-terminus of the first Fc domain. This embodiment further utilizes a common light chain comprising both variable and constant light chain domains, which is coupled to the heavy chain to form two identical Fabs binding to the target. For many embodiments herein, these constructs include, as desired and described herein, skew variants, pI variants, ablation variants, additional Fc variants, etc.

[0166] Another heterodimeric scaffold that can be used in the context of this disclosure is the single-arm center-scFv type shown in FIG18C. In this embodiment, one monomer contains only the Fc domain, while the other monomer uses an inserted scFv domain, thus forming a second antigen-binding domain. In this type, the Fab portion binds to one target, and the scFv binds to another target. The scFv domain is inserted between the Fc domain and the CH1-Fv region of one of the monomers. In this embodiment, one monomer contains a first heavy chain comprising a first variable heavy chain domain, a CH1 domain, and an Fc domain, wherein the scFv comprises a scFv variable light chain domain, an scFv connector, and a scFv variable heavy chain domain. Using the domain connector, the scFv is covalently attached between the C-terminus of the CH1 domain of the heavy constant domain and the N-terminus of the first Fc domain. The second monomer contains the Fc domain. This embodiment further utilizes a light chain comprising a variable light chain domain and a constant light chain domain, which binds to the heavy chain to form the Fab. For many embodiments described herein, these constructs include, as desired and as described herein, skew variants, pI variants, ablation variants, additional Fc variants, etc.

[0167] Additionally, the Fc structural domain of the single-arm center-scFv type optionally includes skew variants (e.g., selected from the following group, which consists of: S364K / E357Q:L368D / K370S; L368D / K370S:S364K; L368E / K370S:S364K; T411T / E360E / Q362E:D401K; L368D / K370S:S364K / E357L; K370S:S364K / E357Q; T366S / L368A / Y407V:T366W; and T366S / L368A / Y407V). Y349C:T366W / S354C), optionally comprising an ablation variant, optionally comprising a charged scFv connector, and a heavy chain comprising a pI variant. In some embodiments, the single-arm center-scFv type includes a skew variant, a pI variant, and an ablation variant. Thus, some embodiments include opener types comprising: a) a first monomer comprising the skew variant S364K / E357Q, the ablation variant E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv for binding a first target with the first variable light chain domain of the light chain), and a second variable heavy chain domain; b) a second monomer comprising the skew variant L368D / K370S The formula includes: c) a pI variant N208D / Q295E / N384D / Q418E / N421D, an ablation variant E233P / L234V / L235A / G236del / S267K, a first variable heavy chain domain (forming an Fv binding to a first target together with a first variable light chain domain), and a second variable light chain (forming an Fv binding to a second target together with a second variable heavy chain); and c) a light chain comprising a first variable light chain domain and a constant light chain domain. In some embodiments, the single-arm center-scFv morphology includes a skew variant, a pI variant, an ablation variant, and an FcRn variant.Therefore, some embodiments include the following types, which include: a) a first monomer comprising the skew variant S364K / E357Q, the ablation variant E233P / L234V / L235A / G236del / S267K, the FcRn variant M428L / N434S, and a first variable heavy chain domain (forming an Fv binding to a first target with the first variable light chain domain of the light chain), and a second variable heavy chain domain; b) a second monomer comprising the skew variant L368D / K370S, the pi variant N208D / Q295E / N384D / Q418E / N421D, ablation variants E233P / L234V / L235A / G236del / S267K, FcRn variant M428L / N434S, and a first variable heavy chain domain (forming an Fv with a first variable light chain domain that binds to a first target as outlined herein), and a second variable light chain (forming an Fv with a second variable heavy chain that binds to a second target); and c) a light chain comprising a first variable light chain domain and a constant light chain domain.

[0168] Another heterodimeric scaffold that can be used in this disclosure is the single-arm scFv-mAb type shown in Figure 18D. In this embodiment, one monomer contains only the Fc domain, while the other monomer uses an scFv domain attached at the N-terminus of the heavy chain, typically by using a connector: vh-scFv connector-vl-[optional domain connector]-CHl-hinge-CH2-CH3 or (in opposite orientation) vl-scFv connector-vh-[optional domain connector]-CHl-hinge-CH2-CH3. In this type, the Fab portion is bonded to one target, and the scFv is bonded to another target. This embodiment further utilizes a light chain containing variable light chain domains and constant light chain domains, which are bonded to the heavy chain to form the Fab. For many embodiments herein, these constructs include skewed variants, pI variants, ablation variants, additional Fc variants, etc., as desired and described herein.

[0169] The Fc domain of a single-arm scFv-mAb contains skew variants (e.g., selected from the group consisting of: S364K / E357Q:L368D / K370S; L368D / K370S:S364K; L368E / K370S:S364K; T411T / E360E / Q362E:D401K; L368D / K370S:S364K / E357L; K370S:S364K / E357Q; T366S / L368A / Y407V:T366W; and T366S / L368A / Y407V / Y349C:T366W / S354C), optionally contains ablation variants, optionally contains charged scFv connectors, and heavy chains containing pi variants. In some embodiments, the single-arm scFv-mAb type includes a skew variant, a p1 variant, and an ablation variant. Therefore, some embodiments include a bottle opener type comprising: a) a first monomer comprising the skew variant S364K / E357Q, the ablation variant E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv binding to a first target with the first variable light chain domain of the light chain), and a second variable heavy chain domain; b) a second monomer comprising the skew variant L368D / K370S, p1, and p1. Variants N208D / Q295E / N384D / Q418E / N421D, ablation variants E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv bound to a first target as outlined herein with a first variable light chain domain), and a second variable light chain (forming an Fv bound to a second target together with a second variable heavy chain); and c) a light chain comprising a first variable light chain domain and a constant light chain domain. In some embodiments, the single-arm scFv-mAb type includes skew variants, pI variants, ablation variants, and FcRn variants.Therefore, some embodiments include bottle opener types comprising: a) a first monomer comprising the skew variant S364K / E357Q, the ablation variant E233P / L234V / L235A / G236del / S267K, the FcRn variant M428L / N434S, and a first variable heavy chain domain (forming an Fv binding to a first target with the first variable light chain domain of the light chain), and a second variable heavy chain domain; b) a second monomer comprising the skew variant L368D / K370S, pi Variants N208D / Q295E / N384D / Q418E / N421D, ablation variants E233P / L234V / L235A / G236del / S267K, FcRn variant M428L / N434S, and a first variable heavy chain domain (forming an Fv that binds to a first target as outlined herein with a first variable light chain domain), and a second variable light chain (forming an Fv that binds to a second target together with a second variable heavy chain); and c) a light chain comprising a first variable light chain domain and a constant light chain domain.

[0170] Another heterodimeric scaffold that can be used in this disclosure is the mAb-scFv type shown in Figure 18E. In this embodiment, this type relies on attaching an scFv to the N-terminus of one of the monomers, thus forming a third antigen-binding domain, wherein the Fab portions of the two monomers bind to a target, and the “additional” scFv domain binds to a different target. In this embodiment, the first monomer comprises a first heavy chain (containing a variable heavy chain domain and a constant domain), which includes an scFv variable light chain domain, an scFv connector, and an scFv covalently attached to the N-terminus of the scFv variable heavy chain domain in either orientation ((vhl-scFv connector-vll-[optional domain connector]-vh2-CHl-hinge-CH2-CH3) or (wherein the scFv is in the opposite orientation) (vll-scFv connector-vhl-[optional domain connector]-vh2-CHl-hinge-CH2-CH3)). This embodiment further utilizes a common light chain comprising a variable light chain domain and a constant light chain domain, which binds to the heavy chain to form two identical Fabs that bind one of the target antigens. For many embodiments herein, these constructs include, as desired and described herein, skewed variants, pi variants, ablation variants, additional Fc variants, etc.

[0171] The Fc domain of the scFv-mAb type optionally includes skew variants (e.g., selected from the following group, which consists of: S364K / E357Q:L368D / K370S; L368D / K370S:S364K; L368E / K370S:S364K; T411T / E360E / Q362E:D401K; L368D / K3 70S:S364K / E357L; K370S:S364K / E357Q; T366S / L368A / Y407V:T366W; and T366S / L368A / Y407V / Y349C:T366W / S354C), optionally including an ablation variant, optionally including a charged scFv connector, and a heavy chain including a pI variant. In some embodiments, the mAb-scFv morphology includes a skew variant, a pI variant, and an ablation variant. Therefore, some embodiments include bottle opener types comprising: a) a first monomer comprising a skew variant S364K / E357Q, an ablation variant E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv binding to a first target with the first variable light chain domain of the light chain), and a second variable heavy chain domain; b) a second monomer comprising a skew variant L368D / K370S, pi Variants N208D / Q295E / N384D / Q418E / N421D, ablation variants E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv with a first variable light chain domain bound to a first target as outlined herein), and a second variable light chain (forming an Fv with a second variable heavy chain bound to a second target); and c) a light chain comprising a first variable light chain domain and a constant light chain domain. In some embodiments, the mAb-scFv morphology includes skew variants, pI variants, ablation variants, and FcRn variants.Therefore, some embodiments include a bottle opener type comprising: a) a first monomer comprising the skew variant S364K / E357Q, the ablation variant E233P / L234V / L235A / G236del / S267K, the FcRn variant M428L / N434S, and a first variable heavy chain domain (forming an Fv binding to a first target with the first variable light chain domain of the light chain), and a second variable heavy chain domain; b) a second monomer comprising the skew variant L368D / K370S The following are variants: pI variant N208D / Q295E / N384D / Q418E / N421D, ablation variant E233P / L234V / L235A / G236del / S267K, FcRn variant M428L / N434S, and a first variable heavy chain domain (forming an Fv binding to a first target together with a first variable light chain domain), and a second variable light chain (forming an Fv binding to a second target together with a second variable heavy chain); and c) a light chain comprising a first variable light chain domain and a constant light chain domain.

[0172] This disclosure also provides a dual scFv configuration, as depicted, for example, in Figure 18B. In this embodiment, the heterodimeric antigen-binding protein is composed of two scFv-Fc monomers (the two monomers are in the form of (vh-scFv linker-vl-[optional domain linker]-CH2-CH3) or (vl-scFv linker-vh-[optional domain linker]-CH2-CH3), or one monomer is in one orientation and the other is in another orientation). The Fc domain of the dual scFv type optionally includes skew variants (e.g., selected from the group consisting of: S364K / E357Q:L368D / K370S; L368D / K370S:S364K; L368E / K370S:S364K; T411T / E360E / Q362E:D401K; L368D / K370S:S364K / E357L; K370S:S364K / E357Q; T366S / L368A / Y407V:T366W; and T366S / L368A / Y407V / Y349C:T366W / S354C), optionally includes ablation variants, optionally includes charged scFv junctions, and heavy chains including pI variants.

[0173] In some embodiments, the dual scFv variant includes a skew variant, a pI variant, and an ablation variant. Therefore, some embodiments include variants comprising: a) a first monomer comprising the skew variant S364K / E357Q, the ablation variant E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv binding to a first target together with the first variable light chain domain of the light chain), and a second variable heavy chain domain; b) a second monomer comprising the skew variant L368D / K370S, the pI variant, and a pI variant. N208D / Q295E / N384D / Q418E / N421D, ablation variant E233P / L234V / L235A / G236del / S267K, and a first variable heavy chain domain (forming an Fv with a first variable light chain domain bound to a first target as outlined herein), and a second variable light chain (forming an Fv with a second variable heavy chain bound to a second target); and c) a light chain comprising a first variable light chain domain and a constant light chain domain. In some embodiments, the dual scFv morphology includes a skew variant, a pI variant, an ablation variant, and an FcRn variant. Therefore, some embodiments include a bottle opener type comprising: a) a first monomer comprising the skew variant S364K / E357Q, the ablation variant E233P / L234V / L235A / G236del / S267K, the FcRn variant M428L / N434S, and a first variable heavy chain domain (forming an Fv binding to a first target with the first variable light chain domain of the light chain), and a second variable heavy chain domain; b) a second monomer comprising the skew variant L368D / K370S The following are variants of the pi variant N208D / Q295E / N384D / Q418E / N421D, ablation variant E233P / L234V / L235A / G236del / S267K, FcRn variant M428L / N434S, and a first variable heavy chain domain (forming an Fv binding to a first target together with a first variable light chain domain), and a second variable light chain (forming an Fv binding to a second target together with a second variable heavy chain); and c) a light chain comprising a first variable light chain domain and a constant light chain domain.

[0174] Further description of the antibody type is provided in International Patent Publication No. WO 2017 / 218707, which is incorporated herein by reference.

[0175] antibody binding

[0176] In several respects, the bispecific antigen-binding proteins disclosed herein (e.g., heterodimeric antibodies) bind to CD3 and STEAP1. The different binding regions independently exhibit a KD (knockout) against their respective antigens, which is less than or equal to 10. -4 M, less than or equal to 10-5 M, less than or equal to 10 -6 M, less than or equal to 10 -7 M, less than or equal to 10 -8 M, less than or equal to 10 -9 M, less than or equal to 10 -10 M, less than or equal to 10 -11 M, or less than or equal to 10 -12 M, where KD refers to the dissociation rate of a specific antibody-antigen interaction. Binding affinity is further described above. The STEAP1 binding region does not need to bind STEAP1 with the same affinity as, for example, the CD3 binding region binding CD3. The binding affinity disclosed in the context of bispecific antigen-binding proteins also applies to any single-specific constructs described herein, including constructs that bind PD-1.

[0177] Other antibody modifications

[0178] In addition to the modifications outlined above, other modifications can be made. For example, the molecule can be stabilized by incorporating a disulfide bridge connecting the VH and VL domains (Reiter et al., 1996, Nature Biotech. 14:1239-1245, incorporated herein by reference in its entirety). Furthermore, various covalent modifications exist for antibodies, which can be prepared as outlined below.

[0179] Covalent modifications of antibodies are included within the scope of this disclosure and are typically, but not always, post-translational. For example, several types of covalent modifications of antibodies are introduced into the molecule by reacting specific amino acid residues of the antibody with an organic derivatizer capable of reacting with selected side chain or N- or C-terminal residues.

[0180] Cysteine ​​residues most commonly react with α-haloacetic esters (and corresponding amines), such as chloroacetic acid or chloroacetamide, to yield carboxymethyl or carboxamide-methyl derivatives. Cysteine ​​residues can also be derived by reactions with bromotrifluoroacetone, α-bromo-β-(5-imidazolyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimide, 3-nitro-2-pyridyl disulfide, methyl-2-pyridyl disulfide, p-chloromercuric benzoate, 2-chloromercuric-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole, etc.

[0181] Furthermore, cysteine ​​modification is particularly useful in antibody-drug conjugate (ADC) applications, as further described below. In some embodiments, the constant region of the antibody can be engineered to contain one or more cysteine ​​residues, particularly those that are "thiol-reactive," to allow for more specific and controlled placement of the drug moiety. See, for example, U.S. Patent No. 7,521,541, which is incorporated herein by reference in its entirety.

[0182] Histidine residues are derived by reacting with diethyl pyrocarbonate at pH 5.5–7.0, as this agent is relatively specific to histidine side chains. p-Bromobenzoylmethyl bromide is also useful; this reaction is preferably carried out in 0.1 M sodium dimethylarsinate at pH 6.0.

[0183] Lysyl residues and amino-terminal residues react with succinic anhydride or other carboxylic anhydrides. Derivatization with these agents reverses the charge of the lysyl residue. Other suitable reagents for derivatizing α-amino residues include imine esters such as methylpyridinium imide; pyridoxal phosphate; pyridoxal; chlorine borohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; and transaminase-catalyzed reactions with glyoxylates.

[0184] Arginyl residues are modified by reaction with one or more conventional reagents, including benzoylcarboxaldehyde, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Due to the high pKa of the guanidine functional group, the derivatization of arginine residues requires the reaction to be carried out under basic conditions. Furthermore, these reagents can react with lysine groups as well as the ε-amino group of arginine.

[0185] Tyrosine residues can be specifically modified, with particular interest in introducing spectral labeling into tyrosine residues through reaction with aromatic diazo compounds or tetranitromethane. Most commonly, N-acetylimidazole and tetranitromethane are used to form O-acetyltyrosine substances and 3-nitro derivatives, respectively. The chloramine-T method described above is suitable for preparing labeled proteins for radioimmunoassays using iodination of tyrosine residues with 125I or 131I.

[0186] The carboxyl side group (aspartic or glutamic) is selectively modified by reacting with a carbodiimide (R'—N=C=N--R'), wherein R and R' are optionally different alkyl groups, such as 1-cyclohexyl-3-(2-morpholino-4-ethyl)carbodiimide or 1-ethyl-3-(4-azainium-4,4-dimethylpentyl)carbodiimide. Furthermore, the aspartic and glutamic residues are converted to asparaginic and glutamic residues by reacting with ammonium ions.

[0187] Derivatization with bifunctional agents can be used to crosslink antibodies to water-insoluble carrier matrices or surfaces for use in a variety of methods. Commonly used crosslinking agents include, for example, 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters (e.g., esters with 4-azidosalicylic acid), and homodifunctional imine esters (including disuccinimide esters, such as 3,3'-dithiobis(succinimide propionate), and bifunctional maleimides, such as bis-N-maleimide-1,8-octane). Derivatizing agents such as methyl 3-[(p-azidophenyl)dithio]propionimide produce photoactivated intermediates capable of forming crosslinks in the presence of light. Alternatively, the reactive water-insoluble matrix (such as cyanogen bromide-activated carbohydrates) and reactive substrates described in U.S. Patent Nos. 3,969,287, 3,691,016, 4,195,128, 4,247,642, 4,229,537, and 4,330,440 (all incorporated herein by reference in their entirety) may be used for protein immobilization.

[0188] Glutamine acyl residues and asparagine acyl residues are typically deamidated to their respective glutamine acyl residues and asparagine acyl residues. Alternatively, these residues are deamidated under weakly acidic conditions. Both forms of these residues are within the scope of this disclosure.

[0189] Other modifications include hydroxylation of proline and lysine, phosphorylation of the hydroxyl groups of serine or threonyl residues, methylation of the α-amino groups of the lysine, arginine, and histidine side chains (TECreighton, Proteins: Structure and Molecular Properties, WH Freeman & Co., San Francisco, pp. 79-86

[1983] , incorporated herein by reference in its entirety), acetylation of N-terminal amines, and amidation of any C-terminal carboxyl group.

[0190] Additionally, as those skilled in the art will understand, markers (including fluorescent, enzymatic, magnetic, radioactive, etc.) can be added to any of the antigen-binding proteins described herein (as well as other compositions disclosed herein).

[0191] Glycosylation

[0192] Another type of covalent modification is a change in glycosylation. In another embodiment, the antibodies (or other types of antigen-binding proteins) disclosed herein can be modified to include one or more engineered glycoforms. The term "engineered glycoform" as used herein refers to a carbohydrate composition covalently attached to an antibody, wherein the carbohydrate composition differs from the chemical composition of the parent antibody. Engineered glycoforms can be used for a variety of purposes, including, but not limited to, enhancing or reducing effector function. A preferred form of engineered glycoform is non-fucosylation, which has been shown to be associated with increased ADCC function, possibly through a tighter binding to the FcγRIIIa receptor. In this context, "non-fucosylation" means that the majority of antibodies produced in host cells are substantially free of fucose; for example, 90%, 95%, or 98% of the produced antibodies do not have significant fucose as a component of the carbohydrate portion of the antibody (typically attached at N297 of the Fc region). Functionally defined non-fucosylated antibodies typically exhibit at least 50% or higher affinity for the FcγRIIIa receptor.

[0193] Optionally, the heterodimeric antibody includes a sequence modification that removes one or more glycosylation sites, for example, at one or more of positions 292, 297, or 302. A non-limiting example includes the introduction of one or more stable effector nonfunctional (SEFL2) mutations (e.g., in the IgG1 backbone), further described in, for example, U.S. Patent No. 9,546,203, which is incorporated herein by reference in its entirety, and particularly with respect to the description of SEFL2 mutations. In addition to any other modifications disclosed herein, modifications (e.g., N67Q modification) may also be used to reduce deamidation.

[0194] Engineered glycoforms can be produced using a variety of methods known in the art. See, for example, Davies et al., 1999, Nat Biotechnol, 17:176-180; Davies et al., 2001, Biotechnol Bioeng, 74:288-294; Shields et al., 2002, J Biol Chem, 277:26733-26740; Shinkawa et al., 2003, J Biol Chem, 278:3466-3473; US Patent No. 6,602,684; US Patent Publications 2003 / 0157108 and 2003 / 0003097; and International Patent Publications WO 00 / 61739A1, WO 01 / 29246A1, WO 02 / 31140A1 and WO 02 / 30954A1, all of which are incorporated herein by reference in their entirety. Technology [Biowa Corporation, Princeton, New Jersey] and Glycosylation engineered technologies [Glycart Biotechnology AG, Zurich, Switzerland]. Many of these technologies are based on controlling the levels of fucosylation and / or dimeric oligosaccharides covalently attached to the Fc region, for example, by expressing IgG in different organisms or cell lines, engineered or otherwise (e.g., Lec-13 CHO cells or rat hybridoma YB2 / 0 cells); by modulating enzymes involved in the glycosylation pathway (e.g., FUT8 [α1,6-fucosyltransferase] and / or β1-4-N-acetylglucosamine transferase III [GnTIII]); or by modifying one or more carbohydrates after IgG has been expressed. For example, “glycosylated antibody technology” works by adding modified sugars that inhibit fucosylation during the production process; see, for example, U.S. Patent Publication No. 20090317869, which is incorporated herein by reference in its entirety. Engineered glycoforms generally refer to different carbohydrates or oligosaccharides; therefore, antibodies may include engineered glycoforms.

[0195] Alternatively, engineered glycoforms can refer to IgG variants containing different carbohydrates or oligosaccharides. As is known in the art, glycosylation patterns can depend on the protein sequence (e.g., the presence or absence of specific glycosylated amino acid residues discussed below) or the host cell or organism from which the protein is produced. Specific expression systems are discussed below.

[0196] Glycosylation of peptides is typically N-linked or O-linked. N-linking refers to the attachment of the carbohydrate moiety to a side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine (where X is any amino acid except proline) are recognition sequences for the enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Therefore, the presence of either of these tripeptide sequences in a peptide creates a potential glycosylation site. O-linked glycosylation involves attaching one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyl amino acid, most commonly serine or threonine, but 5-hydroxyproline or 5-hydroxylysine can also be used.

[0197] Adding glycosylation sites (for N-linked glycosylation sites) to an antibody can be conveniently accomplished by altering the amino acid sequence to include one or more of the aforementioned tripeptide sequences. Alterations (for O-linked glycosylation sites) can also be made by adding or substituting one or more serine or threonine residues into the starting sequence. For convenience, the antibody amino acid sequence is preferably altered at the DNA level, particularly by mutating the DNA encoding the target polypeptide at preselected bases to produce a codon that will be translated into the desired amino acid.

[0198] Another means of increasing the amount of carbohydrate moiety on antigen-binding proteins (e.g., antibodies) is by chemically or enzymatically coupling glycosides to the protein. An advantage of these procedures is that they do not require the production of proteins in host cells with glycosylation capabilities for N- and O-linking glycosylation. Depending on the coupling method used, one or more sugars may be linked to (a) arginine and histidine, (b) a free carboxyl group, (c) a free thiol group, such as those of cysteine, (d) a free hydroxyl group, such as those of serine, threonine, or hydroxyproline, (e) an aromatic residue, such as those of phenylalanine, tyrosine, or tryptophan, or (f) an amide group of glutamine. These methods are described in International Patent Publication No. WO 87 / 05330 and in Aplin and Wriston, 1981, CRC Crit. Rev. Biochem. [CRC Critical Review of Biochemistry], pp. 259–306, both of which are incorporated herein by reference in their entirety.

[0199] Removal of the carbohydrate moiety present on the initiating antibody (e.g., post-translational) can be accomplished chemically or enzymatically. Chemical deglycosylation requires exposing the protein to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylglucosamine), while keeping the polypeptide intact. Chemical deglycosylation is described by Hakimuddin et al., 1987, Arch. Biochem. Biophys. [Journal of Biochemistry and Biophysics] 259:52 and by Edge et al., 1981, Anal. Biochem. [Analytical Biochemistry] 118:131, both of which are incorporated herein by reference in their entirety. Enzymatic cleavage of the carbohydrate moiety on the polypeptide can be achieved using a variety of endoglucosidases and exoglucosidases, as described by Thotakura et al., 1987, Meth. Enzymol. [Enzymological Methods] 138:350, which is incorporated herein by reference in its entirety. Glycosylation at potential glycosylation sites can be prevented by using the compound tunicamycin, as described by Duskin et al., 1982, J. Biol. Chem. [Journal of Biochemistry] 257:3105, which is incorporated herein by reference in its entirety. tunicamycin blocks the formation of protein-N-glycosidic bonds.

[0200] Another type of covalent modification of antibodies involves linking the antibody to a variety of non-protein polymers, including but not limited to various polyols such as polyethylene glycol, polypropylene glycol, or polyoxyethylene, in a manner listed, for example, in Nektar Therapeutics' 2005-2006 PEG catalogue (available from the Nektar website), or U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337 (all incorporated herein by reference in their entirety). Furthermore, as is known in the art, amino acid substitutions can be made at different positions within the antibody to facilitate the addition of polymers such as PEG. See, for example, U.S. Patent Publication No. 2005 / 0114037A1, incorporated herein by reference in its entirety.

[0201] Additional Fc variants for other functions

[0202] In addition to the pI amino acid variants and other variants mentioned above, there are many useful Fc amino acid modifications that can occur for a variety of reasons, including but not limited to altering binding to one or more FcγR receptors, altering binding to FcRn receptors, etc. The following modifications may be used in addition to or alternatively to any of the modifications mentioned above.

[0203] FcγR variant

[0204] Many useful Fc substitutions can be made to alter binding to one or more FcγR receptors. Substitutions that result in both increased and decreased binding can be useful. For example, increased binding to FcγRIIIa is known to generally lead to increased ADCC (antibody-dependent cell-mediated cytotoxicity; a cell-mediated reaction in which nonspecific cytotoxic cells expressing FcγR recognize binding antibodies on target cells and subsequently cause lysis of the target cells). Similarly, in some cases, decreased binding to FcγRIIb (inhibitory receptor) is also beneficial. Useful amino acid substitutions that can be used in this disclosure include those listed in U.S. Patent Publications 2006 / 0024298 (particularly Figure 41), 2006 / 0121032, 2006 / 0235208, and 2007 / 0148170, all of which are expressly incorporated herein by reference, and in particular the variants disclosed therein. Specific variants that may be used include, but are not limited to, 236A, 239D, 239E, 332E, 332D, 239D / 332E, 267D, 267E, 328F, 267E / 328F, 236A / 332E, 239D / 332E / 330Y, 239D, 332E / 330L, and 299T.

[0205] In addition, other Fc substitutions have been discovered that can be used to increase binding to the FcRn receptor and increase serum half-life, as specifically disclosed in U.S. Patent Publication No. 2009 / 0163699, which is incorporated herein by reference in its entirety. The substitutions include, but are not limited to, 434S, 428L, 308F, 259I, 428L / 434S, 259I / 308F, 436I / 428L, 436I or V / 434S, 436V / 428L, and 259I / 308F / 428L.

[0206] Fc ablation variant

[0207] Other variants that may be used in the context of this disclosure are variants that ablate (e.g., reduce or eliminate) binding to the Fcγ receptor. A potential mechanism of action that reduces heterodimeric antibodies (e.g., decreases ADCC activity) may be desirable. Many suitable Fc ablation variants are described in Figure 6 It may optionally and independently include or exclude combinations with any other heterodimerization variants (including pI variants and spatial variants).

[0208] Particularly useful in some embodiments is a first monomer (“negative-charged side”) paired with the positive-charged side (which does not contain pI variants, skew variants S364K / E357Q and ablation variants E233P / L234V / L235A / G236del / S267K (optionally both monomers contain FcRn variants 428L / 434S)) (containing pI variants N208D / Q295E / N384D / Q418E / N421D, skew variants 368D / 370S, and ablation variants E233P / L234V / L235A / G236del / S267K), wherein the positive-charged side is a monomer containing scFv and contains a charged scFv connector. The second embodiment utilizes a first negatively charged side monomer (containing I199) paired with the positively charged side (including pI variants Q196K / I199T / P271R / P228R / N276K, skew variants S364K / E357Q, and ablation variants E233P / L234V / L235A / G236del / S267K (optionally both monomers contain FcRn variants 428L / 434S)). T / N203D / K274Q / R355Q / Q419E / K447del, skew variant S364K / E357Q and ablation variant E233P / L234V / L235A / G236del / S267K (optionally both monomers contain FcRn variant 428L / 434S)), wherein the positive charge side is a monomer containing scFv and contains a charged scFv connector. The third embodiment utilizes a first negatively charged side monomer (containing I199T / N203D / K274Q / R355Q / N384S / K392N / V397M / Q419E / K447del, skew variant S364K / E357Q, and ablation variant E233P / L234V / L235A / G236del / S267K (optionally both monomers contain FcRn variant 428L / 434S)) paired with a positively charged side monomer (excluding pI variant, skew variant S364K / E357Q, and ablation variant E233P / L234V / L235A / G236del / S267K (optionally both monomers contain FcRn variant 428L / 434S)), wherein the positively charged side is a monomer containing scFv and includes a charged scFv connector.The fourth embodiment utilizes a first monomer (“negative charge side”) paired with the positive charge side (excluding pI variants, skew variants S364K / E357Q and ablation variants E233P / L234V / L235A / G236del / S239K (optionally both monomers contain FcRn variants 428L / 434S)) (containing pI variants N208D / Q295E / N384D / Q418E / N421D, skew variants 368D / 370S and ablation variants E233P / L234V / L235A / G236del / S239K). The fifth embodiment utilizes a first negatively charged side monomer (containing I199T / N203D / K274Q / R355Q / Q419E / K447del, skew variant S364K / E357Q, and ablation variant E233P / L234V / L235A / G236del / S239K (optionally both monomers contain FcRn variant 428L / 434S)) paired with the positively charged side (containing pI variant Q196K / I199T / P271R / P228R / N276K, skew variant S364K / E357Q, and ablation variant E233P / L234V / L235A / G236del / S239K (optionally both monomers contain FcRn variant 428L / 434S)). The sixth embodiment utilizes a first negatively charged monomer (containing I199T / N203D / K274Q / R355Q / N384S / K392N / ) paired with a positively charged monomer (containing the skew variant S364K / E357Q and the ablation variant E233P / L234V / L235A / G236del / S239K (optionally both monomers contain the FcRn variant 428L / 434S)). V397M / Q419E / K447del, skew variant S364K / E357Q, and ablation variant E233P / L234V / L235A / G236del / S267K (optionally both monomers contain FcRn variants 428L / 434S)), wherein the positive charge side is an scFv monomer and contains a charged scFv junction (especially when the scFv is anti-CD3). The seventh embodiment utilizes a first monomer (“negative charge side”) paired with the positive charge side (excluding pI variants, skew variants S364K / E357Q and ablation variants S239K / S267K (optionally both monomers contain FcRn variants 428L / 434S)) (containing pI variants N208D / Q295E / N384D / Q418E / N421D, skew variants 368D / 370S and ablation variants S239K / S267K), wherein the positive charge side is an scFv monomer and contains a charged scFv connector.The eighth embodiment utilizes a first negatively charged side monomer (containing I199T / N203D / K274Q / R355Q / Q419E / K447del, skew variant S364K / E357Q, and ablation variant S239K / S267K (optionally both monomers contain FcRn variant 428L / 434S)) paired with a positively charged side monomer (containing pI variant Q196K / I199T / P271R / P228R / N276K, skew variant S364K / E357Q, and ablation variant S239K / S267K (optionally both monomers contain FcRn variant 428L / 434S)), wherein the positively charged side is an scFv monomer and includes a charged scFv connector. The ninth embodiment utilizes a first negatively charged side monomer (containing I199T / N203D / K274Q / R355Q / N384S / K392N / V397M / Q419E / K447del, skew variant S364K / E357Q, and ablation variant S239K / S267K (optionally both monomers contain FcRn variant 428L / 434S)) paired with a positively charged side monomer (excluding pI variant, skew variant S364K / E357Q, and ablation variant S239K / S267K (optionally both monomers contain FcRn variant 428L / 434S)), wherein the positively charged side is an scFv monomer and includes a charged scFv connector. The tenth embodiment utilizes a first monomer (“negative charge side”) paired with the positive charge side (excluding pI variants, skew variants S364K / E357Q and ablation variants S267K / P329K (optionally both monomers contain FcRn variants 428L / 434S)) (containing pI variants N208D / Q295E / N384D / Q418E / N421D, skew variants 368D / 370S and ablation variants S267K / P329K), wherein the positive charge side is an scFv monomer and contains a charged scFv connector. The eleventh embodiment utilizes a first negatively charged side monomer (containing I199T / N203D / K274Q / R355Q / Q419E / K447del, skew variant S364K / E357Q, and ablation variant S267K / P329K (optionally both monomers contain FcRn variant 428L / 434S)) paired with a positively charged side monomer (containing pI variant Q196K / I199T / P271R / P228R / N276K, skew variant S364K / E357Q, and ablation variant S267K / P329K (optionally both monomers contain FcRn variant 428L / 434S)), wherein the positively charged side is an scFv monomer and includes a charged scFv connector.The 12th embodiment utilizes a first negatively charged side monomer (containing I199T / N203D / K274Q / R355Q / N384S / K392N / V397M / Q419E / K447del, skew variant S364K / E357Q, and ablation variant S267K / P329K (optionally both monomers contain FcRn variant 428L / 434S)) paired with a positively charged side monomer (excluding pI variant, skew variant S364K / E357Q, and ablation variant S267K / P329K (optionally both monomers contain FcRn variant 428L / 434S)), wherein the positively charged side is an scFv monomer and includes a charged scFv connector.

[0209] In several aspects, the first monomer comprises a first heavy chain (which includes a first variable heavy chain domain, a first constant heavy chain containing a first CH1 domain and a first Fc domain), scFv (which is incorporated into CD3 and includes a scFv variable light chain domain, a scFv connector, and a scFv variable heavy chain domain (i.e., a “Fab-scFv-Fc” heavy chain)), the first monomer comprising a deletion in the upper hinge and introducing CH2 and CH3 substitutions. These substitutions include, for example, one or more (e.g., all) of E233P, delL234, L235V, G236A, S267K, r292c, n297g, v302c, E357Q, and S364K (EU designation, referring to the lowercase letters of SEFL2 substitutions). The second monomer comprises a second heavy chain (which contains a second variable heavy chain domain and a second constant heavy chain containing a second Fc domain), and the second monomer optionally contains one or more (e.g., all) of the following mutations: N208D, E233P, delL234, L235V, G236A, S267K, r292c, Q295E, n297g, v302c, L368D, K370S, N384D, Q418E, and N421D (EU number, refer to lowercase letters in SEFL2 substitution).

[0210] connector

[0211] The term "connector" as used herein is also referred to as a "connector sequence" or "spacer" or syntactic equivalents. Homologous or heterologous bifunctional connectors are well-known (see, 1994 Pierce Chemical Company catalogue, technical section on cross-linkers, pp. 155–200, fully incorporated by reference). (Note the distinction between the general term "linker," "scFv linker," and "charged scFv linker.") Many strategies can be used to covalently link molecules together. These include, but are not limited to, peptide linkages between the N-terminus and C-terminus of proteins or protein domains, linkages via disulfide bonds, and linkages via chemical cross-linking agents. In one aspect of this embodiment, the linker is a peptide bond generated by recombinant technology or peptide synthesis. The linker peptide may primarily comprise the following amino acid residues: Gly, Ser, Ala, or Thr. The linker peptide should have a length suitable for linking two molecules such that they present the correct conformation relative to each other, allowing both molecules to retain the desired activity. In one embodiment, the linker length is from about 1 to 50 amino acids, preferably from about 1 to 30 amino acids. In one embodiment, linkers with a length of 1 to 20 amino acids can be used. Useful linkers include glycine-serine polymers (including, for example, (GS)n, (GSGGS)n (SEQ ID NO: 178), (GGGGS)n (SEQ ID NO: 179), and (GGGS)n (SEQ ID NO: 179). NO:180), where n is at least one integer, glycine-alanine polymers, alanine-serine polymers, and other flexible connectors. Alternatively, various non-protein polymers, including but not limited to polyethylene glycol (PEG), polypropylene glycol, polyoxoalkyl, or copolymers of polyethylene glycol and polypropylene glycol, may be used as connectors.

[0212] Other linker sequences may include any sequence of any length of the CL / CH1 domain (but not all residues of the CL / CH1 domain); for example, the first 5-12 amino acid residues of the CL / CH1 domain. Linkers may be derived from immunoglobulin light chains, such as Cκ or Cλ. Linkers may be derived from any isotype of immunoglobulin heavy chain, including, for example, Cγ1, Cγ2, Cγ3, Cγ4, Cα1, Cα2, Cδ, Cε, and Cμ. Linker sequences may also be derived from other proteins, such as Ig-like proteins (e.g., TCR, FcR, KIR), hinge region-derived sequences, and other native sequences from other proteins.

[0213] In some embodiments, the connector is a “domain connector” for joining any two domains outlined herein. For example, in Figure 18F, there is a domain connector that attaches the C end of the CH1 domain of Fab to the N end of scFv, and another optional domain connector that attaches the C end of scFv to the CH2 domain (although in many embodiments, a hinge is used as this domain connector). In some embodiments, the connector is a hinge region or a segment thereof.

[0214] Antibody-drug conjugates

[0215] The antigen-binding proteins disclosed herein (e.g., antibodies or heterodimeric antibodies) are optionally conjugated with drugs to form antibody-drug conjugates (ADCs). ADCs are typically used in various contexts, including oncology applications, where the use of antibody-drug conjugates for local delivery of cytotoxic or cytotoxic inhibitors allows for partial targeted delivery of drugs to tumors, which can allow for higher efficacy, lower toxicity, etc. Reviews of this technology are provided in Ducry et al., Bioconjugate Chem., 21:5-13 (2010); Carter et al., Cancer J., 14(3):154 (2008); and Senter, Current Opin. Chem. Biol., 13:235-244 (2009), all of which are incorporated herein by reference in their entirety.

[0216] Typically, conjugation is achieved through covalent attachment to the antibody, as further described below, and usually depends on a linker, typically a peptide linker (as described herein, which may be designed to be sensitive or insensitive to protease cleavage at the target site). Alternatively, linker-drug unit (LU-D) conjugation can be achieved by attachment to a cysteine ​​residue within the antibody. The drug moiety / antibody ratio can vary depending on the reaction conditions and can range from 1:1 to 10:1 drug:antibody. As those skilled in the art will understand, the actual figures are averages.

[0217] The drug of an ADC can be selected from any of a number of agents, including but not limited to cytotoxic agents (e.g., chemotherapeutic agents, growth inhibitors), toxins (e.g., enzymatically active toxins of bacterial, fungal, plant, or animal origin or fragments thereof), or radioactive isotopes (i.e., radioactive conjugates). This disclosure further provides methods for using ADCs.

[0218] In the context of this disclosure, "medicines" includes cytotoxic drugs, particularly those used for cancer treatment. These medicines generally include DNA damaging agents, antimetabolites, natural products, and analogues. Exemplary classes of cytotoxic agents include enzyme inhibitors (e.g., dihydrofolate reductase inhibitors and thymidine synthase inhibitors), DNA intercalators, DNA cleaving agents, topoisomerase inhibitors, anthracycline family drugs, vinblastine drugs, mitomycin, bleomycin, cytotoxic nucleosides, pteridine family drugs, diynenes, podophyllotoxin, dolastatins, maytansine alkaloids, differentiation inducers, and paclitaxel.

[0219] Members of these categories include, for example, methotrexate, methotrexate, dichloromethhotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, melphalan, cyclovinylcholine, leurosideine, actinomycin, daunorubicin, doxorubicin, mitomycin C, mitomycin A, kamimycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives (such as etoposide or etoposide phosphate), vinblastine, vincristine, vinblastine, etc. Diosmin, taxanes (including paclitaxel), docetaxel, retinoids, butyric acid, N8-acetylsemine, camptothecin, calicheamicin, espomycin, ene-diyne, duocarmycin A, duocarmycin SA, calicheamicin, camptothecin, maytansine alkaloids (including DM1), monomethylolpropionate E (MMAE), monomethylolpropionate F (MMAF), and maytansine alkaloids (DM4) and their analogues.

[0220] Toxins can be used as antibody-toxin conjugates, including bacterial toxins (e.g., diphtheria toxin), plant toxins (e.g., ricin), small molecule toxins (e.g., gledycin) (Mandler et al. (2000) J. Nat. Cancer Inst. 92(19):1573-1581; Mandler et al. (2000) Bioorganic & Med. Chem. Letters 10:1025-1028; Mandler et al. (2002) Bioconjugate Chem. 13:786-791), maytansine alkaloids (EP 1391213; Liu et al. (1996) Proc. Natl. Acad. Sci. USA 93:8618-8623), and cazithromycin (Lode et al. (1998) ...conjugate Chem. 92(19):1573-1581; Mandler et al. (2000) Bioconjugate Chem. 92(19):1573-1581; Man Res. [Cancer Research] 58:2928; Hinman et al. (1993) Cancer Res. [Cancer Research] 53:3336-3342. Toxins can exert their cytotoxic and inhibitory effects through mechanisms including tubulin binding, DNA binding, or topoisomerase inhibition.

[0221] Conjugates of antibodies (or other antigen-binding proteins) and one or more small molecule toxins (such as maytansine alkaloids, dolalastatin, trichothecene, kazimidam, and CC1065) and derivatives of these toxins with toxic activity were considered.

[0222] Maytansine compounds suitable for use as the pharmaceutical fraction of maytansine alkaloids are well known in the art and can be isolated from natural sources by known methods, produced using genetic engineering techniques (see Yu et al. (2002) PNAS 99:7968-7973), or synthesized synthetically using known methods. As described below, drugs can be modified to conjugate antibodies by incorporating functionally active groups (such as thiols or amine groups).

[0223] Exemplary maytansine alkaloid pharmaceutical portions include those having modified aromatic rings, such as: C-19-dechlorination (US Patent No. 4,256,746) (prepared by reducing ansamytocin P2 with lithium aluminum hydride); C-20-hydroxy (or C-20-demethyl) + / -C-19-dechlorination (US Patent Nos. 4,361,650 and 4,307,016) (prepared by demethylation using Streptomyces or Actinomycetes or by dechlorination using LAH); and C-20-demethoxy, C-20-acyloxy (--OCOR), + / -dechlorination (US Patent No. 4,294,757) (prepared by acyl chloride acylation) and those modified at other positions.

[0224] The exemplary maytansine alkaloid pharmaceutical portion also includes those having the following modifications: C-9-SH (US Patent No. 4,424,219) (prepared by reaction of maytansine with H2S or P2S5); C-14-alkoxymethyl (demethoxy / CH2OR) (US Patent No. 4,331,598); C-14-hydroxymethyl or acylmethyl (CH2OH or CH2OAc) (US Patent No. 4,450,254) (prepared by Nocardia); C-15-hydroxy / acylmethyl (US Patent No. 4,450,254) (prepared by Nocardia); Patent No. 4,364,866 (prepared by conversion of maytanol by Streptomyces); C-15-methoxy (US Patent Nos. 4,313,946 and 4,315,929) (isolated from Trewiana udlflora); C-18-N-demethyl (US Patent Nos. 4,362,663 and 4,322,348) (prepared by demethylation of maytanol by Streptomyces); and 4,5-deoxy (US Patent No. 4,371,533) (prepared by LAH reduction of titanium trichloride / maytanol).

[0225] Of particular useful are DM1 (disclosed in U.S. Patent No. 5,208,020, incorporated herein by reference) and DM4 (disclosed in U.S. Patent No. 7,276,497, incorporated herein by reference). See also U.S. Patent Nos. 5,416,064, 6,441,163, 7,303,749, 7,368,565, and 7,601,354; International Patent Publications Nos. WO / 01 / 24763, WO 02 / 098883, WO 02 / 16368, and WO 04 / 1033272; and numerous other maytansine alkaloid derivatives and methods in USSN 12 / 631,508, all of which are expressly incorporated herein by reference in their entirety.

[0226] ADCs containing maytansine alkaloids, their preparation methods, and their therapeutic uses are disclosed, for example, in U.S. Patent Nos. 5,208,020, 5,416,064, 6,441,163 and European Patent EP 0 425235B1, the disclosures of which are expressly incorporated herein by reference. Liu et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences] 93:8618-8623 (1996) describes an ADC containing a maytansine alkaloid named DM1 (which is linked to a monoclonal antibody C242 against human colorectal cancer).

[0227] Chari et al., Cancer Research 52:127-131 (1992) described ADCs in which maytansine alkaloids are conjugated to either mouse antibody A7 (which binds to an antigen on a human colon cancer cell line) or another mouse monoclonal antibody TA.1 (which binds to the HER-2 / neu oncogene) via a disulfide linker. The drug conjugates achieved a level of cytotoxicity similar to that of free maytansine alkaloids, which could be increased by increasing the number of maytansine alkaloid molecules per antibody molecule.

[0228] In some embodiments, the ADC comprises dolastatin or a dolastatin peptide analog or derivative, or auristatin (US Patent Nos. 5,635,483 and 5,780,588). Dolastatin and auristatin have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cell division (Woyke et al. (2001) Antimicrob. Agents and Chemother. 45(12):3580-3584), and have anticancer activity (US Patent No. 5,663,149) and antifungal activity (Pettit et al. (1998) Antimicrob. Agents and Chemother. 42:2961-2965). The drug portion of dolalastatin or olresatin can be attached to an antibody via the N (amino) terminus or C (carboxyl) terminus of the peptide drug portion (International Patent Publication No. WO 02 / 088172). In several respects, the heterodimeric antibody is part of a treatment regimen that also includes the administration of eribulin.

[0229] Exemplary embodiments of oliquistatin include the N-terminally linked monomethyl oliquistatin pharmaceutical portions DE and DF as disclosed in Senter et al., Proceedings of the American Association for Cancer Research, Vol. 45, Abstract No. 623, filed March 28, 2004, and in U.S. Patent Publication No. 2005 / 0238648 (the disclosure of which is expressly incorporated herein by reference in its entirety). An exemplary embodiment of oliquistatin is MMAE (see U.S. Patent No. 6,884,869, expressly incorporated herein by reference in its entirety). Another exemplary embodiment of oliquistatin is MMAF (see U.S. Patent No. 2005 / 0238649 and U.S. Patent Nos. 5,767,237 and 6,124,431, expressly incorporated herein by reference in their entirety).

[0230] Typically, peptide-based pharmaceutical moieties can be prepared by forming peptide bonds between two or more amino acids and / or peptide fragments. For example, such peptide bonds can be prepared according to liquid-phase synthesis methods well known in the field of peptide chemistry (see E. Schroder and K. Lubke, “The Peptides”, Vol. 1, pp. 76-136, 1965, Academic Press). The olistatin / dolalastatin drug fraction can be prepared according to the following methods: US Patent Nos. 5,635,483 and 5,780,588; Pettit et al. (1989) J. Am. Chem. Soc. 111:5463-5465; Pettit et al. (1998) Anti-Cancer Drug Design 13:243-277; Pettit, GR, et al. Synthesis, 1996, 719-725; Pettit et al. (1996) J. Chem. Soc. Perkin Trans. 15:859-863; and Doronina (2003) Nat Biotechnol 21(7):778-784.

[0231] In other embodiments, the ADC comprises one or more chachiomycin molecules. For example, gemutumab was the first commercial ADC drug and utilizes chachiomycin γ1 as the active ingredient (see U.S. Patent No. 4,970,198, which is incorporated herein by reference in its entirety). Further chachiomycin derivatives are described in U.S. Patent Nos. 5,264,586, 5,384,412, 5,550,246, 5,739,116, 5,773,001, 5,767,285, and 5,877,296, all of which are expressly incorporated herein by reference. The chachiomycin family of antibiotics is capable of producing double-strand DNA breaks at subpicomolar concentrations. For the preparation of conjugates of the chachimycin family, see U.S. Patent Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296 (all belonging to American Cyanamid Company). Structural analogues of chachimycin that can be used include, but are not limited to, γ1I, α2I, α2I, N-acetyl-γ1I, PSAG, and θI1 (Hinman et al., Cancer Research 53:3336-3342 (1993), Lode et al., Cancer Research 58:2925-2928 (1998), and the aforementioned U.S. Patents belonging to American Cyanamid Company). Another antitumor drug that antibodies can conjugate is QFA, an antifolate agent. Both chachiin and QFA have intracellular sites of action and do not readily cross the plasma membrane. Therefore, cellular uptake of these agents via antibody-mediated internalization significantly enhances their cytotoxic effects.

[0232] CC-1065 (see U.S. Patent No. 4,169,888, incorporated herein by reference) and docamicin are members of a family of antitumor antibiotics used in ADCs. These antibiotics appear to act by sequence-selectively alkylating adenine N3 in the minor groove of DNA, which triggers a cascade of events leading to apoptosis. Important members of docamicin include docamicin A (U.S. Patent No. 4,923,990, incorporated herein by reference) and docamicin SA (U.S. Patent No. 5,101,038, incorporated herein by reference), as well as those mentioned in U.S. Patent Nos. 7,517,903, 7,691,962, 5,101,038, 5,641,780, 5,187,186, 5,070,092, 5, 070,092, 5,641,780, 5,101,038, 5,084,468, 5,475,092, 5,585,499, 5,703,080, 6,989,452, 7,087,600, 7,129,261, 7,498,302, 7,507,420, and 5,846,545; and numerous similarities described in International Patent Publications WO 2007 / 089149 and WO 2009 / 017394A1, all of which are expressly incorporated by reference.

[0233] Other cytotoxic agents

[0234] Other antitumor agents that can conjugate with antigen-binding proteins include BCNU, streptozotocin, vincristine, and 5-fluorouracil, the family of agents known collectively referred to as the LL-E33288 complex as described in U.S. Patent Nos. 5,053,394 and 5,770,710, and esperamicins (U.S. Patent No. 5,877,296).

[0235] Usable enzymatically active toxins and their fragments include diphtheria toxin A chain, non-bound active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, *Sargentoxin A chain*, *Alternaria alternifolia*, tung oil protein, carnation toxin protein, *Phytolacca americana* protein (PAPI, PAPII, and PAP-S), bitter melon inhibitor, jatropha toxin protein, croton toxin, soapwort inhibitor, white tree toxin, mitogellin, aspergillus oryzae, phenolmycin, enoxacin, and trichothecene. See, for example, International Patent Publication No. WO 93 / 21232.

[0236] This disclosure further considers the formation of ADCs between antigen-binding proteins and compounds with nucleolytic activity (e.g., ribonucleases or DNA endonucleases, such as deoxyribonucleases; DNases).

[0237] For selective destruction of tumors, antigen-binding proteins (e.g., antibodies or heterodimeric antibodies) can contain highly radioactive atoms. A variety of radioactive isotopes can be used to produce radioactive conjugates. Examples include radioactive isotopes of At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212, and Lu.

[0238] Radioactive labels or other labels can be incorporated into conjugates in known ways. For example, peptides can be biosynthesized or synthesized via chemical amino acid synthesis using suitable amino acid precursors, such as fluorine-19 replacing hydrogen. Labels (e.g., Tc99m or I123, Re186, Re188, and In111) can be attached via cysteine ​​residues in the peptide. Yttrium-90 can be attached via lysine residues. The IODOGEN method (Fraker et al. (1978) Biochem. Biophys. Res. Commun. 80:49-57) can be used for incorporation of iodine-123. Other methods are described in detail in "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press, 1989).

[0239] In some cases, the separation, purification, and characterization of homogeneous ADCs can be achieved by methods such as reversed-phase HPLC or electrophoresis (where p is a specific value from an ADC with other drug loadings). In exemplary embodiments, p is 2, 3, 4, 5, 6, 7, or 8, or a fraction thereof.

[0240] It should be understood that the desired compound can also be chemically modified to facilitate its reaction for the preparation of the conjugates of the present invention. For example, functional groups (e.g., amines, hydroxyl groups, or thiol groups) can be attached to the drug at positions that have minimal or acceptable impact on the drug's activity or other properties.

[0241] Connector unit

[0242] Typically, antigen-binding protein-drug conjugates comprise a linker unit between a drug unit and an antigen-binding protein unit. In some embodiments, the linker is cleavable under intracellular or extracellular conditions, such that cleavage of the linker releases the drug unit from the antigen-binding protein in an appropriate environment. For example, solid tumors secreting certain proteases can serve as targets for cleavable linkers; in other embodiments, intracellular proteases are utilized. In still other embodiments, the linker unit is not cleavable, and the drug is released, for example, through antibody degradation in lysosomes.

[0243] In some embodiments, the linker can be cleaved by a cleaving agent present in the intracellular environment (e.g., in lysosomes, nucleosomal bodies, or cell indentations). The linker can be, for example, a peptide linker that is cleaved by intracellular peptidases or proteases (including, but not limited to, lysosomal or nucleosomal proteases). In some embodiments, the peptide linker is at least two amino acids long or at least three amino acids long or longer.

[0244] Cleavage agents may include, but are not limited to, cathepsins B and D and plasmin, all of which are known to hydrolyze dipeptide drug derivatives, resulting in the release of the active drug from within the target cell (see, for example, Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123). Peptide linkers can be cleaved by enzymes present in cells expressing CD38. For example, peptide linker bodies that can be cleaved by the thiol-dependent protease cathepsin-B (which is highly expressed in cancerous tissue) can be used (e.g., the Phe-Leu or Gly-Phe-Leu-Gly linker (SEQ ID NO:181)). Other examples of such linkers are described, for example, in U.S. Patent No. 6,214,345, which is incorporated herein by reference in its entirety.

[0245] In some embodiments, the peptide linker cleaved by the intracellular protease is a Val-Cit linker or a Phe-Lys linker (see, for example, U.S. Patent No. 6,214,345, which describes the synthesis of doxorubicin with a wval-cit linker).

[0246] In other embodiments, the cleavable adapter is pH sensitive, i.e., sensitive to hydrolysis at certain pH values. Typically, this pH-sensitive adapter is hydrolyzable under acidic conditions. For example, acid-instable adapters that are hydrolyzable in lysosomes (e.g., hydrazones, thioureas, cis-aconitamides, orthoesters, acetals, ketals, etc.) can be used. (See, for example, U.S. Patents 5,122,368; 5,824,805; and 5,622,929; Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123; Neville et al., 1989, Biol. Chem. 264:14653-14661). These adapters are relatively stable under neutral pH conditions (such as those in blood) but unstable below pH 5.5 or 5.0 (approximately the pH of lysosomes). In some embodiments, the hydrolyzable connector is a thioether connector (e.g., a thioether attached to a therapeutic agent via an acylhydrazone bond (see, for example, U.S. Patent No. 5,622,929)).

[0247] In other embodiments, the connector is cleavable under reducing conditions (e.g., a disulfide connector). Various disulfide connectors are known in the art, including, for example, those formed using SATA (N-succinimidyl-5-acetylthioacetate), SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB (N-succinimidyl-3-(2-pyridyldithio)butyrate), and SMPT (N-succinimidyl-oxycarbonyl-α-methyl-α-(2-pyridyl-dithio)toluene), as well as SPDB and SMPT. See, for example, Thorpe et al., 1987, Cancer Res. 47:5924-5931; Wawrzynczak et al., In Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of Cancer (edited by CW Vogel, Oxford University Press, 1987). See also U.S. Patent No. 4,880,935.

[0248] In other embodiments, the connector is a malonic acid ester connector (Johnson et al., 1995, Anticancer Res. 15:1387-93), a maleimide benzoyl connector (Lau et al., 1995, Bioorg-Med-Chem. 3(10):1299-1304), or a 3'-N-amide analog (Lau et al., 1995, Bioorg-Med-Chem. 3(10):1305-12).

[0249] In yet another embodiment, the connector unit is non-cuttable, and the drug is released via antibody degradation. See, for example, U.S. Patent Publication No. 2005 / 0238649, which is incorporated herein by reference in its entirety.

[0250] In many embodiments, the linker is self-sacrificing. As used herein, the term "self-sacrificing spacer" refers to a bifunctional chemical moiety capable of covalently linking two spacer chemical moieties together to form a stable triplet molecule. If its bond with the first moiety breaks, it will spontaneously separate from the second chemical moiety. See, for example, International Patent Publications WO2007059404A2, WO 06110476A2, WO 05112919A2, WO 2010 / 062171, WO 09 / 017394, WO 07 / 089149, WO 07 / 018431, WO 04 / 043493, and WO 02 / 083180, which relate to drug-cleavable substrate conjugates in which the drug and the cleavable substrate are optionally linked by a self-sacrificing linker, and all of these patents are expressly incorporated herein by reference.

[0251] Typically, linkers are substantially insensitive to the extracellular environment, meaning that when the antigen-binding protein-drug conjugate is present in the extracellular environment (e.g., in plasma), no more than about 20%, 15%, 10%, 5%, 3%, or no more than about 1% of the linker is cleaved in the antigen-binding protein-drug conjugate sample. Whether a linker is substantially insensitive to the extracellular environment can be determined, for example, by incubating the antigen-binding protein-drug conjugate compound with plasma for a predetermined period of time (e.g., 2, 4, 8, 16, or 24 hours) and then quantifying the amount of free drug present in the plasma.

[0252] In other non-mutually exclusive embodiments, the adapter promotes cell internalization. In some embodiments, the adapter promotes cell internalization when conjugated with a therapeutic agent (i.e., in the context of the adapter-therapeutic agent portion of an ADC as described herein). In still other embodiments, the adapter promotes cell internalization when conjugated with the olistatin compound and antigen-binding protein disclosed herein.

[0253] Various exemplary connectors that can be used with the compositions and methods of the present invention are described in International Patent Publication No. WO 2004-010957 and U.S. Patent Publications Nos. 2006 / 0074008, 20050238649, and 2006 / 0024317 (each incorporated herein by reference in its entirety).

[0254] It should be understood that, in many embodiments, the above-described therapeutic agent can be administered alone, i.e., without conjugation to antigen-binding proteins.

[0255] Drug load

[0256] Drug load is denoted by p and is the average number of drug moieties / antigen-binding proteins in the molecule. Drug load (“p”) can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more moieties (D) / antigen-binding proteins, although the average is usually a fraction or decimal. Typically, drug loads of 1 to 4 are useful, and 1 to 2 are also useful. The ADC disclosed herein comprises a collection of antigen-binding proteins conjugated to a series of drug moieties (from 1 to 20). The average number of drug moieties / antigen-binding proteins in the ADC formulation derived from the conjugation reaction can be characterized by conventional methods such as mass spectrometry and ELISA assays.

[0257] The quantitative distribution of ADCs based on p can also be determined. In some cases, homogeneous ADCs can be separated, purified, and characterized by methods such as electrophoresis (where p is a specific value from an ADC with other drug loadings).

[0258] For some ADCs, p may be limited by the number of attachment sites on the antigen-binding protein. For example, when the attachment is cysteine ​​thiol, as in the exemplary embodiments described above, the antigen-binding protein may have only one or more cysteine ​​thiol groups, or may have only one or more fully reactive thiol groups through which the adapter can be attached. In some embodiments, higher drug loading (e.g., p > 5) may lead to aggregation, insolubility, toxicity, or loss of cell permeability of certain antibody-drug conjugates. In some embodiments, the drug loading range for the ADCs disclosed herein is 1 to about 8; from about 2 to about 6; from about 3 to about 5; from about 3 to about 4; from about 3.1 to about 3.9; from about 3.2 to about 3.8; from about 3.2 to about 3.7; from about 3.2 to about 3.6; from about 3.3 to about 3.8; or from about 3.3 to about 3.7. Indeed, it has been shown that for some ADCs, the optimal ratio of drug moiety / antigen-binding protein may be less than 8, and may be from about 2 to about 5. See U.S. Patent Publication No. 2005 / 0238649A1 (which is incorporated herein by reference in its entirety).

[0259] In some embodiments, during the conjugation reaction, less than the theoretical maximum amount of the drug moiety conjugates with the antigen-binding protein. The antigen-binding protein may contain, for example, lysine residues that do not react with the drug-connector intermediates or connector reagents described below. Typically, antibodies do not contain a large number of free and reactive cysteine ​​thiols that can be linked to the drug moiety; in fact, most cysteine ​​thiols in antibodies are present as disulfide bonds. In some embodiments, the antibody can be reduced with a reducing agent (such as dithiothreitol (DTT) or tricarbonylethylphosphine (TCEP)) under partial or total reducing conditions to produce reactive cysteine ​​thiols. In some embodiments, the antibody is subjected to denaturing conditions to reveal reactive nucleophilic groups (e.g., lysine or cysteine).

[0260] The loading capacity (drug / antigen-binding protein ratio) of an ADC can be controlled in various ways, for example by: (i) limiting the molar excess of the drug-adaptor intermediate or adaptor reagent relative to the antibody; (ii) limiting the conjugation reaction time or temperature; (iii) using partial or restrictive reduction conditions for cysteine ​​thiol modification; (iv) by recombinant technology to engineer the amino acid sequence of the antigen-binding protein such that the number and position of cysteine ​​residues are modified to control the number and / or position of adaptor-drug attachments (such as thioMab or thioFab prepared as disclosed, for example, in International Patent Publication No. WO 2006 / 034488 (which is incorporated herein by reference in its entirety).

[0261] It should be understood that when more than one nucleophilic group reacts with a drug-linker intermediate or linker reagent, followed by a reaction with a drug moiety reagent, the resulting product is a mixture of ADC compounds, in which one or more drug moieties are distributed and attached to antigen-binding proteins. The drug-to-antigen-binding protein ratio can be calculated from the mixture using a dual ELISA antibody assay that is specific for both the antigen-binding protein and the drug. Individual ADC molecules can be identified in the mixture by mass spectrometry and separated by HPLC, such as hydrophobic interaction chromatography.

[0262] In some embodiments, homogeneous ADCs with a single loading value can be separated from conjugated mixtures by electrophoresis or chromatography.

[0263] Composition

[0264] Formulations used according to this disclosure are prepared by mixing an antigen-binding protein of desired purity with an optional pharmaceutically acceptable carrier, excipient, or stabilizer for storage (Remington's Pharmaceutical Sciences 16th edition, Osol, A. editor

[1980] ), in the form of a lyophilized formulation or an aqueous solution. The compositions disclosed herein are preferably sterile. Acceptable carriers, excipients, or stabilizers are non-toxic to the recipient at the doses and concentrations used and include buffers (such as phosphates, citrates) and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyl dimethyl benzyl ammonium chloride; hexamethyl ammonium chloride; benzalkonium chloride, benzyl chloride; phenol, butyl or benzyl alcohol; alkyl parabens, such as methyl parabens or propyl parabens; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 1... 0 residues) polypeptides; proteins (such as serum albumin, gelatin, or immunoglobulins); hydrophilic polymers (such as polyvinylpyrrolidone); amino acids (such as glycine, glutamine, asparagine, histidine, arginine, or lysine); monosaccharides, disaccharides, and other carbohydrates (including glucose, mannose, or dextrin); chelating agents (such as EDTA); sugars (such as sucrose, mannitol, trehalose, or sorbitol); salt-forming counterions (such as sodium); metal complexes (such as Zn-protein complexes); and / or nonionic surfactants (such as TWEEN). TM PLURONICS TM Or polyethylene glycol (PEG)).

[0265] The formulation may also contain one or more active compounds necessary for the specific indication being treated, preferably those with complementary activities that will not adversely affect each other. For example, it may be necessary to provide antigen-binding proteins with other specificities. Alternatively or additionally, the composition may contain cytotoxic agents, cytokines, growth inhibitors, and / or small molecule antagonists, such as any of the drugs mentioned herein. Such molecules are suitably present in a combination in amounts effective for the intended purpose.

[0266] Active ingredients can also be encapsulated in microcapsules (e.g., hydroxymethyl cellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively) prepared by cohesive techniques or interfacial polymerization, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in coarse-drop emulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. (1980).

[0267] Sustained-release formulations can be prepared. Suitable examples of sustained-release formulations include a semi-permeable matrix of a solid hydrophobic polymer containing an antigen-binding protein, in the form of a molded article (e.g., a film or microcapsule). Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)), polylactic acid (US Patent No. 3,773,919), copolymers of L-glutamic acid and γ-ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, and degradable lactic acid-glycolic acid copolymers, such as LUPRON DEPOT. TM (Injectable microspheres composed of lactic-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers (such as ethylene-vinyl acetate and lactic-glycolic acid) can release molecules for more than 100 days, some hydrogels release proteins for a shorter period of time.

[0268] When encapsulated antibodies are stored in vivo for extended periods, they may denature or aggregate due to exposure to moisture at 37°C, leading to loss of biological activity and potential changes in immunogenicity. Stability can be achieved by designing appropriate strategies based on the mechanisms involved. For example, if the aggregation mechanism is found to be the formation of intermolecular SS bonds through thio-disulfide exchange, stabilization can be achieved by modifying thiol residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

[0269] Application mode

[0270] The antigen-binding protein and optional co-treatment (e.g., one or more chemotherapeutic agents or another antibody therapy (e.g., anti-PD-1 antibody)) are administered to the subject via clinically acceptable methods, such as intravenous, intramuscular, intraperitoneal, subcutaneous, intra-articular, intralesional, intrasynovial, intrathecal, oral, local, intratumoral, lymphatic infusion, or aspiration. Intravenous or subcutaneous administration of the antigen-binding protein is preferred. Booster and continuous infusion are anticipated, such as local administration at the site of disease or injury. The use of the antigen-binding protein (optionally with another therapeutic agent) in ex vivo methods is also considered. For example, the patient's blood or other bodily fluids can be contacted with the antigen-binding protein ex vivo and optionally administered. The antigen-binding protein can be bound to a suitable insoluble matrix or solid support.

[0271] How to use

[0272] This disclosure provides methods for treating a subject in need, including administering the antigen-binding protein described herein (e.g., an antibody or a heterodimeric antibody) to the subject. In several embodiments, this disclosure provides methods for treating cancer (e.g., prostate cancer or Ewing sarcoma) in a subject in need, including administering the antigen-binding protein described herein (e.g., an antibody or a heterodimeric antibody) to the subject. This disclosure further provides the use of the antigen-binding protein (e.g., an antibody or a heterodimeric antibody) of this disclosure for treating a subject in need, such as for treating cancer (e.g., prostate cancer or Ewing sarcoma) in the subject. The cancer is preferably a cancer associated with increased STEAP1 expression (e.g., more than 10,000 STEAP1 / cell). Examples of cancers include, but are not limited to, prostate cancer, breast cancer, pancreatic cancer, bladder cancer, gastrointestinal cancer, testicular cancer, ovarian cancer, cervical cancer, and sarcoma (Ewing sarcoma) and melanoma.

[0273] The methods used to treat the subjects described herein are intended to provide improvement in the disease or condition, and / or improvement in symptoms associated with the disease or condition. For example, a treatment response is defined as one or more of the following improvements in the disease: (1) a reduction in the number of neoplasms; (2) an increase in neoplasm death; (3) inhibition of neoplasm survival; (5) inhibition of tumor growth or the appearance of new lesions (i.e., to some extent slowing down, preferably stopping); (6) improved patient survival; and / or (7) some relief from one or more symptoms associated with the disease or condition (e.g., in the case of prostate cancer, urinary frequency, nocturia, hematuria, dysuria, or bone pain; in the case of Ewing sarcoma in the affected area, pain, swelling, or tenderness).

[0274] Treatment response in any given disease or condition can be determined using standardized response criteria specific to that disease or condition. Tumor response can be assessed using screening techniques such as magnetic resonance imaging (MRI), X-ray imaging, computed tomography (CT) scans, positron emission tomography (PET), bone scans, ultrasound, tumor biopsy, counting of circulating tumor cells, and / or measurement of tumor antigens (e.g., prostate-specific antigen (PSA) and / or alpha-fetoprotein (AFP)). In addition to these treatment responses, treated subjects may experience beneficial effects such as improvement in disease-related symptoms.

[0275] Subjects are mammals, preferably humans, and optionally human males. In the case of cancer, subjects may be diagnosed with any stage of the disease (i.e., stage I, II, III, or IV prostate cancer) or may be at risk of developing a cancer that has not yet been clinically confirmed.

[0276] For prostate cancer, subjects may experience a reduction in prostate cancer-related symptoms (such as those described herein), a decrease in tumor size, a decrease in prostate cancer marker levels, a decrease in the incidence of new lesions, etc. In several respects, the methods disclosed herein further include monitoring the subject's treatment. Any improvement in the subject's health status (e.g., absence of clinically detectable disease, any reduction in measurable tumor burden (e.g., at least a reduction of about 50%) in the absence of new lesions (i.e., the number of malignant cells present in the subject or the measured mass of the tumor mass), pain relief, and improved urination) should be considered.

[0277] The treatments disclosed herein include a “therapeutic effective amount” of the drug used. A “therapeutic effective amount” is an effective amount, measured in dose and sustained for the required period of time, to achieve the desired therapeutic outcome. A “therapeutic effective amount” can vary depending on various factors, such as an individual’s disease state, age, sex, and weight, as well as the drug’s ability to elicit a desired response in the individual. A therapeutic effective amount is also an amount in which any toxicity or adverse effect is outweighed by the beneficial effect of the treatment. A “therapeutic effective amount” for cancer treatment can also be measured by its ability to stabilize disease progression. An exemplary, non-limiting range of antigen-binding proteins for therapeutic effective amounts disclosed herein is about 0.1-100 mg / kg. For ease of administration and dose uniformity, parenteral compositions can be formulated into unit dosage forms. When used herein, the term “dose unit” refers to a physically discrete unit suitable as a single dose to a subject to be treated; each unit contains a predetermined amount of therapeutic agent, calculated to produce the desired biological effect, in combination with the desired pharmaceutical carrier.

[0278] In some embodiments, an antigen-binding protein (e.g., a monospecific antibody or a heterodimeric antibody) is used in combination with one or more additional therapeutic agents (e.g., a chemotherapeutic agent or an immunotherapeutic agent). One or more additional therapeutic agents may be administered sequentially (within minutes, hours, days, or weeks) or in parallel; they may also be administered to the patient as a pre-mixed single composition.

[0279] Non-limiting examples of DNA-damaging chemotherapeutic agents include topoisomerase I inhibitors (e.g., irinotecan, topotecan, camptothecin and its analogues or metabolites, and doxorubicin); topoisomerase II inhibitors (e.g., etoposide, teniposide, and daunorubicin); alkylating agents (e.g., melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, carmustine, lomustine, semustine, streptozotocin, aminopyrimidine, methotrexate, mitomycin C, and cyclophosphamide); DNA intercalating agents (e.g., cisplatin, oxaliplatin, epirubicin, and carboplatin); DNA intercalating agents and free radical generating agents (e.g., bleomycin); and nucleoside mimics (e.g., 5-fluorouracil, capecitabine, gemcitabine, fludarabine, cytarabine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea).

[0280] Chemotherapy agents that disrupt cell replication include, but are not limited to, paclitaxel, docetaxel and related analogues; cabzitaxel; vincristine, vinblastine and related analogues; thalidomide, lenalidomide and related analogues (e.g., CC-5013 and CC-4047); tyrosine protein kinase inhibitors (e.g., imatinib mesylate and gefitinib); proteasome inhibitors (e.g., bortezomib); NF-κB inhibitors (including IκB kinase inhibitors); antibodies that bind to proteins overexpressed in cancer, thereby downregulating cell replication (e.g., trastuzumab, rituximab, cetuximab, and bevacizumab); and other inhibitors of proteins or enzymes known to be upregulated, overexpressed, or activated in cancer (inhibition of which downregulates cell replication).

[0281] In some embodiments, the antigen-binding protein disclosed herein (e.g., a monospecific antibody or a heterodimer antibody) may be used before, concurrently with, or after treatment with docetaxel. In several aspects, the antigen-binding protein (e.g., a monospecific antibody or a heterodimer antibody) is administered as part of a treatment plan that includes surgery and / or radiation (e.g., external beam or brachytherapy).

[0282] In several respects, antigen-binding proteins (e.g., monospecific antibodies or heterodimer antibodies) are provided as part of a treatment regimen that also includes the administration of hormone therapy (e.g., androgen deprivation therapy, such as agents that block the release or production of luteinizing hormone-releasing hormone (e.g., leuprorelin, goserelin, triptorelin, or degarelix); antiandrogens (e.g., bicalutamide, flutamide, or nilumid); ketoconazole; abiraterone acetate; enzalutamide)).

[0283] In several respects, antigen-binding proteins (e.g., monospecific antibodies or heterodimer antibodies) are provided as part of a treatment regimen that also includes the administration of another immunotherapy (e.g., sipuleucel-T, bevacizumab, atezolizumab, avelumab, iplimumab, tremelimumab, AM-224, MDX-1105, eftilagimod alpha (IMP321), or enoblituzumab (MGA271)). In this regard, the method optionally includes the administration of another antigen-binding protein targeting a different antigen, such as a cancer-associated antigen or an antigen associated with an immune response. For example, in several embodiments, an anti-STEAP1 antigen-binding protein is administered to a subject together with a PD-1-targeting antigen-binding protein (e.g., an antibody), which reduces, blocks, inhibits, eliminates, or interferes with signal transduction arising from the interaction of PD-1 with one or more binding partners (e.g., PD-L1 or PD-L2). In a specific aspect, the PD-1 antigen-binding protein inhibits the binding of PD-1 to PD-L1 and / or PD-L2. In one embodiment, the PD-1 antigen-binding protein reduces negative co-stimulatory signals mediated by or mediated by cell surface proteins expressed on T lymphocytes via PD-1 signaling, thereby reducing dysfunction in dysfunctional T cells (e.g., enhancing effector responses to antigen recognition). Examples of anti-PD-1 antibodies include nivolumab (BMS-936558), pembrolizumab (MK-3475), BMS 936558, BMS-936559, TSR-042 (Tesaro), ePDR001 (Novartis), and pidilizumab (CT-011). While this disclosure relates to PD-1 antigen-binding proteins, it also considers the use of other PD-1 binding antagonists that reduce, block, inhibit, eliminate, or interfere with signal transduction induced by the interaction of PD-1 with one or more of its binding partners, such as PD-L1 or PD-L2.

[0284] This disclosure regarding anti-STEAP1 antigen-binding proteins also applies to anti-PD-1 antigen-binding proteins. For example, in various cases, the anti-PD-1 antigen-binding protein is an antibody (e.g., monoclonal IgG). The anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product is monovalent or bivalent. In an exemplary aspect, the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product binds to human PD-1 (which has the amino acid sequence SEQ ID NO: 187). In an exemplary aspect, the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product binds to cynomolgus monkey PD-1 (which has the amino acid sequence SEQ ID NO: 188). In an exemplary instance, the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product binds to both human PD-1 and cynomolgus monkey PD-1.

[0285] In exemplary embodiments, the binding strength of an anti-PD-1 antibody, its antigen-binding antibody fragment, or anti-PD-1 antibody protein product to PD-1 can be described by KD. In an exemplary aspect, the KD of the anti-PD-1 antibody, its antigen-binding antibody fragment, or anti-PD-1 antibody protein product provided herein is about 10. -1 M, approximately 10 -2 M, approximately 10 -3 M, approximately 10 -4 M, approximately 10 -5 M, approximately 10 -6 M, approximately 10 -7 M, approximately 10 -8 M, approximately 10 -9 M, or lower. In an exemplary aspect, the KD of the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product provided herein is micromolar, nanomolar, picomolar, or femtomolar. In an exemplary aspect, the KD of the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product provided herein is approximately 10. -4 Up to 10 -6 M, or 10 -7 Up to 10 -9 M, or 10 -10 Up to 10 -12 M, or 10 -13 Up to 10 -15Within the range of M. In an exemplary aspect, the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product has high affinity for human PD-1, cynomolgus monkey PD-1, or both. In an exemplary aspect, the KD of the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product for human PD-1 is less than 100 pM, optionally from about 1 pM to about 50 pM. In an exemplary aspect, the KD of the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product for human PD-1 is in the range of about 1 pM to about 20 pM or less than about 10 pM. In an exemplary aspect, the KD of the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product for cynomolgus monkey PD-1 is less than 100 pM, optionally from about 1 pM to about 75 pM. In an exemplary aspect, the KD of anti-PD-1 antibody, its antigen-binding antibody fragment, or anti-PD-1 antibody protein product against cynomolgus monkey PD-1 is in the range of about 1 pM to about 20 pM or less than 10 pM.

[0286] In an exemplary aspect, an anti-PD-1 antibody, its antigen-binding antibody fragment, or an anti-PD-1 antibody protein product inhibits the binding interaction between PD-1 and PD-L1 or PD-L2 by at least 50%. In an exemplary aspect, an anti-PD-1 antibody, its antigen-binding antibody fragment, or an anti-PD-1 antibody protein product exhibits inhibition of at least about 50%, at least about 60%, or at least about 70% of the binding interaction between PD-1 and PD-L1 or PD-L2.

[0287] In an exemplary embodiment, in a mixed lymphocyte reaction (MLR), PD-1-mediated T cell IL-2 production is inhibited by an anti-PD-1 antibody, its antigen-binding antibody fragment, or an anti-PD-1 antibody protein product. In an exemplary embodiment, the IC50 of the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product in the MLR is in the range of about 0.1 nM to about 5 nM. In an exemplary embodiment, the IC50 of the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product in the MLR is less than 2 nM or less than 1 nM. In an exemplary embodiment, the IC50 of the anti-PD-1 antibody, its antigen-binding antibody fragment, or the anti-PD-1 antibody protein product in the MLR is about 0.5 nM to about 2 nM.

[0288] Methods for testing the ability of antibodies to bind to PD-1 are known in the art and include any suitable antibody-antigen binding assay, such as radioimmunoassay (RIA), ELISA, Western blotting, immunoprecipitation, SPR, and competitive inhibition assays (see, for example, Janeway et al., hereinafter, and U.S. Patent Application Publication No. 2002 / 0197266, and the foregoing section relating to competitive assays). Other binding assays (e.g., competitive binding assays or competitive assays that test the ability of an antibody to compete with a second antibody for binding to an antigen or its epitope) can be used to test the ability of an antibody to bind to PD-1. See, for example, U.S. Patent Application Publication No. 2014 / 0178905; Chand et al., Biologicals 46:168-171 (2017); Liu et al., Anal Biochem 525:89-91 (2017); and Goolia et al., J Vet Diagn Invest 29(2):250-253 (2017). Furthermore, other methods for comparing two antibodies are known in the art and include, for example, surface plasmon resonance (SPR). SPR can be used to determine the binding constants of the antibody and the second antibody, and the two binding constants can be compared. This disclosure contemplates the use of an anti-PD1 antigen-binding protein, which, in the context of the methods disclosed herein, competes with or cross-blocks the binding of any anti-PD-1 antibody described herein to the PD-1 protein.

[0289] A representative method for characterizing human / cynomolgus monkey PD-1 binding affinity is as follows. The antibody is incubated in wells containing soluble recombinant receptor human PD-1 (1-170)-FLAG-His or cynomolgus monkey PD-1 (1-167)-FLAG-His at 3-fold serial dilutions. In both cases, a maximum PD-1 concentration of 30 nM can be selected. Associativity for 300 seconds and dissociation for 500 seconds can be used, as these parameters generally produce sufficient curvature for accurate kinetic fitting. Human / cynomolgus monkey PD-1 binding affinity can be quantified using a ForteBio OctetHTX and RED384 instrument. Standard Octet sample buffers are used for sample dilution and binding baseline, association, and dissociation steps (e.g., 10 mM Tris, pH 7.5, 150 mM NaCl, 1 mM CaCl2, 0.10 mg / ml BSA, 0.13% (v / v) Triton X-100). ForteBio raw data can be processed using standard instrument data analysis software (v9 and v10) in the following ways: (a) averaging two reference curves with a fixed target but no interaction (i.e., buffer only) and subtracting them from the remaining sample curves in the same column; (b) separating the association and dissociation curves and aligning them with the Y-axis; (c) aligning the association and dissociation stages; (d) implementing Savitzky-Golay filtering to reduce signal noise; and (e) globally fitting a single 1:1 binding model to the set of association and dissociation curves for each sample-target interaction to determine the measured values ​​of the binding rate constant ka and the dissociation rate constant kd; the equilibrium dissociation constant KD is calculated as the ratio of the dissociation and association rate constants (=kd / ka).

[0290] In an exemplary example, the anti-PD-1 antibody (or its antigen-binding antibody fragment or antibody protein product) comprises: the amino acid sequence of heavy chain (HC) complementarity-determining region 1 (vhCDR1) listed in SEQ ID NO:189, the amino acid sequence of HC CDR2 (vhCDR2) listed in SEQ ID NO:190, the amino acid sequence of HC CDR3 (vhCDR3) listed in SEQ ID NO:191, the amino acid sequence of light chain (LC) CDR1 (vlCDR1) listed in SEQ ID NO:192, the amino acid sequence of LC CDR2 (vlCDR2) listed in SEQ ID NO:193, and the amino acid sequence of LC CDR3 (vlCDR3) listed in SEQ ID NO:194. In an exemplary embodiment, the anti-PD-1 antibody (or its antigen-binding antibody fragment or antibody protein product) comprises a heavy chain variable region (vh) and / or a light chain variable region (vl), wherein the heavy chain variable region comprises an amino acid sequence having at least 90% identity (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) with the amino acid sequence of SEQ ID NO:195; and the light chain variable region comprises an amino acid sequence having at least 90% identity (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) with the amino acid sequence of SEQ ID NO:196. In an exemplary embodiment, the anti-PD-1 antibody (or its antigen-binding antibody fragment or antibody protein product) comprises a heavy chain and / or a light chain, wherein the heavy chain comprises an amino acid sequence having at least 90% identity (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) with the amino acid sequence of SEQ ID NO:197; and the light chain comprises an amino acid sequence having at least 90% identity (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) with the amino acid sequence of SEQ ID NO:198.

[0291] In an exemplary aspect, the anti-STEAP1 construct described herein is part of a treatment regimen that includes the administration of cytokines, lymphokines, growth factors, or hematopoietic factors that effectively inhibit tumor metastasis and / or have antiproliferative effects on at least one cell population. Such cytokines, lymphokines, growth factors, or other hematopoietic factors include, but are not limited to: M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IFN, TNFα, TNF1, TNF2, G-CSF, Meg-CSF, GM-CSF, thrombopoietin, stem cell factors, and erythropoietin.Other growth factors include, for example, angiopoietin, bone morphogenetic protein-1, bone morphogenetic protein-2, bone morphogenetic protein-3, bone morphogenetic protein-4, bone morphogenetic protein-5, bone morphogenetic protein-6, bone morphogenetic protein-7, bone morphogenetic protein-8, bone morphogenetic protein-9, bone morphogenetic protein-10, bone morphogenetic protein-11, bone morphogenetic protein-12, bone morphogenetic protein-13, bone morphogenetic protein-14, bone morphogenetic protein-15, and bone morphogenetic protein-16. Protein receptor IA, bone morphogenetic protein receptor IB, brain-derived neurotrophic factor, ciliary neurotrophic factor, ciliary neurotrophic factor receptor α, cytokine-induced neutrophil chemokine 1, cytokine-induced neutrophil chemokine 2α, cytokine-induced neutrophil chemokine 2β, β-endothelial growth factor, endothelin 1, epithelial-derived neutrophil attractant, glial cell line-derived neurotrophic factor receptor α1, glial cell line-derived neurotrophic factor receptor α2, growth-related proteins Growth-associated protein α, growth-associated protein β, growth-associated protein γ, heparin-binding epidermal growth factor, hepatocyte growth factor, hepatocyte growth factor receptor, insulin-like growth factor I, insulin-like growth factor receptor, insulin-like growth factor II, insulin-like growth factor binding protein, keratinocyte growth factor, leukemia inhibitory factor, leukemia inhibitory factor receptor α, nerve growth factor, nerve growth factor receptor, neurotrophic factor-3, neurotrophic factor-4, pre-B cell growth stimulating factor, stem cell factor, stem cell factor receptor, transforming growth factor α, transforming growth factor β, transforming growth factor β1, transforming growth factor β1.2, transforming growth factor β2, transforming growth factor β3, transforming growth factor β5, potential transforming growth factor β1, transforming growth factor β-binding protein I, transforming growth factor β-binding protein II, transforming growth factor β-binding protein III, tumor necrosis factor receptor type I, tumor necrosis factor receptor type II, urokinase-type plasminogen activator receptor, and chimeric proteins and their biologically or immunologically active fragments. In an exemplary embodiment, the anti-STEAP1 construct is administered as part of a treatment regimen that involves administering an antibody specific to any of the aforementioned cytokines, lymphokines, growth factors, or other hematopoietic factors.

[0292] This disclosure considers the use of anti-STEAP1 antigen-binding protein or heterodimer antibody in the preparation of a medicament for treating cancer in subjects in need of it. Optionally, the medicament is an effective amount of anti-STEAP1 antigen-binding protein or heterodimer antibody for administration in combination with an effective amount of an anti-PD-1 antigen-binding protein (e.g., any of the anti-PD-1 antigen-binding proteins described herein).

[0293] This disclosure further considers the use of the anti-STEAP1 antigen-binding protein or heterodimer antibody described herein in the treatment of cancer (i.e., methods of treating cancer (such as prostate cancer or Ewing sarcoma)) in subjects in need of it. Optionally, the anti-STEAP1 antigen-binding protein or heterodimer antibody may be administered together with the anti-PD1 antigen-binding protein. The phrase “administered together with” indicates that the anti-STEAP1 antigen-binding protein or heterodimer antibody is part of a treatment regimen that includes the administration of the anti-PD1 antigen-binding protein. In practice, the anti-STEAP1 antigen-binding protein (e.g., the heterodimer antibody) may be used before, concurrently with, or after treatment with the anti-PD1 antigen-binding protein. The administration of the anti-STEAP1 antigen-binding protein or heterodimer antibody and the anti-PD1 antigen-binding protein does not need to occur simultaneously, although this disclosure considers examples in which the components are contained in the same pharmaceutical composition and administered together. This disclosure also provides treatment methods in which anti-STEAP1 antigen-binding protein or heterodimer antibody and anti-PD1 antigen-binding protein are present in separate pharmaceutical compositions, which are administered in parallel or in close proximity. Anti-STEAP1 antigen-binding protein or heterodimer antibody and anti-PD1 antigen-binding protein can be administered sequentially in any order (e.g., within minutes, hours, days, or weeks of each other). The administration pattern is as described above.

[0294] For example, the anti-STEAP1 antigen-binding protein described herein can also be used in assays for detecting the presence of STEAP1 in vitro or in vivo. STEAP1 can also be purified using the antigen-binding protein, for example, by immunoaffinity chromatography.

[0295] Nucleic acid, vector, host cell

[0296] This disclosure further provides nucleic acid compositions encoding antigen-binding proteins described herein (e.g., monospecific antibodies or heterodimeric antibodies). The nucleic acid component encoding the antigen-binding protein of this disclosure may be incorporated into an expression vector as known in the art and depending on the host cell used to produce the antigen-binding protein. Examples of expression vectors include, but are not limited to, plasmids, viral vectors, non-free mammalian vectors, and other expression vectors. Typically, the nucleic acid sequence encoding the desired polypeptide is operatively linked to any number of regulatory elements (promoters, origins of replication, selection markers, ribosome binding sites, inducers, etc.). The expression vector may be an extrachromosomal vector or an integrative vector.

[0297] The nucleic acids and / or expression vectors disclosed herein may optionally be introduced into any number of different types of host cells (including mammalian, bacterial, yeast, insect, and / or fungal cells) well known in the art, wherein mammalian cells (e.g., CHO cells) may be used in many embodiments. In another aspect, this disclosure provides host cells in which an expression vector encoding an antigen-binding protein has been introduced. Examples of suitable mammalian host cell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651) (Gluzman et al., 1981, Cell 23:175), L cells, human embryonic kidney 293 cells or their derivatives (e.g., HEK293T, HEK293-EBNA), C127 cells, mouse embryonic fibroblasts (3T3 cells) (ATCCCCCL 163), Chinese hamster ovary (CHO) cells and their derivatives (e.g., CHO-K1, CHO pro-3), mouse myeloma cells (e.g., NS0, GS-NS0, Sp2 / 0), human cervical cancer cells (HeLa cells), and young hamster kidney (BHK) cells (ATCC CRL 1651). The transformed cells included CRL10 cell lines, human osteosarcoma epithelial cells U2-OS, adenocarcinoma human alveolar basal epithelial cells (A549), human fibrosarcoma cells (HT1080), mouse brain tumor cells (CAD), embryonal tumor cells (P19), mouse neuroblastoma cells (N2a), human breast cancer cells (MCF-7), retinoblastoma cells (Y79), human retinoblastoma cells (SO-Rb50), human liver cancer cells (Hep G2), mouse B myeloma cells (J558L), and African green monkey kidney cells (e.g., COS cells, VERO cells, and their derivatives, including the CVI / EBNA cell line derived from the African green monkey kidney cell line CVI (ATCC CCL 70) as described by McMahan et al., 1991, EMBO J. [Journal of the European Society for Molecular Biology] 10:2821). The transformed cells could be cultured under conditions that promoted antigen-binding protein expression, and the proteins could be recovered using standard protein purification procedures. One such purification procedure involves using affinity chromatography, for example, to pass through a matrix to which STEAP1 binds in whole or in part (e.g., one or more extracellular loops). Antigen-binding proteins considered for use herein include substantially homogeneous recombinant antigen-binding proteins that are substantially free of contaminating endogenous substances.

[0298] Regarding heterodimeric antibodies, compositions are provided in several aspects, comprising a nucleic acid encoding a first monomer, a nucleic acid encoding a second monomer, and a nucleic acid encoding a common light chain. This disclosure also provides nucleic acid constructs encoding portions of the monomer and the common light chain (e.g., anti-STEAP1 Fab binding to STEAP1 or antibody fragments containing the six CDRs disclosed herein), anti-CD3 scFv, variable light chain and / or variable heavy chain domains binding to STEAP1 and / or CD3, etc.

[0299] In some embodiments, typically under different or the same promoter control, the nucleic acid encoding each monomer and optionally the nucleic acid encoding a common light chain are each contained within a single expression vector. In many embodiments, each of the two or three nucleic acids is contained on a different expression vector. As described in U.S. Patent Publication No. 2016 / 0215063 (incorporated herein by reference in its entirety, and particularly with respect to the discussion of recombinant antibody production), different vector ratios can be used to drive heterodimer formation. Surprisingly, in cases where the antibody construct contains a first monomer: second monomer: light chain in a 1:1:2 ratio, these are not necessarily the optimal ratios for producing results. See Figure 65 of U.S. Patent Publication No. 2016 / 0215063, by reference and herein. In several aspects, this disclosure provides nucleic acid compositions comprising: a) a first expression vector containing a first nucleic acid encoding a first monomer; b) a second expression vector containing a second nucleic acid encoding a second monomer; and c) a third expression vector containing a third nucleic acid encoding a common light chain. In an alternative embodiment, the third nucleic acid encoding the common light chain is present on the same expression vector as the first or second nucleic acid.

[0300] Heterodimeric antibodies are optionally prepared by culturing host cells containing one or more expression vectors. Once generated, antibody purification steps are performed, typically including ion-exchange chromatography. As discussed herein, making the pIs of the two monomers differ by at least 0.5 allows for separation by ion-exchange chromatography, isoelectric focusing, or other methods sensitive to the isoelectric point. In other words, pI substitutions that alter the isoelectric point (pI) of each monomer result in each monomer having a different pI, and the heterodimer also having a different pI, thereby facilitating isoelectric purification of the heterodimer (e.g., anion-exchange columns, cation-exchange columns). These substitutions also help identify and monitor any contaminating mAb homodimers after purification (e.g., IEF gels, cIEF, and analytical IEX columns).

[0301] medicine box

[0302] In some embodiments, the antigen-binding protein disclosed herein is provided in a kit. In an exemplary aspect, the kit contains the antigen-binding protein as a unit dose (i.e., a discrete amount dispersed in a suitable carrier). In an exemplary aspect, the kit contains several unit doses, for example, a weekly or monthly supply of unit doses, optionally each unit dose individually packaged or otherwise packaged separately from other unit doses. In some embodiments, the components of the kit / unit dose are packaged together with instructions for patient administration. In some embodiments, the kit contains one or more devices for administration to a patient, such as needles and delivery devices (e.g., syringes). In some aspects, the antigen-binding protein is pre-packaged in a ready-to-use form (e.g., syringe, intravenous infusion bag, etc.), but it is also contemplated that the antigen-binding protein may be provided in a lyophilized form reconfigurable as needed. In some aspects, the kit further contains other therapeutic or diagnostic agents or pharmaceutically acceptable carriers (e.g., solvents, buffers, diluents, etc.) including any of those described herein.

[0303] All references cited herein (including publications, patent applications, and patents) are incorporated herein by reference to the extent that each reference is individually and explicitly indicated to be incorporated by reference and to the extent that its entire contents are expressed herein.

[0304] The following examples are provided for illustrative purposes only and do not limit the scope of this disclosure in any way.

[0305] Example

[0306] Example 1

[0307] This example describes the detection of STEAP1 on the surface of prostate cancer cells using a monospecific antibody as described above.

[0308] Prostate cancer cells (C4-2B luc cells) were engineered using a CRISPR construct targeting STEAP1 to lose STEAP1 expression. Figure 11 A) or C4-2B luc STEAP1 KO cell( Figure 11 B) Incubate with isotype control antibody or anti-STEAP1 mouse monoclonal antibody (Ab-Am) at a concentration of 10 μg / mL at 4°C for 1 hour. In the FITC-conjugated ( Figure 11 A) or APC combination ( Figure 11 After incubation with anti-mouse IgG secondary antibody B), cell-bound Ab-Am was detected by flow cytometry. FITC or APC fluorescence, used to identify STEAP1-dependent signaling, was plotted in a histogram (solid gray histogram) and compared with an isotype control (white histogram). Results were shown... Figure 11 In A and 11B.

[0309] Example 2

[0310] This example describes the characterization of the anti-STEAP1 antibody.

[0311] A group of 22 anti-human STEAP1 mouse monoclonal antibodies were generated. Compared with other tests, antibody A showed improved flow cytometry binding properties (parental mAb binding to LnCAP(+) / DU145(-) FACS conversion (fold)): Ab-A (60.1), Ab-B (3.6), Ab-C (2.4), and Ab-D (4.3).

[0312] To identify the STEAP1 region recognized by the antibody disclosed herein, a chimeric construct was generated in which each of the three extracellular loops of STEAP1 was replaced by the corresponding STEAP2 region and expressed in 293 cells. Ab-A binds to STEAP1 but not to STEAP2. Replacing extracellular loops 1 and 3 of STEAP1 with the corresponding loops from STEAP2 eliminated the binding, while the binding of Ab-A to STEAP1 was not disrupted when extracellular loop 2 was replaced with the STEAP2 counterpart. Ab-A appears to bind to extracellular loop 2 of STEAP1.

[0313] As described, for example, in U.S. Patent Publication No. 2016 / 0215063, heterodimeric antibodies comprising a STEAP-1 binding arm and an anti-CD3 binding arm, of the “XmAb” type, were prepared. These heterodimeric antibodies exhibited TDCC activity (pM): Ab-A1x (273.8), Ab-A2x (387.9), and Ab-B1x (128.7).

[0314] Example 3

[0315] This example compares heterodimers with the disclosed anti-STEAP1 / anti-CD3 (Xmab) formulation. 2+1 The binding of different scaffolds of anti-STEAP1 / anti-CD3 bispecific antibodies (XmAb) to C4-2B cells (characterized by EC50).

[0316] For example, as described in U.S. Patent Publication No. 2016 / 0215063 (incorporated herein by reference, particularly with regard to the discussion of the “opener” type), three humanized anti-STEAP1 antibodies (Ab-A1, Ab-A2(N67Q), and Ab-B1) in the “XmAb” type are produced. This XmAb type requires: a first heavy chain containing an Fc domain attached to anti-CD3 scFv; a second heavy chain containing the Fc domain and a first variable heavy chain domain; and a light chain containing a variable light chain domain and a constant light chain domain. The variable heavy chain domain and the variable light chain domain bind to STEAP1. The heterodimer XmAb is used. 2+1 Type (Ab-A1 XmAb 2+1 and Ab-B1 XmAb 2+1 Two humanized antibodies against STEAP1 were produced: Ab-A1 and XmAb. 2+1 and Ab-B1XmAb 2+1 The CDR sequence is listed in SEQ ID NO:11-16(Ab-A1 XmAb) 2+1 ) and SEQ ID NO:30-35(Ab-B1XmAb 2+1 In addition, Ab-A1 XmAb with N67Q modification was also produced. 2+1 The variant, named Ab-A2(N67Q)XmAb in this paper, is... 2+1 Ab-A2(N67Q)XmAb 2+1 The CDR sequences are listed in SEQ ID NO: 11-13, 14, 16, and 21. The antibodies are named Ab-A2 and Ab-A2(N67Q)XmAb. 2+1 The terms are used interchangeably in this article. The ability of the heterodimeric bispecific antibody to bind to STEAP1 expressed on the surface of C4-2B prostate cancer cells was evaluated, as were three unhumanized mouse anti-STEAP1 antibodies in the XmAb form (Ab-Mx1, Ab-Mx2, and Ab-Mx3).

[0317] C4-2B-Luc cells were treated with increasing concentrations of Ab-A1 XmAb. 2+1 Ab-A1 Xmab, Ab-B1 Xmab, Ab-Mx1, Ab-Mx2, and Ab-Mx3 were incubated at 4°C to 5 μM for 1 hour. After incubation with APC-conjugated anti-human IgG secondary antibodies, the cell-bound antibodies were detected by flow cytometry, and the mean fluorescence intensity (MFI) of the APC channels for each antibody at increasing concentrations was measured. As shown in Table 3, Ab-A1 Xmab... 2+1The cell binding EC50 was 65-fold lower than that of the same binder in the XmAb form (i.e., Ab-A1Xmab), indicating a very strong affinity exceeding that of the corresponding XmAb. 2+1 The formulation significantly improved the binding of the Ab-A binder to STEAP1 expressed on prostate cancer cells.

[0318] Table 3. Anti-STEAP XmAb and Anti-STEAP Xmab 2+1 Binding to C4-2B cells EC50

[0319] antibody molecules EC50(nM) Ab-A1 Xmab 144.0 Ab-B1 Xmab 798.1 Ab-Mx1 1226 Ab-Mx2 1252 Ab-Mx3 5005 <![CDATA[Ab-A1 XmAb 2+1 ]]> 2.203

[0320] Repeat the experiment with Ab-A in the following forms (Ab-A (traditional, monospecific antibody, non-humanized): Ab-A1XmAb, Ab-A1Xmab). 2+1 Type, and Ab-A2(N67Q)Xmab 2+1 The formulations included (with N67Q modification) and Ab-B XmAb. C4-2B-Luc cells were treated at 4°C with increasing concentrations of anti-STEAPI XmAb or XmAb. 2+1 The molecules were incubated together at 5 μM for 1 hour. After incubation with the APC-conjugated anti-human IgG secondary antibody, cell-bound XmAb was detected by flow cytometry, and the mean fluorescence intensity (MFI) of the APC channels for each increasing concentration of anti-STEAPI XmAb molecules is shown below. Figures 12A-12C and Figure 13 And in Table 4.

[0321] Table 4. EC50 binding to C4-2B luc cells

[0322] Type STEAP1 binder Types of binders <![CDATA[EC 50 (nM)]]> mAb Ab-A mice 1.2 XmAb Ab-A1 Xmab Humanization 144 <![CDATA[XmAb 2+1 ]]> <![CDATA[Ab-A1 XmAb 2+1 ]]> Humanization 2.2 <![CDATA[XmAb 2+1 ]]> <![CDATA[AbA2-(N67Q)XmAb 2+1 ]]> Humanization 1.2 XmAb Ab-B1 XmAb Humanization 48.9

[0323] Regardless of the heterodimer form, these antibodies bind to STEAP1. Compared to other antibody types, XmAb... 2+1 The model indicates an integration with improvements to STEAP1.

[0324] TDCC activity was also assessed using methods similar to those described above. All tested antibodies showed TDCC activity, with XmAb showing the highest activity. 2+1 The antibodies exhibited better activity than Xmab antibodies: Ab-A XmAb (EC50 = 274 pM, EC90 = 438 pM), Ab-A1 Xmab (EC50 = 388 pM, EC90 = 722 pM), Ab-B1 Xmab (EC50 = 129 pM, EC90 = 265 pM), Ab-A1 Xmab 2+1(EC50 = 6 pM, EC90 = 11 pM), and Ab-B1 Xmab 2+1 (EC50=19pM, EC90=43pM).

[0325] Example 5

[0326] This instance characterizes the anti-STEAP1 XmAb and XmAb. 2+1 Mediated human T cell lysis of human tumor cell line C4-2B luc.

[0327] C4-2B luc prostate cancer cells were compared with human pan-T cells at an E:T cell ratio of 10:1, and at increasing concentrations of ( Figure 14 A)Ab-A1 XmAb、( Figure 14 B)Ab-A1XmAb 2+1 ,or( Figure 14 C)Ab-A2(N67Q)XmAb 2+1 Cells of the appropriate form (with N67Q substitution) were co-cultured for 48 hours. Target cell lysis was monitored by luciferase activity assays, and specific cytotoxicity was plotted at each concentration compared to the control condition without XmAb. Figure 14 As shown in A-14C, Ab-A1 Xmab and Ab-A1 XmAb 2+1 And Ab-A2(N67Q)XmAb 2+1 Successfully mediated target cell lysis.

[0328] Example 6

[0329] This example demonstrates the ability of the disclosed heterodimer antibody to distinguish between cells expressing STEAP1 and cells not expressing STEAP.

[0330] STEAP1-positive C4-2B luc prostate cancer cells (●) and STEAP1-negative C4-2B luc STEAP1 KO Cells (■) and human pan-T cells at an E:T cell ratio of 10:1 and increasing concentrations of Ab-A1 XmAb 2+1 Cells were co-cultured for 48 hours. Target cell lysis was monitored by luciferase activity assays, and specific cytotoxicity was plotted at each concentration compared to control conditions (without XmAb). Results are shown below. Figure 15 And in Table 5. Ab-A1 XmAb 2+1 It mediates target cell lysis of the human tumor cell line C4-2B luc in a dose-dependent manner, but does not mediate the lysis of C4-2B luc cells modified to knock out STEAP1 expression.

[0331] Table 5. In anti-STEAP1 XmAb (Ab-A1 XmAb) and XmAb 2+1 (Ab-A1 and Ab-A2(N67Q)) variants for C4-2B luc and C4-2B luc STEAP1KO T cell-dependent cytotoxicity (TDCC) EC50

[0332]

[0333] In addition, 293T cells stably transfected with human STEAP1 ( Figure 16 A) or parental 293T cells ( Figure 16 B) Incubate with isotype control antibody or anti-STEAP1 Ab-A mouse monoclonal antibody (Ab-Am; no bispecific form) at a concentration of 10 μg / mL at 4°C for 1 hour. Incubate with FITC-conjugated anti-mouse IgG secondary antibody (…). Figure 16 A) After incubation, the cell-bound Ab-Am was detected by flow cytometry. FITC fluorescence for identifying STEAP1-dependent signaling was plotted in a histogram (solid gray histogram) and compared with an isotype control (white histogram). Figure 16 As shown in A and 16B, Ab-Am assays were performed to detect STEAP-1 expression in the two cell populations tested.

[0334] Figure 16 C describes the combination of STEAP1-stabilized 293T cells (●) and STEAP1-negative parental 293T cells (■) with human pan-T cells at an E:T cell ratio of 10:1, along with increasing concentrations of Ab-A2 (N67Q)XmAb. 2+1 Results of co-culture for 48 hours. Target cell lysis was monitored by luciferase activity assay, and specific cytotoxicity was plotted at each concentration compared to the XmAb-free control. Results are shown below. Figure 16 In A-16C and Table 6, the anti-STEAP1 / anti-CD3 heterodimer antibody selectively mediates cell lysis in cells expressing STEAP1.

[0335] Table 6. In Ab-A2-N67Q XmAb 2+1 T cell-dependent cytotoxicity (TDCC) EC50 in stable transfected 293T cells with human STEAP1 and parental 293T cells under certain conditions

[0336] Molecular form STEAP1 binder Types of binders target cell lines <![CDATA[TDCC EC 50 (pM)]]> <![CDATA[XmAb 2+1 ]]> Ab-A2(N67Q) Humanization 293T / STEAP1 0.1 <![CDATA[XmAb 2+1 ]]> Ab-A2(N67Q) Humanization 293T / parent >10,000

[0337] STEAP1-positive C4-2B luc prostate cancer cells were also compared with human pan-T cells at an E:T cell ratio of 10:1, and with increasing concentrations of Ab-B1 Xmab (●) or Ab-B1 XmAb. 2+1 (■) The culture lasts for a total of 48 hours. For example... Figure 17 As shown in A, Ab-B1Xmab and Ab-B1 XmAb 2+1 Mediates the lysis of target cells in C4-2B luc prostate cancer cells.

[0338] C4-2B luc prostate cancer cells were mixed with human pan-T cells at an E:T cell ratio of 10:1 and with increasing concentrations of XmAb. 2+1 Ab-B1-G37A (XmAb with G37A substitution) 2+1 (■), XmAb 2+1 Ab-B1-S39A (XmAb with S39A substitution) 2+1 Type)(▲), or XmAb 2+1 Ab-B1-G37A / S39A (XmAb with both G37A and S39A substitutions) 2+1 (Type)(▼) Cultured for a total of 48 hours. For example... Figure 17 Figure B shows that Ab-B1 variants (i.e., Ab-B1-G37A, Ab-B1-S39A, and Ab-B1-G37A / S39A) mediate target cell lysis in C4-2B luc prostate cancer cells. See also Table 7 below. Similarly, STEAP1-negative C4-2B luc... STEAP1 KO Cancer cells and human pan-T cells were used in an E:T cell ratio of 10:1, with increasing concentrations of Ab-B1 and mAb. 2+1 Cells were co-cultured with (●), Ab-B1-G37A (■), Ab-B1-S39A (▲), or Ab-B1-G37A / S39A (▼) for 48 hours. Target cell lysis was monitored by luciferase activity assays, and specific cytotoxicity was plotted at each concentration compared to the control without XmAb. Results are shown below. Figure 17C And as shown in Table 7. The anti-STEAP1 / anti-CD3 heterodimer antibody selectively mediates cell lysis of cells expressing STEAP1, and the XmAb disclosed herein... 2+1 Its form is superior to other forms.

[0339] Table 7. C4-2B luc and C4-2B luc in the case of Ab-B1 variant STEAP1KO T cell-dependent cytotoxicity (TDCC) EC50

[0340]

[0341] Example 7

[0342] This example characterizes the heterodimeric antibody Ab-A2(N67Q)XmAb disclosed herein. 2+1 The equilibrium binding constant (KD) of CD3ε in humans and cynomolgus monkeys.

[0343] The affinity of recombinant human or cynomolgus monkey CD3ε to Ab-A2(N67Q)XmAb was measured using surface plasmon resonance (SPR-Pioneer FE). 2+1 Using a standard amine coupling procedure, recombinant human CD3ε-Fc and cynomolgus monkey CD3ε-Fc were immobilized on the surface of a CM5 chip at approximately 60 RU. Ab-A2(N67Q)XmAb 2+1 Injections were administered at concentrations of 100, 33.3, 11.1, and 3.7 nM. As listed in Table 8 below, Ab-A2(N67Q)×mAb was recorded at 120 seconds and 300 seconds, respectively. 2+1 Association and dissociation rates with ligands. Equilibrium dissociation constant (K). D The values ​​of k are used as the dissociation rate constant and the association rate constant. 解离 / k 缔合 The ratio is derived from ).

[0344] Table 8. Ab-A2-N67Q XmAb 2+ The association and dissociation rates of human and cynomolgus monkey CD3 interactions are indicated by "a". The generated data, where "b" indicates data generated using Octet.

[0345]

[0346] Example 8

[0347] This example illustrates the heterodimeric antibody (Ab-A2(N67Q)XmAb) disclosed herein. 2+1 This mediates the lysis of a series of target cells that exhibit STEAP1 surface density.

[0348] The density of STEAP-1 on the surface of various target cell lines (SNU-5, C4-2B, Sk-N-MC, LOX-IMVI, VCaP, IM-95, TYKNU, 22RV-1, HBSCM, HUCCT1, PC3, HCT116, and NCIH1869) was assessed. See Table 9 below for the identification of STEAP1 density (number of STEAP I antibody binding sites / cell) in column 3, as measured using the Dako Qifikit method.

[0349] Table 9. STEAP1 surface density and T cell-dependent cytotoxicity (TDCC) EC50 and EC90

[0350]

[0351] In separate studies, the density of STEAP-1 on the surface of OE33, EBC1, and A673 cell lines was evaluated. See Table 10 below for the identification of STEAP1 density (number of STEAP I antibody binding sites / cell) in column 3, as measured using the Dako Qifikit method.

[0352]

[0353] T cells from human donors were combined with target cell lines and increasing concentrations of Ab-A2(N67Q)XmAb. 2+1 The molecules were incubated at 37°C for 48 hours. After 48 hours, cell viability was measured using stable glo(B) or cell titer glo to measure target cell viability. Ab-A2(N67Q)XmAb 2+1 Killer cell lines, among which EC90 is different.

[0354] Ab-A2(N67Q)XmAb 2+1 It is capable of killing cancer cell lines with STEAP1 densities ranging from approximately 200,000 STEAP1 receptors / cell (SNU5 cell line) to approximately 10,000 STEAP1 receptors / cell (LOX-IMV cell line). When the STEAP1 receptor density drops to 10,000 receptors / cell, Ab-A2(N67Q)XmAb... 2+1 The efficacy is reduced. In this respect, Ab-A2(N67Q)XmAb 2+1 Preferentially mediates T cell-dependent killing of cells with a surface density of STEAP1 greater than 10,000 (e.g., EC90 is at least 10-fold lower for cells with a surface density of STEAP1 greater than 10,000 compared to cells with a surface density of STEAP1 less than 10,000).

[0355] With Ab-A2-N67G XmAb 2+1 In comparison, using Xmab 2+1 Type (Ab-B-G52A XmAb) 2+1 and mouse antibody Ab-Cm XmAb 2+1 Other antibodies used to assess differential killing of cancer cells include Ab-A2-N67G and XmAb. 2+1 This indicates differential killing between cells with high and low STEAP1 expression; however, Ab-B-G52A XmAb...2+1 There was no distinction between cells expressing high and low levels of STEAP1; instead, every STEAP1-expressing cell was killed. See Table 11. Ab-A2-N67G XmAb 2+1 It does not harm normal cells that express STEAP1 at low levels (i.e., less than 10,000 / cell), such as HSMBC (naïve human smooth muscle bronchial cells).

[0356] Table 11. Ab-B1 XmAb 2+1 and Ab-Cm XmAb 2+1 It kills cells that express high or low levels of STEAP1.

[0357]

[0358]

[0359] Example 9

[0360] This example demonstrates that the combination of the anti-CD3 / anti-STEAP1 heterodimer antibody and the anti-PD-1 antibody described herein enhances T cell-dependent cytotoxicity.

[0361] Generation of PD-L1 overexpressing cell lines: GP2-293 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, 1% Pen / Strep, 1% HEPES, and 1% GlutaMAX. Cells were seeded at 75% confluence in 10 cm culture dishes and incubated overnight at 37°C and 5% CO2. The next morning, cells were transfected. 45 μL of liposome 3000 and 500 μL of OptiMEM medium were added to tube A. 15 μg of MSCV_GFP_PD-L1 plasmid, 1.8 μg of VSV-g plasmid, 30 μL of P3000 reagent, and 500 μL of OptiMEM medium were added to tube B. Tubes A and B were mixed and incubated at room temperature for 10 minutes. The mixture was then added dropwise to the GP2-293 cell culture dish and incubated overnight at 37°C and 5% CO2. The following morning, the culture medium was removed and replaced with 10 mL of fresh medium. That afternoon, target cells were plated at 75% confluence in 6-well plates and incubated overnight at 37°C and 5% CO2. The following morning, viral supernatant was collected from GP2-293 cells and centrifuged (5 min, 1200 rpm). The supernatant was collected in a new tube and polybrene was added at a 1:1000 ratio. The culture medium was removed from the plate containing target cells, and 2 mL of viral supernatant was added. For suspension cells, 1E6 cells were centrifuged at 1500 rpm for 5 min, resuspended in 500 μL of RPMI supplemented with 10% fetal bovine serum and 1% pen / strep, and plated in 6-well plates, with 2 mL of viral supernatant added. The plates containing target cells and viral supernatant were centrifuged at 1200 x g at 32°C for 1.5 h, and then incubated at 37°C and 5% CO2. Culture medium was added after 5 hours. Four days later, GFP and PD-L1 expression in cells were analyzed by flow cytometry using FACSymphony. PD-L1 was detected using a PE-conjugated antibody (clone 29E.2A3). Cells with PD-L1 expression <70% were sorted on a BD Melody sorter to select cells expressing high levels of PD-L1.

[0362] T-cell-dependent cytotoxicity (TDCC) assay: Ab-A2(N67Q)XmAb 2+1Diluted in cell culture medium (RPMI, 10% heat-inactivated fetal bovine serum, 1X GlutaMAX, 1X Pen / Strep) serially (1:3, 22 times in total) and transferred to 384-well plates with a black, clear bottom using a Bravo liquid handling machine. Pre-activated human pan-T cells (n=4) of CD3 / CD28 Dynabeads (1:1, 48 hours) were separated from the beads using a magnet and diluted in cell culture medium. (PD-1 expression in aliquots of activated T cells from each donor was assessed by flow cytometry. Cells were stained as described above, and data were collected on a FACSymphony flow cytometer and analyzed using FlowJo v10.1.) Activated T cells (2500 cells / 20 μL; 4 rows / donor) followed by PD-L1-overexpressing target cells were plated in 384-well assay plates (2500 cells / 20 μL; whole plate) to achieve a final effector-to-target cell (E:T) ratio of 1:1. The disclosed anti-PD-1 antibody (finally 10 μg / mL in 5 μL) containing the CDR sequence of SEQ ID NO: 189-194 was added to two rows for each T cell donor. The plates were covered with a MicroClime cap and incubated at 37°C, 5% CO2 for 24 hours. For assays with target cells expressing luciferase, add 30 μL of Steady-Glo, Bright-Glo, or One-Glo reagent (Promega). Wash plates containing adherent target cells that do not express luciferase with PBS to remove T cells using an EL406 plate washer, and add 25 μL of cell titer Glo reagent. Incubate the plates in the dark at room temperature with the reagent for 10 minutes. Detect luminescence using a BioTek Neo plate reader. (Comparison with Ab-A2-free XmAb) 2+1 Target cells incubated with T cells were used to calculate specific cytotoxicity. Dose curves were plotted using Graphpad Prism software, and EC50 values ​​were calculated by fitting a four-parameter variable slope curve.

[0363] The results of the TDCC measurement are shown in Figure 20A and 20B In. Compared with Ab-A2(N67Q)XmAb alone. 2+1 In comparison, Ab-A2(N67Q)XmAb 2+1 The combination with anti-PD-1 antibody showed enhanced cytotoxicity and reduced EC50.

[0364] Example 10

[0365] This example illustrates the heterodimeric antibody disclosed herein (e.g., Ab-A2(N67Q)XmAb). 2+1The ability to reduce the volume of Ewing sarcoma tumors in vivo.

[0366] On day 1, use 5 x 10 6 SK-N-MC tumor cells expressing STEAP1 were transplanted into sublethal irradiated NOD / SCID female immunocompromised mice. On day 8, 2x10⁻⁶ cells were injected intraperitoneally. 7 CD3+ human T cells. Ab-A2(N67Q)XmAb was administered intravenously (IV) bolus at days 12, 19, and 26 at doses of 0.01, 0.1, or 1 mg / kg. 2+1 Or a mediator control. Tumor volume data over time are presented graphically. Figure 22 ).

[0367] Ab-A2(N67Q)XmAb 2+1 Induced initial tumor regression, with relative tumor volume (RTV) <1 in all dose groups between days 15 and 22, while RTV continued to increase in vector-treated animals until the end of the study. Animals receiving the lowest dose of Ab-A2(N67Q)XmAb... 2+1 Tumors in animals treated with (0.01 mg / kg) began to continue growing after day 22, while those treated with higher doses of Ab-A2(N67Q)XmAb... 2+1 Mice treated with doses (0.1 and 1 mg / kg) had a mean RTV <1 up to day 28 and 25, respectively (Table 12).

[0368] Table 12. Relative tumor volume compared to day 11

[0369]

[0370] Between days 15 and 22, when compared with control group 2 treated with the medium, in all Ab-A2(N67Q)XmAb 2+1 At the dose level, p-values ​​<0.001 were achieved, and after day 22, at 0.1 and 1 mg / kg Ab-A2(N67Q)XmAb 2+1 The p-value was <0.001 at the dose point. Figure 23 On day 28, the tumors in the mediator-treated mice (Group 2) were on average 5.29 times larger than their initial volume before initial treatment, while those in Ab-A2(N67Q)XmAb... 2+1 The mean RTV in the treatment groups was 0.61 (Group 3), 1.13 (Group 4), and 4.24 (Group 5) (Table 1). At the end of the 28-day lifespan, the highest Ab-A2(N67Q)×mAb... 2+1Nine out of ten animals in the dosage group (Group 3) were considered tumor-free, with a tumor growth inhibition (TGI) rate of 97% (Table 13).

[0371] Table 13. Tumor growth inhibition (tumor volume)

[0372]

[0373] Therefore, in relevant xenotransplantation models in clinical practice, Ab-A2(N67Q)XmAb 2+1 It exhibits convincing antitumor activity. sequence list <110> Amgen Inc. <120> Anti-STEAP1 antigen-binding protein <130> 32512 / 52601 <150> US 62 / 693216 <151> 2018-07-02 <150> US 62 / 800,259 <151> 2019-02-01 <160> 214 <170> PatentIn version 3.5 <210> 1 <211> 207 <212> PRT <213> Homo sapiens <400> 1 Met Gln Ser Gly Thr His Trp Arg Val Leu Gly Leu Cys Leu Leu Ser 1 5 10 15 Val Gly Val Trp Gly Gln Asp Gly Asn Glu Glu Met Gly Gly Ile Thr 20 25 30 Gln Thr Pro Tyr Lys Val Ser Ile Ser Gly Thr Thr Val Ile Leu Thr 35 40 45 Cys Pro Gln Tyr Pro Gly Ser Glu Ile Leu Trp Gln His Asn Asp Lys 50 55 60 Asn Ile Gly Gly Asp Glu Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp 65 70 75 80 His Leu Ser Leu Lys Glu Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr 85 90 95 Val Cys Tyr Pro Arg Gly Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu 100 105 110 Tyr Leu Arg Ala Arg Val Cys Glu Asn Cys Met Glu Met Asp Val Met 115 120 125 Ser Val Ala Thr Ile Val Ile Val Asp Ile Cys Ile Thr Gly Gly Leu 130 135 140 Leu Leu Leu Val Tyr Tyr Trp Ser Lys Asn Arg Lys Ala Lys Ala Lys 145 150 155 160 Pro Val Thr Arg Gly Ala Gly Ala Gly Gly Arg Gln Arg Gly Gln Asn 165 170 175 Lys Glu Arg Pro Pro Pro Val Pro Asn Pro Asp Tyr Glu Pro Ile Arg 180 185 190 Lys Gly Gln Arg Asp Leu Tyr Ser Gly Leu Asn Gln Arg Arg Ile 195 200 205 <210> 2 <211> 339 <212> PRT <213> Homo sapiens <400> 2 Met Glu Ser Arg Lys Asp Ile Thr Asn Gln Glu Glu Leu Trp Lys Met 1 5 10 15 Lys Pro Arg Arg Asn Leu Glu Glu Asp Asp Tyr Leu His Lys Asp Thr 20 25 30 Gly Glu Thr Ser Met Leu Lys Arg Pro Val Leu Leu His Leu His Gln 35 40 45 Thr Ala His Ala Asp Glu Phe Asp Cys Pro Ser Glu Leu Gln His Thr 50 55 60 Gln Glu Leu Phe Pro Gln Trp His Leu Pro Ile Lys Ile Ala Ala Ile 65 70 75 80 Ile Ala Ser Leu Thr Phe Leu Tyr Thr Leu Leu Arg Glu Val Ile His 85 90 95 Pro Leu Ala Thr Ser His Gln Gln Tyr Phe Tyr Lys Ile Pro Ile Leu 100 105 110 Val Ile Asn Lys Val Leu Pro Met Val Ser Ile Thr Leu Leu Ala Leu 115 120 125 Val Tyr Leu Pro Gly Val Ile Ala Ala Ile Val Gln Leu His Asn Gly 130 135 140 Thr Lys Tyr Lys Lys Phe Pro His Trp Leu Asp Lys Trp Met Leu Thr 145 150 155 160 Arg Lys Gln Phe Gly Leu Leu Ser Phe Phe Phe Ala Val Leu His Ala 165 170 175 Ile Tyr Ser Leu Ser Tyr Pro Met Arg Arg Ser Tyr Arg Tyr Lys Leu 180 185 190 Leu Asn Trp Ala Tyr Gln Gln Val Gln Gln Asn Lys Glu Asp Ala Trp 195 200 205 Ile Glu His Asp Val Trp Arg Met Glu Ile Tyr Val Ser Leu Gly Ile 210 215 220 Val Gly Leu Ala Ile Leu Ala Leu Leu Ala Val Thr Ser Ile Pro Ser 225 230 235 240 Val Ser Asp Ser Leu Thr Trp Arg Glu Phe His Tyr Ile Gln Ser Lys 245 250 255 Leu Gly Ile Val Ser Leu Leu Leu Gly Thr Ile His Ala Leu Ile Phe 260 265 270 Ala Trp Asn Lys Trp Ile Asp Ile Lys Gln Phe Val Trp Tyr Thr Pro 275 280 285 Pro Thr Phe Met Ile Ala Val Phe Leu Pro Ile Val Val Leu Ile Phe 290 295 300 Lys Ser Ile Leu Phe Leu Pro Cys Leu Arg Lys Lys Ile Leu Lys Ile 305 310 315 320 Arg His Gly Trp Glu Asp Val Thr Lys Ile Asn Lys Thr Glu Ile Cys 325 330 335 Ser Gln Leu <210> 3 <211> 121 <212> PRT <213> Mus musculus <400> 3 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Met Met Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Thr Tyr 20 25 30 Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Leu Pro Gly Ser Gly Asn Thr Asp Phe Asn Glu Lys Phe 50 55 60 Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asp Thr Ala Tyr 65 70 75 80 Met His Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Trp Gly Tyr Tyr Gly Thr Arg Gly Tyr Phe Asn Val Trp Gly 100 105 110 Ala Gly Ser Thr Val Thr Val Ser Ser 115 120 <210> 4 <211> 5 <212> PRT <213> Mus musculus <400> 4 Thr Tyr Trp Ile Glu 1 5 <210> 5 <211> 17 <212> PRT <213> Mus musculus <400> 5 Glu Ile Leu Pro Gly Ser Gly Asn Thr Asp Phe Asn Glu Lys Phe Lys 1 5 10 15 Gly <210> 6 <211> 12 <212> PRT <213> Mus musculus <400> 6 Trp Gly Tyr Tyr Gly Thr Arg Gly Tyr Phe Asn Val 1 5 10 <210> 7 <211> 106 <212> PRT <213> Mus musculus <400> 7 Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 20 25 30 His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 35 40 45 Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Arg Ser Phe Pro Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 8 <211> 10 <212> PRT <213> Mus musculus <400> 8 Ser Ala Ser Ser Ser Val Ser Tyr Met His 1 5 10 <210> 9 <211> 7 <212> PRT <213> Mus musculus <400> 9 Ser Thr Ser Asn Leu Ala Ser 1 5 <210> 10 <211> 9 <212> PRT <213> Mus musculus <400> 10 Gln Gln Arg Arg Ser Phe Pro Tyr Thr 1 5 <210> 11 <211> 10 <212> PRT <213> Homo sapiens <400> 11 Arg Ala Ser Ser Ser Val Ser Tyr Met His 1 5 10 <210> 12 <211> 7 <212> PRT <213> Homo sapiens <400> 12 Ser Thr Ser Asn Leu Ala Ser 1 5 <210> 13 <211> 9 <212> PRT <213> Homo sapiens <400> 13 Gln Gln Arg Arg Ser Phe Pro Tyr Thr 1 5 <210> 14 <211> 5 <212> PRT <213> Homo sapiens <400> 14 Thr Tyr Trp Ile Glu 1 5 <210> 15 <211> 17 <212> PRT <213> Homo sapiens <400> 15 Glu Ile Leu Pro Gly Ser Gly Asn Thr Asp Phe Asn Glu Lys Phe Gln 1 5 10 15 Gly <210> 16 <211> 12 <212> PRT <213> Homo sapiens <400> 16 Trp Gly Tyr Tyr Gly Thr Arg Gly Tyr Phe Asn Val 1 5 10 <210> 17 <211> 232 <212> PRT <213> Homo sapiens <400> 17 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu 20 25 30 Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Ser Ser Val 35 40 45 Ser Tyr Met His Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu 50 55 60 Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe 65 70 75 80 Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu 85 90 95 Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Arg Ser Phe 100 105 110 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val 115 120 125 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 130 135 140 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 145 150 155 160 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 165 170 175 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 180 185 190 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 195 200 205 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 210 215 220 Lys Ser Phe Asn Arg Gly Glu Cys 225 230 <210> 18 <211> 469 <212> PRT <213> Homo sapiens <400> 18 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 20 25 30 Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 Ser Thr Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Arg Leu 50 55 60 Glu Trp Met Gly Glu Ile Leu Pro Gly Ser Gly Asn Thr Asp Phe Asn 65 70 75 80 Glu Lys Phe Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Ser Asp 85 90 95 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110 Tyr Tyr Cys Thr Arg Trp Gly Tyr Tyr Gly Thr Arg Gly Tyr Phe Asn 115 120 125 Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro Ser Asp Thr Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Pro 245 250 255 Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 260 265 270 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 275 280 285 Lys His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 290 295 300 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Glu Tyr Asn Ser 305 310 315 320 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 325 330 335 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 340 345 350 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 355 360 365 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 370 375 380 Val Ser Leu Thr Cys Asp Val Ser Gly Phe Tyr Pro Ser Asp Ile Ala 385 390 395 400 Val Glu Trp Glu Ser Asp Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 405 410 415 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425 430 Thr Val Asp Lys Ser Arg Trp Glu Gln Gly Asp Val Phe Ser Cys Ser 435 440 445 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 450 455 460 Leu Ser Pro Gly Lys 465 <210> 19 <211> 742 <212> PRT <213> Homo sapiens <400> 19 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 20 25 30 Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 Ser Thr Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Arg Leu 50 55 60 Glu Trp Met Gly Glu Ile Leu Pro Gly Ser Gly Asn Thr Asp Phe Asn 65 70 75 80 Glu Lys Phe Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Ser Asp 85 90 95 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110 Tyr Tyr Cys Thr Arg Trp Gly Tyr Tyr Gly Thr Arg Gly Tyr Phe Asn 115 120 125 Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240 Lys Ser Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile 290 295 300 Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu 325 330 335 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asp Ser Tyr Val Ser Trp Phe Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Lys Pro Gly Ser Gly 370 375 380 Lys Pro Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly Ser Gln Ala 385 390 395 400 Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val 405 410 415 Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr 420 425 430 Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ser Pro Arg Gly Leu Ile 435 440 445 Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg Phe Ser Gly 450 455 460 Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Ile Ser Gly Ala Gln Pro 465 470 475 480 Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn His Trp 485 490 495 Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser 500 505 510 Gly Gly Gly Gly Ser Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 515 520 525 Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 530 535 540 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 545 550 555 560 Val Lys His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 565 570 575 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 580 585 590 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 595 600 605 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 610 615 620 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 625 630 635 640 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Gln Met Thr Lys Asn 645 650 655 Gln Val Lys Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 660 665 670 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 675 680 685 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 690 695 700 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 705 710 715 720 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 725 730 735 Ser Leu Ser Pro Gly Lys 740 <210> 20 <211> 745 <212> PRT <213> Homo sapiens <400> 20 Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp 1 5 10 15 Leu Arg Gly Ala Arg Cys Gln Val Gln Leu Val Gln Ser Gly Ala Glu 20 25 30 Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly 35 40 45 Tyr Thr Phe Ser Thr Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly 50 55 60 Gln Arg Leu Glu Trp Met Gly Glu Ile Leu Pro Gly Ser Gly Gln Thr 65 70 75 80 Asp Phe Asn Glu Lys Phe Gln Gly Arg Val Thr Phe Thr Ala Asp Thr 85 90 95 Ser Ser Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp 100 105 110 Thr Ala Val Tyr Tyr Cys Thr Arg Trp Gly Tyr Tyr Gly Thr Arg Gly 115 120 125 Tyr Phe Asn Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala 130 135 140 Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser 145 150 155 160 Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe 165 170 175 Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly 180 185 190 Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu 195 200 205 Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr 210 215 220 Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys 225 230 235 240 Val Glu Pro Lys Ser Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asp Ser Tyr Val Ser Trp Phe 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Lys Pro 370 375 380 Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly 385 390 395 400 Ser Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly 405 410 415 Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr 420 425 430 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ser Pro Arg 435 440 445 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 450 455 460 Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Ile Ser Gly 465 470 475 480 Ala Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Trp Tyr Ser 485 490 495 Asn His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly 500 505 510 Gly Gly Ser Gly Gly Gly Gly Ser Lys Thr His Thr Cys Pro Pro Cys 515 520 525 Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 530 535 540 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 545 550 555 560 Val Val Asp Val Lys His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 565 570 575 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu 580 585 590 Gln Tyr Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His 595 600 605 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 610 615 620 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 625 630 635 640 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Gln Met 645 650 655 Thr Lys Asn Gln Val Lys Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 660 665 670 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 675 680 685 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 690 695 700 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 705 710 715 720 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 725 730 735 Lys Ser Leu Ser Leu Ser Pro Gly Lys 740 745 <210> 21 <211> 17 <212> PRT <213> Homo sapiens <400> 21 Glu Ile Leu Pro Gly Ser Gly Gln Thr Asp Phe Asn Glu Lys Phe Gln 1 5 10 15 Gly <210> 22 <211> 121 <212> PRT <213> Mus musculus <400> 22 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Gln Trp Met 35 40 45 Gly Trp Met Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Arg Thr Val Ser 65 70 75 80 Leu Asp Ile Asn Asp Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Thr Arg Ala Gly Gly Gln Leu Arg Pro Gly Ala Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 23 <211> 5 <212> PRT <213> Mus musculus <400> 23 Asn Tyr Gly Met Asn 1 5 <210> 24 <211> 17 <212> PRT <213> Mus musculus <400> 24 Trp Met Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys 1 5 10 15 Gly <210> 25 <211> 12 <212> PRT <213> Mus musculus <400> 25 Ala Gly Gly Gln Leu Arg Pro Gly Ala Met Asp Tyr 1 5 10 <210> 26 <211> 111 <212> PRT <213> Mus musculus <400> 26 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Val Ala Ser Asn Leu Glu Ser Gly Ile Pro Asp 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Glu Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 27 <211> 15 <212> PRT <213> Mus musculus <400> 27 Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Phe Met Asn 1 5 10 15 <210> 28 <211> 7 <212> PRT <213> House mouse <400> 28 Val Ala Ser Asn Leu Glu Ser 1 5 <210> 29 <211> 9 <212> PRT <213> House mouse <400> 29 Gln Gln Ser Asn Glu Glu Pro Pro Thr 1 5 <210> 30 <211> 15 <212> PRT <213> Homo sapiens <400> 30 Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Phe Met Asn 1 5 10 15 <210> 31 <211> 7 <212> PRT <213> Homo sapiens <400> 31 Val Ala Ser Asn Leu Glu Ser 1 5 <210> 32 <211> 9 <212> PRT <213> Homo sapiens <400> 32 Gln Gln Ser Asn Glu Glu Pro Pro Thr 1 5 <210> 33 <211> 5 <212> PRT <213> Homo sapiens <400> 33 Asn Tyr Gly Met Asn 1 5 <210> 34 <211> 17 <212> PRT <213> Homo sapiens <400> 34 Trp Met Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Lys Phe Gln 1 5 10 15 Gly <210> 35 <211> 12 <212> PRT <213> Homo sapiens <400> 35 Ala Gly Gly Gln Leu Arg Pro Gly Ala Met Asp Tyr 1 5 10 <210> 36 <211> 237 <212> PRT <213> Homo sapiens <400> 36 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Asp Ile Val Leu Thr Gln Thr Pro Leu Ser Leu Ser Val 20 25 30 Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys Ala Ser Gln Ser Val 35 40 45 Asp Tyr Asp Gly Asp Ser Phe Met Asn Trp Tyr Leu Gln Lys Pro Gly 50 55 60 Gln Pro Pro Gln Leu Leu Ile Tyr Val Ala Ser Asn Leu Glu Ser Gly 65 70 75 80 Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 85 90 95 Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln 100 105 110 Gln Ser Asn Glu Glu Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu 115 120 125 Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser 130 135 140 Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn 145 150 155 160 Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala 165 170 175 Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys 180 185 190 Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp 195 200 205 Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu 210 215 220 Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 225 230 235 <210> 37 <211> 469 <212> PRT <213> Homo sapiens <400> 37 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Glu Ile Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 20 25 30 Pro Gly Ala Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 Thr Asn Tyr Gly Met Asn Trp Val Gln Gln Ala Pro Gly Gln Gly Leu 50 55 60 Glu Trp Met Gly Trp Met Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala 65 70 75 80 Asp Lys Phe Gln Gly Arg Val Thr Phe Thr Leu Asp Thr Ser Ala Arg 85 90 95 Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110 Tyr Phe Cys Ala Arg Ala Gly Gly Gln Leu Arg Pro Gly Ala Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro Ser Asp Thr Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Pro 245 250 255 Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 260 265 270 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 275 280 285 Lys His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 290 295 300 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Glu Tyr Asn Ser 305 310 315 320 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 325 330 335 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 340 345 350 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 355 360 365 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 370 375 380 Val Ser Leu Thr Cys Asp Val Ser Gly Phe Tyr Pro Ser Asp Ile Ala 385 390 395 400 Val Glu Trp Glu Ser Asp Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 405 410 415 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425 430 Thr Val Asp Lys Ser Arg Trp Glu Gln Gly Asp Val Phe Ser Cys Ser 435 440 445 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 450 455 460 Leu Ser Pro Gly Lys 465 <210> 38 <211> 742 <212> PRT <213> Homo sapiens <400> 38 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Glu Ile Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 20 25 30 Pro Gly Ala Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 Thr Asn Tyr Gly Met Asn Trp Val Gln Gln Ala Pro Gly Gln Gly Leu 50 55 60 Glu Trp Met Gly Trp Met Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala 65 70 75 80 Asp Lys Phe Gln Gly Arg Val Thr Phe Thr Leu Asp Thr Ser Ala Arg 85 90 95 Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110 Tyr Phe Cys Ala Arg Ala Gly Gly Gln Leu Arg Pro Gly Ala Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240 Lys Ser Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile 290 295 300 Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu 325 330 335 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asp Ser Tyr Val Ser Trp Phe Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Lys Pro Gly Ser Gly 370 375 380 Lys Pro Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly Ser Gln Ala 385 390 395 400 Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val 405 410 415 Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr 420 425 430 Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ser Pro Arg Gly Leu Ile 435 440 445 Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg Phe Ser Gly 450 455 460 Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Ile Ser Gly Ala Gln Pro 465 470 475 480 Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn His Trp 485 490 495 Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser 500 505 510 Gly Gly Gly Gly Ser Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 515 520 525 Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 530 535 540 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 545 550 555 560 Val Lys His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 565 570 575 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 580 585 590 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 595 600 605 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 610 615 620 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 625 630 635 640 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Gln Met Thr Lys Asn 645 650 655 Gln Val Lys Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 660 665 670 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 675 680 685 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 690 695 700 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 705 710 715 720 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 725 730 735 Ser Leu Ser Pro Gly Lys 740 <210> 39 <211> 262 <212> PRT <213> Homo sapiens <400> 39 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asp Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Lys Pro 115 120 125 Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly 130 135 140 Ser Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly 145 150 155 160 Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr 165 170 175 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ser Pro Arg 180 185 190 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 195 200 205 Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Ile Ser Gly 210 215 220 Ala Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Trp Tyr Ser 225 230 235 240 Asn His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ser 245 250 255 His His His His His His 260 <210> 40 <211> 254 <212> PRT <213> Homo sapiens <400> 40 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asp Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Lys Pro 115 120 125 Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly 130 135 140 Ser Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly 145 150 155 160 Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr 165 170 175 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ser Pro Arg 180 185 190 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 195 200 205 Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Ile Ser Gly 210 215 220 Ala Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Trp Tyr Ser 225 230 235 240 Asn His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 245 250 <210> 41 <211> 125 <212> PRT <213> Homo sapiens <400> 41 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asp Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 42 <211> 109 <212> PRT <213> Homo sapiens <400> 42 Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ser Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Ile Ser Gly Ala 65 70 75 80 Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn 85 90 95 His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 43 <211> 262 <212> PRT <213> Homo sapiens <400> 43 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asp Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Lys Pro 115 120 125 Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly 130 135 140 Ser Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly 145 150 155 160 Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr 165 170 175 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ser Pro Arg 180 185 190 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 195 200 205 Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Ile Ser Gly 210 215 220 Ala Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Trp Tyr Ser 225 230 235 240 Asn His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ser 245 250 255 His His His His His His 260 <210> 44 <211> 254 <212> PRT <213> Homo sapiens <400> 44 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asp Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Lys Pro 115 120 125 Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly Ser Gly Lys Pro Gly 130 135 140 Ser Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly 145 150 155 160 Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr 165 170 175 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ser Pro Arg 180 185 190 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 195 200 205 Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Ile Ser Gly 210 215 220 Ala Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Trp Tyr Ser 225 230 235 240 Asn His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 245 250 <210> 45 <211> 125 <212> PRT <213> Homo sapiens <400> 45 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asp Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 46 <211> 109 <212> PRT <213> Homo sapiens <400> 46 Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ser Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Ile Ser Gly Ala 65 70 75 80 Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn 85 90 95 His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 47 <211> 262 <212> PRT <213> Homo sapiens <400> 47 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 ...

Claims

1. An antibody or an antigen-binding fragment thereof, the antibody or antigen-binding fragment thereof specifically binding to STEAP1 of SEQ ID NO: 2 and comprising... The following heavy chain CDRs are: vhCDR1 listed in SEQ ID NO: 14, vhCDR2 listed in SEQ ID NO: 15 or vhCDR2 listed in SEQ ID NO: 21, and vhCDR3 listed in SEQ ID NO: 16; and The following light chain CDRs are: vlCDR1 listed in SEQ ID NO: 11, vlCDR2 listed in SEQ ID NO: 12, and vlCDR3 listed in SEQ ID NO:

13.

2. The antibody or antigen-binding fragment thereof as claimed in claim 1, wherein the antibody or antigen-binding fragment thereof comprises the heavy chain variable domain listed in SEQ ID NO: 184 and the light chain variable domain listed in SEQ ID NO:

183.

3. The antibody or antigen-binding fragment thereof as claimed in claim 1, wherein the antibody or antigen-binding fragment thereof comprises the heavy chain variable domain listed in SEQ ID NO: 182 and the light chain variable domain listed in SEQ ID NO:

183.

4. The antibody or antigen-binding fragment thereof as described in any one of claims 1-3, wherein the antibody or antigen-binding fragment thereof is an antibody.

5. The antibody or antigen-binding fragment thereof as described in claim 4, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody, a chimeric antibody, or a humanized antibody.

6. The antibody or antigen-binding fragment thereof as described in any one of claims 1-3, wherein the antibody or antigen-binding fragment thereof is an antigen-binding antibody fragment.

7. The antibody or antigen-binding fragment thereof as claimed in any one of claims 1-3, wherein the antibody or antigen-binding fragment thereof comprises a single-chain antibody.

8. A pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof as described in any one of claims 1-7 and a physiologically acceptable carrier.

9. The pharmaceutical composition of claim 8, further comprising an anti-PD-1 antibody or an antigen-binding fragment thereof, the anti-PD-1 antibody or antigen-binding fragment comprising: vhCDR1 listed in SEQ ID NO: 189, vhCDR2 listed in SEQ ID NO: 190, vhCDR3 listed in SEQ ID NO: 191, vlCDR1 listed in SEQ ID NO: 192, vhCDR2 listed in SEQ ID NO: 193, and vlCDR3 listed in SEQ ID NO:

194.

10. A polynucleotide comprising a nucleic acid sequence encoding a light chain variable domain and a heavy chain variable domain of an antibody or an antigen-binding fragment thereof as described in claim 2 or 3.

11. An expression vector comprising the polynucleotide as described in claim 10.

12. A composition comprising: a polynucleotide containing a nucleic acid sequence encoding a light chain variable domain of an antibody or an antigen-binding fragment thereof as claimed in claim 2 or 3, and a polynucleotide containing a nucleic acid sequence encoding a heavy chain variable domain of an antibody or an antigen-binding fragment thereof as claimed in claim 2 or 3.

13. A bispecific antibody or an antigen-binding fragment thereof, the bispecific antibody or the antigen-binding fragment thereof binding to STEAP1 and CD3, the bispecific antibody or the antigen-binding fragment thereof comprising: The antibody or antigen-binding fragment thereof as described in any one of claims 1-3; and CD3 binding domains include vhCDR1 listed in SEQ ID NO: 170, vhCDR2 listed in SEQ ID NO: 171, vhCDR3 listed in SEQ ID NO: 172, vlCDR1 listed in SEQ ID NO: 174, vhCDR2 listed in SEQ ID NO: 175, and vlCDR3 listed in SEQ ID NO:

176.

14. A heterodimeric antibody, the heterodimeric antibody comprising: a) A first monomer comprising a first heavy chain, the first heavy chain comprising: 1) First variable heavy chain structural domain; 2) The first constant heavy chain, which contains the first CH1 domain and the first Fc domain. structural domain; 3) scFv, which binds to human CD3 and comprises a scFv variable light chain domain containing a light chain CDR, an scFv connector, and a scFv variable heavy chain domain, wherein the light chain CDR includes vlCDR1 listed in SEQ ID NO: 174, vlCDR2 listed in SEQ ID NO: 175, and vlCDR3 listed in SEQ ID NO: 176, and the scFv variable heavy chain domain includes vhCDR1 listed in SEQ ID NO: 170, vhCDR2 listed in SEQ ID NO: 171, and vhCDR3 listed in SEQ ID NO: 172; wherein the scFv is covalently attached between the C-terminus of the CH1 domain and the N-terminus of the first Fc domain using one or more domain connectors; b) A second monomer comprising a second heavy chain, the second heavy chain comprising a second variable heavy chain domain and a second constant heavy chain containing a second Fc domain; and c) Common light chains, which contain variable light chain structural domains and constant light chain structural domains; The first variable heavy chain domain and the variable light chain domain are combined with STEAP1, the second variable heavy chain domain and the variable light chain domain are combined with STEAP1, and wherein... The first variable heavy chain domain and the second variable heavy chain domain comprise the following heavy chain CDRs: vhCDR1 listed in SEQ ID NO: 14; vhCDR2 listed in SEQ ID NO: 15 or SEQ ID NO: 21; and vhCDR3 listed in SEQ ID NO: 16, and the variable light chain domain comprises the following light chain CDRs: vlCDR1 listed in SEQ ID NO: 11, vlCDR2 listed in SEQ ID NO: 12, and vlCDR3 listed in SEQ ID NO:

13.

15. The heterodimeric antibody of claim 14, wherein the scFv comprises the variable heavy chain domain and the variable light chain domain of SEQ ID NO: 169 and SEQ ID NO:

173.

16. The heterodimeric antibody of claim 14 or claim 15, wherein the scFv has a charged scFv linker.

17. The heterodimeric antibody of claim 14 or claim 15, wherein the amino acid sequence of the scFv linker is selected from SEQ ID NO: 143 to 153.

18. The heterodimeric antibody of claim 16, wherein the amino acid sequence of the scFv linker is SEQ ID NO:

152.

19. The heterodimeric antibody of claim 14 or claim 15, wherein the scFv comprises the sequence of SEQ ID NO:

44.

20. The heterodimeric antibody of any one of claims 14-19, wherein the first variable heavy chain domain and the second variable heavy chain domain comprise the following CDR sequences: vhCDR1 listed in SEQ ID NO: 14, vhCDR2 listed in SEQ ID NO: 15, and vhCDR3 listed in SEQ ID NO: 16, and wherein the variable light chain domain comprises the following CDR sequences: vlCDR1 listed in SEQ ID NO: 11, vlCDR2 listed in SEQ ID NO: 12, and vlCDR3 listed in SEQ ID NO:

13.

21. The heterodimeric antibody according to any one of claims 14-19, wherein the amino acid sequences of the first variable heavy chain domain and the second variable heavy chain domain are SEQ ID NO: 182, and the amino acid sequence of the variable light chain domain is SEQ ID NO:

183.

22. The heterodimeric antibody of any one of claims 14-19, wherein the first variable heavy chain domain and the second variable heavy chain domain comprise the following CDR sequences: vhCDR1 listed in SEQ ID NO: 14, vhCDR2 listed in SEQ ID NO: 21, and vhCDR3 listed in SEQ ID NO: 16, and wherein the variable light chain domain comprises the following CDR sequences: vlCDR1 listed in SEQ ID NO: 11, vlCDR2 listed in SEQ ID NO: 12, and vlCDR3 listed in SEQ ID NO:

13.

23. The heterodimeric antibody according to any one of claims 14-19, wherein the amino acid sequence of the first variable heavy chain domain and the amino acid sequence of the second variable heavy chain domain are SEQ ID NO: 184, and the amino acid sequence of the variable light chain domain is SEQ ID NO:

183.

24. A heterodimeric antibody comprising a STEAP1-binding domain and a CD3-binding domain, the heterodimeric antibody comprising... A first monomer containing the sequence of SEQ ID NO: 19, a second monomer containing the sequence of SEQ ID NO: 18, and a common light chain containing the sequence of SEQ ID NO: 17, wherein the STEAP1 binding domain comprises the following CDR: vhCDR1, listed in SEQ ID NO: 14 vhCDR2, listed in SEQ ID NO: 15 vhCDR3, listed in SEQ ID NO: 16 vlCDR1, listed in SEQ ID NO: 11 vlCDR2 and listed in SEQ ID NO: 12 vlCDR3 listed in SEQ ID NO: 13; and The CD3 binding domain contains the following CDRs: vhCDR1, listed in SEQ ID NO: 170 vhCDR2, listed in SEQ ID NO: 171 vhCDR3, listed in SEQ ID NO: 172 vlCDR1, listed in SEQ ID NO: 174 vlCDR2 and listed in SEQ ID NO: 175 vlCDR3 is listed in SEQ ID NO:

176.

25. A heterodimeric antibody comprising a STEAP1-binding domain and a CD3-binding domain, the heterodimeric antibody comprising... A first monomer containing the sequence of SEQ ID NO: 202, a second monomer containing the sequence of SEQ ID NO: 201, and a common light chain containing the sequence of SEQ ID NO: 200, wherein the STEAP1 binding domain comprises the following CDR: vhCDR1, listed in SEQ ID NO: 14 vhCDR2, listed in SEQ ID NO: 15 vhCDR3, listed in SEQ ID NO: 16 vlCDR1, listed in SEQ ID NO: 11 vlCDR2 and listed in SEQ ID NO: 12 vlCDR3 listed in SEQ ID NO: 13; and The CD3 binding domain contains the following CDRs: vhCDR1, listed in SEQ ID NO: 170 vhCDR2, listed in SEQ ID NO: 171 vhCDR3, listed in SEQ ID NO: 172 vlCDR1, listed in SEQ ID NO: 174 vlCDR2 and listed in SEQ ID NO: 175 vlCDR3 is listed in SEQ ID NO:

176.

26. A heterodimeric antibody comprising a STEAP1-binding domain and a CD3-binding domain, the heterodimeric antibody comprising... A first monomer containing the sequence of SEQ ID NO: 207, a second monomer containing the sequence of SEQ ID NO: 203, and a common light chain containing the sequence of SEQ ID NO: 200, wherein the STEAP1 binding domain comprises the following CDR: vhCDR1, listed in SEQ ID NO: 14 vhCDR2, listed in SEQ ID NO: 21 vhCDR3, listed in SEQ ID NO: 16 vlCDR1, listed in SEQ ID NO: 11 vlCDR2 and listed in SEQ ID NO: 12 vlCDR3 listed in SEQ ID NO: 13; and The CD3 binding domain contains the following CDRs: vhCDR1, listed in SEQ ID NO: 170 vhCDR2, listed in SEQ ID NO: 171 vhCDR3, listed in SEQ ID NO: 172 vlCDR1, listed in SEQ ID NO: 174 vlCDR2 and listed in SEQ ID NO: 175 vlCDR3 is listed in SEQ ID NO:

176.

27. A nucleic acid composition comprising: a) Encoding the first nucleic acid of the first monomer as described in any one of claims 14-26; b) Encoding a second nucleic acid of the second monomer as described in any one of claims 14-26, and c) Encoding a third nucleic acid of the common light chain as described in any one of claims 14-26.

28. A nucleic acid composition comprising: a) A first expression vector comprising a first nucleic acid, the first nucleic acid encoding a first monomer as described in any one of claims 14-26; b) A second expression vector comprising a second nucleic acid encoding the second monomer as described in any one of claims 14-26; and c) A third expression vector containing a third nucleic acid that encodes the common light chain as described in any one of claims 14-26.

29. A host cell comprising the nucleic acid composition as described in claim 27 or claim 28.

30. A pharmaceutical composition comprising the heterodimeric antibody as described in any one of claims 14-26.

31. The antibody or antigen-binding fragment thereof as described in any one of claims 1-3, wherein it is ligated to a detectable marker.

32. The antibody or antigen-binding fragment thereof as claimed in claim 31, wherein the marker is radioactive.

33. The antibody or antigen-binding fragment thereof as claimed in claim 31 or claim 32, wherein the antibody or antigen-binding fragment thereof is a Fab fragment.

34. The antibody or antigen-binding fragment thereof as claimed in claim 31 or claim 32, wherein the antibody or antigen-binding fragment thereof is an F(ab')2 fragment.

35. Use of the antibody or antigen-binding fragment thereof as described in any one of claims 31-34 in the preparation of a detection reagent for detecting STEAP1 in a subject, wherein the detection comprises detecting the marker.

36. The use as described in claim 35, wherein positron emission tomography (PET) is used to detect the marker.

Citation Information

Patent Citations

  • Cytotoxic agents comprising maytansinoids and their therapeutic use

    EP0425235B1

  • Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents

    EP1391213A1

  • Electrical socket

    US1997270A

  • Bispecific immunoglobulin-like antigen binding proteins and method of production

    US20020103345A1

  • Immunotherapy using interleukin 13 receptor subunit alpha 2

    US20020197266A1